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ABSTRACT 
 
The work described in this thesis addresses two questions relating to benefits of dietary 
omega-3 fatty acids (n-3 LCPUFA).   Accretion of research knowledge indicates that 
adequate n-3 LCPUFA intakes may be instrumental in maintaining good health 
throughout life, including in the optimisation of cardiovascular health.   Sources of n-3 
LCPUFA traditionally include fish oils but concern regarding long-term sustainability of 
fish stocks has led to investigation of alternative sources. Krill oil, obtained from the 
crustacean Euphausia superba, contains n-3 fatty acids as phospholipids and 
triglycerides, astaxanthin and related carotenoid pigments, and has been proposed as 
a more effective alternative than triglyceride oils.    
Some foods rich in n-3-LCPUFA, including prawns, also contain cholesterol; concern 
regarding possible adverse health effects of such dietary cholesterol has led to public 
health advice to limit intake of these potentially beneficial foodstuffs. 
These questions are addressed in two food intake studies in male volunteers by 
monitoring markers of cardiovascular health, food intake and biochemical markers of 
compliance.  Firstly, prawns and a white fish control were compared for effects on 
lipoprotein profiles and other markers.  Dietary supplementation with 225 g prawns 
daily for 4 weeks was associated with a decrease in ApoB of 7.8mg/dL compared an 
increase (+2.4 mg/dL) for the white fish control.  Participants with BMI > 25 kg/m2 also 
showed a reduction in plasma TAG (0.17 mmol/L) compared with baseline following 
prawn intake; those receiving the control showed an increase in plasma TAG (0.30 
mmol/L), a decrease in HDL-C, and increases in VLDL-C and sdLDL-C.  No overall 
adverse effect was found for prawns compared with processed white fish. 
Secondly, effects were compared of fish oil and krill oil on cardiometabolic profiles of a 
cohort of men with metabolic syndrome, using anthropometric measurements, 
biochemical markers of cardiovascular health and assessments of food intake.   Krill oil 
and fish oil at the doses used showed no overall difference in effect on MetS markers 
after 6 weeks; correlations between magnitude of reduction and baseline measurement 
were observed in both groups for TAG, fasting glucose, NEFA and sdLDL after 3 
weeks on both supplements, and for glucose and cholesterol after 6 weeks of fish oil.    
Comparison of analytical methods was also undertaken during both studies; use of a 
point-of-care system using capillary blood correlated well with plasma biochemistry 
using venous blood, while the Hirano method for sdLDL measurement correlated 
favourably with more labour-intensive centrifugation techniques.   Limitations of the 
methods used are discussed, and proposals put forward for future work, including 
improving compliance through the use of newly emerging technologies such as 
metabolomics. 
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CHAPTER 1 
Introduction and Background 
 
1. 1.   LONG-CHAIN OMEGA-3 FATTY ACIDS 
 
1.1.1. Nomenclature 
 
The omega-3 (n-3) series of fatty acids (FA) are synthesised by single-celled 
organisms and marine organisms such as shrimp, which provide the major source of 
these FAs to fish and mammals further up the food chain (Calder, 2004).     They are 
long-chain carboxylic acids characterised by repeated cis-carbon-carbon double bonds 
(-CH=CH-) separated by methylene (-CH2-) groups.   The structural formulae for 
eicosapentaenoic and docosohexaenoic acids (EPA and DHA) are shown in Figure 1.1. 
 
 
Figure 1.1.  Structure of DHA and EPA (from Calder, 2004) 
Together with arachidonic acid (ArA) (Figure 1.2), the major elongation product of the 
n-6 series of FAs, EPA and DHA have key roles in the structure and function of cell 
membranes and modulation of inflammatory processes.  Some features are highly 
specific to either the n-3 or the n-6 family, and between individual FAs (Calder & 
Grimble, 2002; Calder, 2006a; 2006b; 2013; Maskrey et al., 2013).   In the 
nomenclature used here, the n-number refers to the first unsaturated carbon atom, 
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counting from the end furthest away from the carboxyl group:  for EPA, 20:5 gives the 
length of the carbon backbone followed by the number of double bonds.  
  
 
 
 
 
 
Figure 1.2.  Structure of arachidonic acid  (from Calder, 2004) 
 
1.1.2. Biosynthesis 
 
LCPUFAs of the n-3 and n-6 series are synthesised in vivo by elongation and 
desaturation of the essential FAs linoleic acid (LA) and α-linolenic acids (ALA) 
respectively, as shown in Figures 1.3 and 1.4 (Simopoulos, 1991; Calder, 2012a & 
2012b; Calder & Yaqoob, 2012). Whereas marine organisms are capable of 
synthesising LA and ALA in situ, many mammals are not, and an adequate dietary 
supply of these FAs is therefore essential.  
    
 
  
 
Figure 1.3.  Structure of linoleic and α-linolenic acid (from lipidlibrary.aocs.org) 
 
Figure 1.4.  Biosynthesis of LA and ALA (from lipidlibrary.aocs.org) 
 
The elongation and desaturation pathways are similar, but not identical, for the n-6 and 
n-3 series, as shown in Figure 1.5.  This similarity may result in competitive inhibition if 
the components of one pathway are present in much larger concentration.   In humans, 
the rate of conversion of ALA to EPA and DHA is about 10%, less efficient in males 
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than females (Calder, 2004; Burdge & Calder, 2005).   ALA is utilised by the skin, and 
may be more rapidly oxidised than EPA and DHA, thus being less available for 
elongation in the liver (Burdge & Calder, 2005; Burdge, 2006; Brenna et al., 2009).  
This supports the view that the majority of these long-chain FAs should normally be 
furnished from dietary sources containing EPA and DHA such as meat, fish and eggs 
(Givens et al., 2006; Elwood et al., 2008). 
Components of the n-3 series up to and including DHA, with information about 
occurrence and relative importance, are shown in Table 1.1.  
 
1.1.3. Destination and catabolism of n-3 FAs 
 
Dietary FAs are obtained in the form of phospholipids (PL) or triglycerides 
(triacylglycerols, TAG), which are hydrolysed in the gut to produce free or non-
esterified FAs (NEFA).  These enter intestinal cells via FA transport systems and are 
re-esterified to fatty acyl-Coenzyme A thioesters (catalysed by acyl-CoA synthetases); 
FA-CoAs form the substrate for tissue synthesis of neutral lipids  (TAG and cholesterol 
esters) and polar lipids (PLs, sphingolipids and plasmalogens) (Kinsella et al., 1990).  
Re-esterified FAs are packaged into very low density lipoprotein particles (VLDL) in the 
liver or chylomicrons (in the gut) for transport (Jump, 2004, 2011: Jacome-Sosa & 
Parks, 2014). 
LCPUFA are integral components of cell and tissue structures, and also essential 
precursors for signalling molecules controlling developmental, neurological, and 
inflammatory processes. These will be briefly summarised here with reference to 
human health and disease, with particular emphasis on cardiovascular disease (CVD) 
risk.   
 15 
                                                   
 
 
 
Figure 1.5:  Elongation and desaturation pathways for n-6 and n-3 fatty acids (from lipidlibrary.aocs.org)
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 Name Occurrence Major dietary source Importance 
18:3(n-3): α-linolenic acid (ALA) Algae & higher plants.   
Animal tissue lipids (<1%) 
Linseed oil (65%), Soybean (7%), 
Rapeseed (7%) 
Precursor of other n-3 fatty acids, also 
oxidised to shorter chain molecules. 
20:3(n-3): Eicosatrienoic acid Animal tissue PLs (up to 
1%), higher in fish oils. 
No significant source  
18:4(n-3): Stearidonic acid Some plants, also algae and 
fish oils 
Echium oil  
Blackcurrant seed oil 
May be a more efficient source of n-3 
LCPUFAs than α-linolenic acid 
18:5(n-3):  Octadecapentaenoic 
acid 
Dinoflagellates:  enters 
marine food chain from this 
source 
No significant source in human 
diet 
 
20:4(n-3):  Eicosatetraenoic acid Most fish oils, animal PLs, 
algae & mosses.   Rarely in 
higher plants. 
No significant source   
20:5(n-3): Eicosapentaenoic acid 
(EPA) 
Occurs widely in fish oils and 
algae, Rarely if at all in 
higher plants.    
Oily fish & marine organisms.  
Oils extracted from algae, fish & 
crustacea (e.g. krill) 
Important component of PLs in animal 
tissues, especially brain.  
Precursor of PG3 prostaglandins & resolvins  
22:5(n-3): Docosapentaenoic 
acid 
Important component of fish 
oils; animal PLs (2-5%) 
Fish oil and PL Possible source of EPA by interconversion; 
little evidence of interconversion with DHA 
22:6(n-3):  Docosahexaenoic acid 
(DHA) 
Fish oils & animal PLs (brain 
synapses and retina).   
Algae, especially marine 
Oily fish & marine organisms.  
Oils extracted from algae, fish & 
crustacean (krill) 
Correlated with improved cognitive & 
behavioural function in development, also 
with reduction in cardiovascular disease risk. 
Table 1.1:  Fatty acids of the n-3 series  (From:  AOCS Lipid Library, 2013)
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Both ArA and EPA are precursors of leukotrienes and prostaglandins.  The PG2 series 
of prostaglandins and LT4 leukotrienes derived from ArA are mainly pro-inflammatory in 
nature; they contribute to formation of blood clots and atheromas (plaques), resulting in 
increased blood viscosity, vasoconstriction, and reduced bleeding times (Serhan et al., 
2008; Kris-Etherton et al., 2002; Rabkin et al., 2013; Harris & Shearer, 2014). Those 
derived from EPA are PG3 prostanoids and LT5 leukotrienes (LTA5, LTB5 and LTC5), 
which are anti-inflammatory or contribute to the resolution of inflammatory episodes. 
The relationship between arachidonate and eicosanoate–derived signalling molecules 
is shown in Figure 1.6. 
The longer n-3 LCPUFA, DHA, is incorporated into PLs in cell membranes, mainly at 
the sn2 position; it is particularly important in neurological tissues, and imparts an 
increased level of fluidity to cell membranes compared with saturated or n-6 FAs.    
 
1.1.4. The role of n-3 fatty acids in inflammatory processes  
 
Inflammation protects an organism against pathogens, but is also a common feature of 
chronic diseases, including cardiovascular disease (CVD) (Sprecher & Chen, 1999; 
Tricon et al., 2004; Markovic et al., 2004).  The n-6 LCPUFA ArA and n-3 LCPUFAs 
released from the sn-2 position of membrane PLs by the action of phospholipase, 
provide substrates for cycloxygenases (COX), lipoxygenases (LOX) and cytochrome 
P450 monoxygenases, resulting in production of prostanoids and thromboxanes. COX 
products modulate thrombotic, inflammatory and chemotactic responses, whereas LOX 
products play a role in vascular permeability, vasoconstriction and bronchoconstriction 
(Jump, 2002; Spite & Serhan, 2010; Stables & Gilroy, 2011).  Inhibition of COX-1 and 
COX-2 has been a focus of anti-inflammatory drug development in recent years.  The 
effect of aspirin in CVD prevention is attributed to inhibition of prostaglandin and 
prothrombotic thromboxane (TXA2) generation by binding to COX-1. Statins, used in 
reduction of low-density lipoproteins in hyperlipidaemic patients, have also been 
reported to reduce inflammation in vivo (Spite & Serhan, 2010).   
Anti-thrombotic and anti-inflammatory effects of n-3 LCPUFAs had been attributed to 
inhibition of pro-inflammatory cytokine synthesis.  EPA appears to compete with ArA to 
bind to COX-1, but not to COX-2, reducing the production of ArA-derived prostanoids 
(Agarwal et al., 2009; Calder et al., 2009).  More recently EPA and DHA have been 
shown to be precursors for the E and D series of resolvins, respectively (Stables & 
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Gilroy, 2011).   The role of these molecules is to resolve the initial acute inflammatory 
response and effectively bring an episode of inflammation to a structured conclusion.  
They act on specific cell types to increase anti-inflammatory cytokine production and 
decrease pro-inflammatory cytokine production in macrophages.  
Extensive reviews of n-3 PUFA in chronic disease (Sijben & Calder, 2007) and CVD 
(Lovegrove & Griffin, 2013) suggest that the effects of n-3 PUFA on inflammatory 
function are not dose-dependent, that local effects may be more significant than 
systemic effects, and that clinical endpoints may be more valuable measures of 
success than cytokine measurements.    Key cytokines related to inflammation and 
atherosclerosis are listed in Tables 1.2 and 1.3. 
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Figure 1.6:  Derivation of signalling molecules from n-3 and n-6 LCPUFAs (from Merino et al., 2010; lipidworld.com).
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Cytokine  Site(s) of production Role Reference 
IL-1β  (Interleukin -
1β) 
17kDa Monocytes and macrophages Increases expression of adhesion molecules Garlanda et al., 
2013 
IL-6 (Interleukin-6) 2kDa Lymphocytes, monocytes, fibroblasts, vascular 
smooth muscle cells (VSMC) & endothelial cells. 
Production of IL-6 is stimulated by angiotensin II.  
Expression in VSMCs may be upregulated by 
ANg II type 1 receptor (AT1R) and NF-κB. 
Maintenance of inflammatory state:  important local & 
circulating marker for inflammation in cardiovascular 
tissues.  Stimulates: 
 expression of tissue factor, matrix degrading 
enzymes & LDL receptors in macrophages 
 aggregation of platelets 
 proliferation of VSMCs 
 Enhances expression of adhesion molecules & 
other cytokines (IL-1β & TNF-α in endothelial 
cells). 
Scheller & 
Rose-John, 
2006; 
Tanaka et al., 
2012 
IL-8 (Interleukin-8) 8.3kDa Monocytes & macrophages, many tumour cells Recruits neutrophils to the site of inflammation. 
Triggers adhesion of rolling monocytes to vascular 
endothelium, in the earliest step of atherosclerosis.  
Mitogen and chemoattractant factor for VSMCs. May 
reduce cholesterol efflux from macrophages. 
Xie, 2001;  
Ito & Ikeda, 
2003;  
Chen et al., 
2014 
TNFα (Tumour 
necrosis factor–α) 
17kDa Macrophages (foam cells), monocytes Effects include increased body temperature, reduced 
appetite and stimulation of other cytokines. 
Grimble, 1996; 
Baker et al., 
2011;  
Zheng et al., 
2013 
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Cytokine  Site(s) of production Role Reference 
PDGF (Platelet-
derived growth 
factor) 
32-
25kDa 
Platelets, vascular cells, lymphocytes Stimulates smooth muscle cell proliferation & has a 
role in cell migration into new muscle tissue following 
injury.   Also thought to play a major role in the 
proliferation of atherosclerotic lesions.    
Raines, 2004; 
Murray & 
Wynn, 2011 
MCP-1 (Monocyte 
chemoattractant 
protein) 
 9-
15kDa 
Lymphocytes, monocytes Thought to play an early role in the recruitment of 
monocytes to atherosclerotic lesions, & in 
development of intimal hyperplasia after injury. 
Induces the expression of tissue factor, superoxide 
anions and pro-inflammatory genes.  
Ito & Ikeda, 
2003;   
Charo & 
Taubman, 
2004; 
Yadav et al., 
2010 
CRP (C-reactive 
protein) 
 Hepatic by-product of IL-6 Commonly used as a marker of systemic 
inflammation; with IL-6, raised levels are thought to 
indicate an increased risk of CVD. 
Tsimikas et al., 
2006; Kaptoge 
et al.,2012 
Table 1.2.   Key pro-inflammatory cytokines 
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Cytokine Site(s) of 
production 
Role Reference 
IL-10 (Interleukin-
10) 
Monocytes, 
macrophages and  
T cells 
Produced by monocytes, macrophages & T cells during inflammatory processes to limit the 
release of pro-inflammatory mediators. 
Ouchi et al., 
2011;  
Jung & Choi, 
2014  
Adhesion molecules 
Endothelial 
adhesion molecules 
VCAM-1 
ICAM-1 
E-selectin 
Endothelial cells Facilitate recruitment and attachment of circulating leukocytes to the walls of blood vessels. 
Endothelial cell activation may lead to increased vasoconstriction, proliferation of smooth 
muscle, platelet aggregation, leukocyte adhesion, LDL oxidation, and MMP activation. 
Zhang et al., 
2011; 
Liao, 2013 
Table 1.3.   Key anti-inflammatory cytokines 
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1.2. THE IMPORTANCE OF n-3 FATTY ACIDS IN HUMAN HEALTH 
 
Fish and marine produce have historically been major components of the diet of 
coastal populations. PUFA constitute approximately 20% of the dry weight of the 
human brain, and a third of FAs in the central nervous system (Bourre, 2004). The diet 
and exercise habits of much of the human population now, particularly in respect of fat 
intake and metabolism, are quite different from those that applied to our ancestors 
(Simopoulos, 2008);  specifically, the proportion of n-3 FAs in the diet has fallen 
dramatically over the past century, especially in the western world.  This is partly due to 
increased use of n-6 vegetable oils in processed foods, and changes in animal-rearing 
practices allowing greater access to animal protein and fat sources (Simopoulos, 
2002a; 2003; 2011). A recent survey of FA intakes in 266 countries reported that 
despite some success of public health initiatives to reduce saturated fat intake, seafood 
n-3 consumption remains below 250 mg per day in nearly 80% of the world’s 
population, with increases mainly in countries where consumption is already higher 
than average (Micha et al., 2014). The n-6:n-3 ratio in the North American diet is 
estimated to be about 20:1, compared with a probable optimum of about 2:1 
(Simopoulos, 2003; Wijendran & Hayes, 2004). The OPTILIP study in the UK (Griffin et 
al., 2006) reported a mean ratio of n-6:n-3 of approximately 8:1 in 258 men and women 
between 45 and 70 years of age. An increase in overall intake of n-3 LCPUFA and 
reduction in the dietary n-6:n-3 FA ratio are seen as desirable objectives in reducing 
the risk of many chronic diseases. 
Children in Britain in the period following the 2nd world war were routinely fed cod liver 
oil supplements in primary school, primarily aimed at prevention of rickets (cod liver oil 
is rich in Vitamin D as well as n-3 LCPUFAs) (Rajakumar, 2003).  The oil used was a 
by-product of fish protein (fillet) production, and as such was regarded of lower 
commercial importance; it would be susceptible to oxidation because of the high 
proportion of unsaturated FAs, and was in poor condition and unpleasant to consume 
(Kaitaranta, 1992). More recently, attention has focussed on the benefits of eating oily 
fish, and of the ‘Mediterranean diet’ for cardiovascular health, reduction of obesity and 
certain types of cancers (Estruch et al., 2013a; 2013b).  This is typically described as 
rich in fruit, vegetables, legumes, nuts and olive oil, with moderate intakes of fish, dairy 
products and wine, and low consumption of meat, poultry and sweets; benefits are 
attributed to high levels of fibre and antioxidants, but also relatively low levels of 
saturated FAs and high levels of oleic acid, n-6 and n-3 FAs (Sofi et al., 2010, 
Trichopoulou et al., 2014). 
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There is a strong perception of the importance of LCPUFAs in maintaining fluidity of 
cell membranes and moderating inflammatory processes; dietary supplementation with 
n-3 LCPUFAs may directly affect gene expression (Calder, 2012b). Recent reports 
infer a direct association between intake of FO or DHA alone and regulation of several 
transcription factors related to TAG or lipoprotein metabolism, with increased 
expression of antioxidative enzymes and decreased expression of pro-oxidative 
enzymes (Dawson et al., 2012; Schmidt et al., 2012a; 2012b; 2012c).   It has also been 
suggested, however, that high levels of LCPUFA in cell membranes may render them 
more susceptible to lipid peroxidation, leading to increased damage to intracellular 
components. Valencak and Ruf (2007) correlated PL membrane composition in 42 
mammalian species with maximum lifespan and basal metabolic rate; they reported a 
decrease in lifespan with an increased n-6:n-3 ratio, but no specific correlation with 
membrane unsaturation or concentration of DHA rather than EPA.  It was suggested 
that this refutes a direct link between high amounts of membrane PUFAs, elevated 
basal metabolic rate and hence impaired longevity. The role of n-3 PUFAs on 
membrane function may be partly via their effect on ‘lipid rafts’, cholesterol- and 
sphingolipid-rich regions within the exoplasmic leaflet of the plasma membrane, which 
selectively incorporate proteins (including cell-signalling proteins) and control protein-
protein and protein-lipid interactions (Ikonen, 2001; Adkins & Kelley, 2010; Calder, 
2013).  Some of the evidence linking diet and lifestyle factors, cytokine production and 
inflammatory processes is summarised in Tables 1.4 and 1.5. 
The balance between FOs and vegetable oils in the diet may be important in 
inflammation.   Wada et al. (2007) compared the effects of vegetable oil, FO and 
combinations of both on prostanoid formation by cultured cells; prostanoids help 
control blood pressure, reduce incidence of allergies and modulate inflammation, but 
those derived from vegetable oils can also increase levels of pain, swelling and 
redness in some tissues.   It was suggested that increasing PL EPA:ArA ratios (by 
increasing the relative proportion of FO to vegetable oil in the diet) may reduce series 2 
prostanoids (PGD, PGE and PGF). 
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Cytokine Factors increasing levels Factors decreasing levels Reference 
IL-1β Increased in response to strenuous exercise: 
not mitigated by previous ingestion of 3.6 g EPA 
plus DHA. This may demonstrate that IL-1β 
responds to the stronger stimulus of the 
exercise stress.   
IL-1β levels reduced by between 61 and 90% in 
patients with rheumatoid arthritis taking oral doses of 
2.7-5.8 g n-3 LCPUFA (fish oil) per day.    
James et al., 2000; 
von Schacky & Harris, 2007 
IL-6 Increased as a result of hyperglycaemia Reduced (with TNF-alpha) following n-3 
supplementation (ex vivo analysis).  It is not clear 
whether this is dose-related. 
Esposito et al., 2002;  
Trebble et al., 2003 
PDGF Increased in diabetes in granulation tissue in 
wounds associated with impaired 
vascularisation 
DHA and EPA supplementation (7g per day) in 
volunteers resulted in reduction of mRNA coding for 
PDGF-A and –B. 
Kaminski et al., 1993; 
Baumann et al., 1999; 
Galiano et al., 2004 
MCP-1 Increases correlated with obesity and increased 
BMI 
DHA and EPA supplementation (7g/day) reduced 
mRNA coding for MCP-1 in unstimulated 
mononuclear cells ex vivo by 40%. This effect of 
EPA/DHA may be linked to a decrease in activation 
of NF-κB. 
Baumann et al., 1999; 
Kim et al., 2006 
CRP Increased levels associated with development 
of diabetes mellitus 
An inverse relationship between EPA and DHA 
intake and levels of CRP was shown in an 
epidemiological study.  Inverse relationship between 
plasma n-3 LCPUFA levels and CRP.  Production 
reduced by statins. 
Pradhan et al., 2001; 
Pischon et al., 2003; 
Mori & Beilin, 2004; 
Micallef et al., 2009; 
Spite & Serhan, 2010 
Table 1.4     Factors affecting expression of pro-inflammatory cytokines and markers 
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Cytokine Factors increasing levels Factors decreasing Reference 
IL-10 Low levels of IL-10, (a potent anti-
inflammatory cytokine) are associated with 
low levels of DHA  
Daily administration of 3.4 g EPA & DHA to heart transplant 
patients resulted in a decrease in IL-10, although a 
supplementation study in healthy volunteers failed to show any 
change in IL-10 levels in stimulated or unstimulated 
mononuclear cells ex vivo. 
Ferrucci et al., 2006; 
Hamer, 2007 
Endothelial activation molecules   
VCAM-1 Production enhanced by pro-inflammatory 
cytokines TNF-α, IFN and IL-6 
In vitro & animal studies have demonstrated reductions in 
plasma levels of sVCAM, sICAM and sE-selectin in the 
presence of n-3 FAs. In vivo results in humans have so far 
produced mixed results: this may be due to disparities in the 
precise conditions and doses used. 
von Schacky, 2007; 
Zhang et al., 2011 
 
ICAM-1 
E-selectin 
Lipoxins Generated from ArA; production may be 
triggered by aspirin, production may be 
promoted by statins 
May be inhibited by selective COX-2 inhibitors Spite & Serhan, 2010 
Resolvins Generated from EPA or DHA by enzymatic 
modification:  production may be triggered 
by aspirin 
Counter-regulate excessive acute inflammation:  stimulate 
molecular and cellular events that define resolution of 
inflammatory processes 
Protectins Generated from DHA  
Maresins Generated from DHA in macrophages  
Table 1.5    Factors influencing expression of cytokines with a role in reducing or resolving inflammatory processes
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There is at present no internationally accepted recommendation for fat or cholesterol 
intake. A recent review (Aranceta & Perez-Rodrigo, 2012) included reports of 
recommendations for intake of n-3 and n-6 FAs, summarised in Table 1.6.  To date 
there has been little formal recommendation regarding intake of individual PUFAs. 
Informal recommendations for n-3 intake in the UK range up to 1.4 g per day (British 
Nutrition Foundation, 2006) for adults, with a consensus that 0.2 g per day is a 
minimum health requirement (Calder, 2004).  Specific recommendations for mitigation 
of cardiovascular risk are discussed later in this chapter. 
 PUFA n-6 n-3 ALA EPA DHA EPA 
+DHA 
FAO/WHO 
2008 
6-11% 
energy 
2.5-9% 
energy 
0.5-2% 
energy 
 None None 0.25-
2g/day 
UK COMA 
1991 
6% 
energy 
1% energy none 0.2% 
energy 
None none 450mg/2 
servings 
fish 
weekly 
USA AHA 
2006, 2009 
5-10% 
energy 
5-10% 
energy 
none None None None 0.5-
1g/day or 
2 portions 
of fatty 
fish a 
week 
Australia/NZ 6-8% 
energy 
13 g/day for 
males, 
8 g/day for 
females 
increase Males 
1.3g/day, 
Females 
0.8 g/day 
None none Males: 
160mg/d, 
Females: 
90mg/day 
ISSFAL 2% 
energy 
none none 0.7% 
energy 
None 200-
300 
mg/day 
None 
Table 1.6     Recommendations for n-3 PUFA and n-6 PUFA intake  
The role of LCPUFA at all stages of life has been extensively reviewed.  In relation to 
pregnancy and the potential effects on neonatal health, a recent meta-analysis of 15 
randomised controlled trials (Imhoff-Kunsch et al., 2012) reported that n-3 LCPUFA 
supplementation in pregnancy is associated with a reduced rate of premature labour, 
but there is no clear association with birthweight or the immediate health of the 
neonate.  The predominant emphasis of research into the nutritional effects of n-3 
LCPUFA in infants and young children has been associated with issues of visual and 
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cognitive development or reduction of allergic disease (Ciccone et al., 2013). It has 
been suggested that n-3 LCPUFA could be an important factor in reducing 
cardiovascular risk factors in children and thus in the prevention of CVD later in life 
(Miles & Calder, 2013). Improvements in indices of CVD risk have been demonstrated 
in studies combining exercise and diet including n-3 LCPUFA; it has been suggested 
that the effects of n-3 LCPUFA and exercise could be synergistic (Carpentier et al., 
2006; Hill et al., 2007). 
Maintenance of good health into old age has been attributed to genetic as well as to 
lifestyle and dietary factors (Haveman-Nies et al., 2003).   Degenerative diseases 
associated with ageing have come to prominence in Western society with the dramatic 
extension of life expectancy during the 20th century.  An inflammatory component is 
recognised in the majority of these including CVD (Gustafson, 2010; Libby, 2012); n-3 
FAs are believed to have a role in ameliorating susceptibility and progression across 
the spectrum (Simopoulos, 2008; Loef & Walach, 2013).   The dramatic increase in the 
incidence of cardiometabolic disease and identification of risk factors has become an 
important public health issue in many countries. 
 
1.3.  CARDIOMETABOLIC DISEASE 
 
Cardiometabolic disease describes the spectrum of conditions including obesity, 
metabolic syndrome (MetS), pre-diabetes, Type 2 diabetes (T2D) and cardiovascular 
disease (CVD) (Despres et al., 2008).  The global epidemic of overweight and obesity 
has been identified as a major public health challenge, with estimates of 1.5 billion 
overweight and obese adults worldwide, and 68% of US adults and 31% of US children 
and adolescents overweight or obese in 2011 (Golub et al., 2011).  Obesity has serious 
health consequences, including increased risk of T2D and CVD (Reaven, 2011).  The 
mechanism of progression from obesity to dyslipidaemia, MetS and thence CVD has 
been extensively reviewed; risk factors and patterns of phenotype associated with 
increased CVD risk are now well understood.    
 
1.3.1.  Metabolic Syndrome 
 
MetS is characterised by a number of strongly inter-related risk factors for CVD, 
including obesity, dyslipidaemia, insulin resistance (IR) and hypertension.  IR occurs 
when adipose, liver and muscle cells do not respond appropriately to insulin, resulting 
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in a failure to process circulating glucose (Huang, 2009).  Risk factors for development 
of MetS and CVD are evident from gestation onwards. Impaired foetal growth is 
associated with an increased risk of later metabolic disease, while accelerated growth 
in the postnatal period and ongoing increased energy intake result in reduced insulin 
sensitivity (Cottrell & Ozanne, 2008). Obesity in childhood is a risk factor for 
development of MetS, as shown in a systematic review of 378 studies published 
between 2003 and 2013 (Friend et al., 2013).  Overall prevalence of MetS was 
reported at 3.3%, increasing in overweight and obese populations to 11.9% and 29.2% 
respectively.  The criteria for diagnosis of MetS in children have been inconsistent, so 
that trends in prevalence over time were not clear; notwithstanding this, central obesity 
at the age of 9-10 years is a risk factor for MetS in early adulthood (Morrison et al., 
2008).  Incidence of MetS was approximately 3-fold higher in women with previous 
gestational diabetes than in a control group (Lauenborg et al., 2005), with obesity an 
additional risk factor.  
Genetic factors and ethnicity contribute to a predisposition to MetS: a genome-wide 
association study of genetic determinants of lipid metabolism in over 17000 individuals 
(Waterworth et al., 2010) identified 4 novel loci associated with circulating lipids, 
including low and high density lipoprotein-cholesterol (LDL-C and HDL-C) and 
circulating TAG.   MetS affects a higher proportion of the South Asian population 
(approximately 30% compared with approximately 20% for European or African-
Caribbean groups) (Tillin et al., 2005).   Low dietary intakes of n-3 LCPUFA may be a 
contributing factor: some intervention studies have resulted in strong recommendations 
for increased n-3 PUFA in the diet of South Asians in Britain (Lovegrove, 2007).   Other 
lifestyle factors including smoking and physical inactivity are reported to increase the 
odds ratio of MetS  (Park et al., 2003). The impact of diet on obesity and hence MetS is 
multifactorial and is addressed in Section 1.4. 
Prevention and mitigation of MetS and sequelae is approached by medication and/or 
lifestyle changes. A series of recommendations for screening, diagnosis and 
management of the spectrum of cardiometabolic diseases has recently been published 
(Anderson et al., 2013; Ryden et al., 2014). An alternative and possibly controversial 
view (Kraushaar & Kramer, 2009) is that widespread screening is inefficient and costly 
in acute care consequences, and that encouraging engagement in population-wide 
lifestyle and diet modification programmes would be a preferable and more affordable 
public health strategy. The effectiveness of lifestyle interventions has been positively 
reported (reviewed in the ECS/EASD taskforce and others). 
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1.3.1.1. Definition of metabolic syndrome (MetS) 
The definition of MetS arose from the recognition of a cluster of risk factors for T2D and 
CVD. Laws and Reaven (1993) initially studied a small group of non-diabetic, 
overweight, sedentary men and observed that although there was little difference in 
BMI, waist/hip ratio or physical endurance capacity, those with higher steady-state 
plasma glucose levels also showed higher fasting insulin and TAG, and lower fasting 
HDL-C.   They suggested that IR affects the modulation of plasma insulin, TAG and 
HDL-C, independent of overall obesity or general physical fitness.   
Characteristic findings in MetS include increased anthropometric measures (waist, 
weight, BMI), blood pressure and changes in plasma TAG and lipoproteins.  
Comparison of definitions of IR or MetS highlighted variation in the criteria used and 
also the relative complexity of some of the measures (Grundy et al., 2004a; 2004b).    
The International Diabetes Federation, recognising the need for a simple diagnostic 
tool convenient to use in clinical practice, and which would enable comparisons 
between data from different countries, proposed a definition of MetS requiring 
increased central obesity according to waist measurement, with two additional criteria 
(Alberti et al., 2006).   This was subsequently adopted as the standard definition for 
MetS (Alberti et al., 2009), recognising that central obesity as defined by waist 
measurement varies between ethnic groups. Criteria compared by the American Heart 
Association (Grundy et al., 2004a; 2004b), with the IDF definition of MetS, are 
summarised in Table 1.7.  
 
 
 
 
 
 
 
 
 
 31 
 
Table 1.7     Alternative criteria for diagnosis of metabolic syndrome (MetS) 
 
 
 ATPIII WHO CRITERIA AACE IDF (2009) 
Insulin resistance - Yes, plus two 
of the 
following: 
- - 
Abdominal obesity 
(waist 
circumference) 
Men:  >102cm 
Women:  >88cm 
- - Men: ≥94cm 
Women: 
≥80cm 
(European) 
plus 2 of the 
following: 
BMI - >30 kg/m
2
 ≥ 25 kg/m
2
 - 
Waist/hip ratio - Men: >0.9 
Women >0.85 
- - 
TAG ≥ 1.7 mmol/L ≥ 1.7 mmol/L ≥ 1.7 mmol/L ≥ 1.7 mmol/L 
HDL-C Men: <1.04 
mmol/L 
Women: < 1.30 
mmol/L 
< 0.9 mmol/L 
<1.0 mmol/L 
Men: <1.04 
mmol/L 
Women: < 1.30 
mmol/L 
<1.0 mmol/L 
 
< 1.3 mmol/L 
Blood pressure  
Systolic 
Diastolic 
 
≥ 130 mm Hg 
≥85 mm Hg 
 
≥ 140 mm Hg 
≥ 90 mm Hg 
 
≥ 130 mm Hg 
≥ 85 mm Hg 
 
≥ 130mm Hg 
≥ 85 mm Hg 
Fasting glucose ≥ 6.1 mmol/L ≥ 6.1 mmol/L 6.1- 6.9 mmol/L ≥ 5.6 mmol/L 
(100mg/dL) 
2-hour post 
glucose challenge 
- - >7.8 mmol/L - 
Urinary albumin 
excretion 
- ≥ 20 ug/min, - - 
Albumin:creatinine 
ratio 
- ≥ 3.4 mg/mmol - - 
Other risk factors - - May include 
family history, 
ethnicity 
- 
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1.3.2. Type 2 Diabetes  
 
The development of T2D often follows from MetS; estimated worldwide diabetes 
prevalence in 2011 was 366 million, projected to rise to 552 million by 2030 (Whiting et 
al., 2011).   Recent estimates for the United Kingdom indicated the frequency of 
diabetes to be greater than 5%, of whom the majority are Type 2: the number of 
diagnosed diabetics rose from 1.4 million to 2.9 million between 1996 and 2012, and is 
expected to reach 5 million by 2025.  It is believed that there may be as many as 
850,000 undiagnosed diabetics in the UK at the present time (information from 
www.diabetes.org.uk, September 2013).  The health economic implications of providing 
care for the increasing numbers of diabetic individuals are significant, as well as 
indirect costs to the national economy from supporting people unable to work 
productively (Hex et al. (2012):  these are summarised in Table 1.8.   
 2010/2011 2035/2036 
Direct costs £9.8bn £16.9bn 
Type 1 £1bn £1.8bn 
Type 2 £8.8bn £15.1bn 
Indirect costs £13.9bn £22.9bn 
Type 1 £0.9bn £2.4bn 
Type 2 £13bn £20.5bn 
Percentage of health 
expenditure 
10% 17% 
Table 1.8    Costs of diabetes to the UK healthcare economy 
 
The major complications of diabetes and associated healthcare costs arise from 
disturbances in lipid and glucose metabolism; these result in overproduction of reactive 
oxygen species, disruption of endothelial cell function and inflammation, manifesting in 
diabetic vascular disease. Microvascular complications include retinopathy leading to 
blindness, nephropathy (with associated kidney dysfunction and failure) and the 
potential of amputation resulting from decreased blood supply to major limbs.  
Macrovascular complications cover the range of cardiovascular problems including 
myocardial infarction (MI) and stroke (Paneni et al., 2013). 
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1.3.3. Cardiovascular disease (CVD) 
 
CVD and cancer are major causes of death worldwide; CVD, including MI and stroke, 
was in 2005 reported to be responsible for 3 out of 10 deaths (WHO report, 2013). As 
described above for T2D, the health economic costs of CVD are considerable.  Recent 
figures of CVD incidence and related costs for the UK (Coronary Heart disease 
Statistics, www.bhf.org.uk) are shown in Table 1.9. 
Coronary heart disease Reported numbers 
Deaths in 2010 180,000 
Prescriptions in 2011 292 million 
People living with CHD 2.3 million 
Heart attacks in 2012 103,000 
Incidence of stroke in 2012 152,000 
Cost to UK health economy £9 bn 
Hospital costs (64%)  £5.76bn 
Medication (23%) £2.07 bn 
Table 1.9:  Reported statistics for CHD in the UK (www.bhf.org.uk, 2012) 
1.3.4. Pathogenesis of MetS, T2D and CVD  
 
The mechanism by which obesity and MetS lead to T2D is via dysregulation of plasma 
lipoproteins:  increased levels of free FAs promote fat deposition and lipotoxicity in 
muscle, liver and pancreatic β-cells (Cusi, 2010; Donath & Shoelson, 2011).  The 
accumulation of cholesterol in β-cells causes disruption of glucose metabolism and 
reduces insulin secretion, thus potentially leading to a diabetic phenotype (Fryirs et al., 
2009).  Cholesterol is important in regulating β -cell membrane organisation:  the 
balance between lipoprotein classes and concomitant effect on cholesterol transport 
may be important in determining β -cell function and survival (Rothblat & Phillips, 2010).  
Lipid dysregulation in MetS is augmented by the presence of large numbers of small, 
dense, low-density lipoprotein particles (sdLDL) (Subramanian & Chait, 2012); in 
combination with raised serum TAG and low concentrations of HDL-C, this has been 
called the ‘atherogenic lipoprotein phenotype’ (Austin, 1991) or ‘atherogenic lipid triad’  
(Toth, 2005). These small particles may be more atherogenic than larger, more 
buoyant particles:  it appears that they are less easily cleared by the LDL receptor and 
are more susceptible to oxidation and scavenging by macrophages (Toth, 2013). 
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1.3.4.1. Role of lipoproteins in CVD 
Lipoproteins are complex aggregates of lipids and proteins, synthesised mainly in the 
liver and intestines, that enable lipids to be transported through the body. Once in the 
circulation, they are continually changing in structure and composition as they deliver 
lipid components (TAG, cholesterol, cholesterol esters and PLs) to tissues or return to 
the liver for removal those components that are not required.  The principal PL 
component of all lipoproteins is phosphatidylcholine (PC) (Cole et al., 2012).   The key 
protein components, the apolipoproteins, determine overall structure and metabolism 
of lipoprotein aggregates, although the presence of other ‘associated proteins’ has also 
been identified. It is common to use a classification based on the methods of 
separating lipoprotein classes or subclasses by size and density.   Generally speaking, 
lower density particles contain a higher proportion of TAG and a lower proportion of PL.   
The main groups are: 
 Chylomicrons (CM) 
 Very low density lipoproteins (VLDL)   
 Low density lipoproteins (LDL)  
 High density lipoproteins (HDL)    
The identification of subclasses within the low density lipoproteins is well established 
(Davies et al., 2003), while the use of computational biology techniques have allowed 
the identification of many distinct apolipoprotein and associated protein species within 
these groups:  for example, there are now known to be at least 53 proteins in HDL 
particles (Davidsson et al., 2010).   Although lipoproteins were previously believed to 
be microemulsions with a central core of non-polar lipids (TAG and cholesterol esters) 
surrounded by polar lipids and apolipoproteins, recent advances in modelling have 
suggested that a significant proportion of TAG may also be located near the surface in 
small HDL subclasses (Kumpula et al., 2008).   
Simplistically, the role of chylomicrons and VLDL is to transport TAG from the liver and 
intestines to peripheral tissues for energy production, synthesis into cell membranes or 
as precursors of signalling molecules, and cholesterol for cell membrane synthesis.  
The functions of HDL are in the removal of excess cholesterol, transportation to the 
liver for processing and excretion as bile acids or recirculation, in the transfer of TAG 
between lipoprotein classes and the removal of VLDL and chylomicron particles that 
are no longer needed (Hodson et al., 2008).  Proteins in HDL aggregates have 
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important anti-inflammatory functions, limiting the effects of the pro-inflammatory 
cytokines in CVD (Brown, 2007).   Some of the key components of lipoprotein 
aggregates and known associations with CVD risk (Krauss, 2010) are summarised in 
Table 1.10.  
The major protein component of lipoproteins, the apolipoproteins, are simple 
polypeptides with little tertiary structure, whose functions are to solubilise non-polar 
lipids for transport in the circulation, and to recognise specific cell receptors.  ApoA1 
and ApoA2 are the main HDL apolipoproteins; with ApoC, these are found in all 
lipoprotein classes (Davidsson et al., 2010).  ApoE is mainly present in lipoproteins 
delivered from the liver; in addition to lipid homeostasis it is believed to have some 
functions on immune response and inflammation. All the apolipoproteins in HDL 
particles are exchangeable: the particles are subject to continuous remodelling and 
lipid and apolipoprotein exchange with other circulating lipoproteins and tissues.     
ApoB100 is present in VLDL, IDL and LDL, while ApoB48 is present in chylomicrons 
and TAG-rich particles:  these are considered to be ‘non-exchangeable’, meaning that 
the lipid component is not exchanged until the lipoproteins are eventually removed 
from circulation.  In addition to apolipoproteins, lipoproteins contain important enzymes, 
transport and anti-oxidative/anti-inflammatory proteins (Chait et al., 2005; Podrez, 
2010). 
A relationship between the levels of lipoprotein subclasses and risk of CVD has been 
the subject of extensive research, although lack of standardisation between analytical 
methods has complicated this (Krauss, 2010).   Despite this, there is a strong 
association between LDL levels and the risk of coronary heart disease, although less 
so for stroke (Helfand et al., 2009).   
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 Key role Key components Association with CVD Reference 
Chylomicron 
(CM) 
Transport of TAG and cholesterol from liver and 
intestines to peripheral tissues and cell 
membranes 
ApoB48  Davidsson et al., 2010 
Very low density 
lipoprotein 
(VLDL 
Transport of TAG and cholesterol from liver and 
intestines to peripheral tissues and cell 
membranes 
ApoB100, ApoB48 Increased hepatic production 
in T2D 
Krauss, 2010 
VLDL1  Large buoyant 
particles high in TG 
 
VLDL2    
Low density 
lipoprotein (LDL) 
 ApoB100, lipoprotein-
associated 
phospholipase A2  
ApoA1 reduced in T2D, 
ApoB100 and ApoCIII 
increased in T2D 
 
Small 
dense 
LDL 
(sdLDL) 
  Increased production in T2D 
associated with 
hypertriglyceridaemia 
Ip et al., 2009; 
Subramanian &Chait, 
2012 
IDL 
 
 
 ApoB100   
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 Key role Key components Association with CVD Reference 
High density 
lipoprotein 
(HDL) 
Removal of excess cholesterol to the liver, 
transfer of TAG between classes, removal of 
redundant VLDL and chylomicron particles 
Proteins with negative 
inflammatory effects 
ApoA1, ApoA2, ApoE 
Serum Amyloid A, 
serum phospholipase 
A2 
Clusterin (ApoJ) 
 
Limiting inflammatory effects in 
CVD.                                  
ApoE in HDL3 reduced by 
statin treatment             
ApoA1-containing HDL 
reduced in T2D and during 
inflammation 
Chait et al., 2005;    
Brown, 2007; Davidsson 
et al, 2010; Krauss, 2010 
Table 1.10   Key lipoproteins and associations with CVD risk
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1.3.4.2. Inflammatory processes in pathogenesis of CVD 
 
There is extensive evidence that atherosclerosis is primarily an inflammatory disease, 
with early infiltration by inflammatory cells and subsequent expression of inflammatory 
cytokines.  Proteins associated with lipoprotein and other non-associated inflammatory 
proteins (complement, fibrinogen, ferritin and caeruloplasmin) are believed to have 
atherogenic potential (Chait et al., 2005).  The key initiating step in atherosclerosis is 
the sub-endothelial accumulation of apoB-containing lipoprotein; this triggers an 
inflammatory response (which may be enhanced if the lipoproteins are oxidised), 
attracting monocytes to the endothelium. Activated endothelial cells secrete 
chemokines (including MCP and IL-8) that interact with monocyte receptors and 
promote migration. Fatty streaks, which are early atherosclerotic lesions, become the 
focus of a non-resolving inflammatory response involving the accumulation of cells, 
lipid and matrix in the subendothelial layer.   These may expand to form a necrotic core, 
which is the trigger for an acute vascular incident (MI, stroke or sudden cardiac death) 
(Moore & Tabas, 2011). 
The role of cytokines as pro-and anti-inflammatory regulators has been summarised in 
Tables 1.2 and 1.3 (Donath & Shoelson, 2011, McLaren et al., 2011).   There is clear 
evidence for the role of pro-inflammatory cytokines in the development of T2D and the 
development and persistence of atherosclerotic lesions and pathology.   Increased 
plasma concentrations of IL-6 and its hepatic degradation product CRP, are observed 
in acute MI and in unstable angina, often associated with a poor prognosis in coronary 
artery disease (Tousoulis et al., 2007); correlation with ischaemic stroke is less reliable. 
 
1.4. DIET & n-3 LCPUFA IN PREVENTION OF CARDIOVASCULAR DISEASE 
 
Given the association between obesity and development of MetS and CVD, it is 
reasonable to infer the relevance of lifestyle factors, including diet and physical 
exercise.   Many adults and children in the western world engage in less physical 
activity than their predecessors, while easy accessibility of convenient food and 
changes in eating patterns encourage higher than necessary consumption 
(Simopoulos, 2008). An additional question is whether the type of food consumed may 
exacerbate or mitigate disease risk (Cho et al., 2013, van Dam et al., 2013, Mirrahimi 
et al., 2014).  
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High levels of fat in the diet may significantly increase the severity of a heart attack, but 
the type of fat in the diet may also be important.   Avoidance of both saturated fat  
(SFA) and trans-fatty acids (TFA) has been widely recommended, although in a recent 
meta-analysis Hoenselaar (2012) has questioned the basis of the recommendations in 
respect of SFA. Dietary SFA are associated with an increase in both LDL-C and HDL-C, 
and the research on which much of the advice was based is open to interpretation.   
Sacks and Katan (2002) reviewed the merits of replacing saturated fat with 
carbohydrate, monounsaturated or polyunsaturated fat, and deduced that LDL-C is 
decreased by all three substitutions, with the relative effect 
carbohydrate<MUFA<PUFA; unsaturated fat decreased LDL-C more than HDL-C, 
resulting in an overall reduction in the LDL-C/HDL-C ratio.   A multi-ethnic study of SFA 
intake (de Oliveira Otto et al., 2012) concluded that SFA per se may not be as 
important in predicting cardiovascular risk as the source of the fat, with dairy products 
associated with lower risk than red meat.  The evidence in respect of TFA suggests 
that those derived from industrial hydrogenation processes pose a higher CVD risk 
than those occurring naturally in ruminant-derived foods, especially grass-fed animals 
(Bendsen et al., 2011; McAfee et al., 2010).    
The investigations described in Chapters 3 and 4 of this thesis are focussed on two 
dietary components, n-3 LCPUFA and cholesterol.  Cholesterol build-up in arteries has 
been shown to be a risk factor for CVD (as described in Section 1.3) but it is not clear 
whether dietary cholesterol may directly contribute to this. An understanding of the 
importance of n-3 FA in development, membrane structure and in cell signalling has 
given rise to speculation and accumulation of evidence regarding benefits in reducing 
cardiometabolic risk, including whether one food source of n-3 FA may be more 
beneficial than another.  
 
1.4.1. Dietary cholesterol 
 
Reduction of CVD risk has been attributed in part to reduction of plasma cholesterol.  
Cholesterol is an essential component of cell membranes and a necessary precursor 
for steroid synthesis; it is not an essential nutrient, since adults and children over 2 
years of age are capable of sufficient production in the liver to satisfy normal 
requirements.   The potential of dietary cholesterol in increasing CVD risk is not clear.  
It has been reported that a Western-type diet is associated with a higher CVD risk than 
a Mediterranean-type diet (Estruch et al., 2013b).  Although such a diet has been 
variously defined, one consistent aspect is that it is lower in dietary cholesterol than a 
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Western-type diet (Djousse & Gaziano, 2009).  Cholesterol in the diet is often 
associated with other potentially atherogenic components which may be found in red 
meat, poultry, and dairy products, (although also with fish and shellfish) and the 
distinction between the relative risk of the various components is not clear:  additionally, 
genetic factors may influence cholesterol absorption and synthesis; studies of statins 
have identified variability in response due to differences in absorption and in vivo 
synthesis (Lecerf & de Lorgeril, 2011). The role of ApoE genes in modulating 
lipoprotein metabolism is also of interest; carriers of the ApoE4 gene are most 
responsive to impact of fat and cholesterol intake (Minihane, 2013).  Dietary guidelines 
for adults in the USA (The National Cholesterol Education Program Adult Treatment 
Panel III) (2005) recommended that daily cholesterol intake should not exceed 300 
mg/day for healthy adults, and 200 mg/day for those with elevated LDL cholesterol.   
There are no comparable guidelines in the UK or Europe.  
Evidence for a specific link between dietary cholesterol and CVD risk has been limited 
and inconsistent.   Studies where a link has been reported (Puddu et al., 2011, Sakurai 
et al., 2011) have not eliminated possible contributions from confounding factors 
(Djousse & Gaziano, 2009), while in other large studies of CVD risk factors, no 
association was found after adjustment of possible confounding factors including other 
dietary components (Kanter et al., 2012).   A review of dietary intake and CVD risk (MI, 
coronary death, or stroke) in adults between 70 and 79 years of age (Houston et al., 
2011) found an increased risk of CVD correlated with dietary cholesterol or egg intake, 
but further analysis suggested that this applied only to those with T2D.  A study of 
34,670 women in Sweden over a 10-year period (Larsson et al., 2012) reported a 
positive association between dietary cholesterol from reported intake and risk of stroke 
(RR = 1.2).  Overall it appears that while there may be some individuals (up to a 
quarter) in whom dietary cholesterol may increase LDL-C, HDL-C is also increased, so 
that the LDL/HDL ratio is maintained at a fairly constant level with little attendant 
increase in CVD risk (Fernandez, 2012). 
 
1.4.2. n-3 LCPUFA 
 
A major emphasis in nutrition research has been on the relative role of PUFAs, in 
particular the potential mitigation of disease risk by n-3 LCPUFA.  Some of the 
evidence in this respect is presented below. 
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1.4.2.1. Reviews  
  
Harris (1996) performed a meta-analysis on seventeen intervention studies; FO was 
shown to reduce plasma TAG and increase LDL-C but have little effect on HDL-C 
(Harris, 1996).   Comparison of later studies (Kelley et al., 2007) suggested that the 
effects of DHA alone on plasma LDL-C and HDL-C and LDL particle diameter are less 
clear-cut, with some studies showing an increase in both, while others have failed to 
demonstrate any change.  Rizos et al. (2012) reviewed 20 publications (selected from 
3635 citations) covering 6860 participants and reported no statistically significant 
correlation between n-3 LCPUFA supplementation and risk of mortality from sudden 
cardiac death, MI or stroke.  However, another meta-analysis in the same year 
(Chowdhury et al., 2012) showed a reduced risk of cardiovascular disease (RR 0.94) in 
individuals eating 2-4 servings of fish weekly.  Benefits were less significant in 
individuals taking FO supplements, which raises the question as to whether nutrients in 
fish besides the n-3 LCPUFA may be providing additional benefits. 
A review of 21 randomised controlled trials reported that FO intake (Balk et al., 2006; 
Wang et al., 2006) may reduce TAG (0.31 mmol/L), increase HDL-C (0.04 mmol/L) and 
LDL-C (0.16 mmol/L):  ranges of n-3 LCPUFA in the studies reviewed were between 
0.045 and 5 g per day, but a beneficial TAG reduction was noted at an intake of 0.9 g 
per day.   Based on another review of 4 major trials covering 40,000 participants a 
recommendation was made for target EPA plus DHA consumption of 500 mg/day for 
individuals without underlying overt CV disease and 800 mg/day for individuals with 
known coronary heart disease and heart failure (Lavie et al., 2009). 
1.4.2.2. Individual studies of intake and intervention 
There is extensive data from intervention and food intake studies with n-3 LCPUFA 
over at least the past 30 years, including comparisons of the relative importance of 
DHA and EPA and total intakes.   Oils enriched with EPA or DHA are reported to be 
comparable in respect of TAG reduction (Mori & Beilin, 2001). The DART (Harris, 
2007) and GISSI intervention trials (Marchioli et al., 2007) reported that dietary intake 
of between 0.3 and 1 g per day of n-3 LCPUFA for 3 months or more showed a 
correlation with reduced mortality from CVD, particularly in individuals who had already 
experienced one MI.  
The Japan EPA Lipid Intervention Study (JELIS) (Yokoyama et al., 2007) followed 
5,859 men between 40 and 75 and 12,786 postmenopausal women up to 75 years of 
age for an average of 4.6 years, randomised to treatment with statins alone or statins 
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with EPA (600mg as ethyl ester daily).   This group reported an improvement in the 
incidence of cardiac events, although a less significant reduction in sudden cardiac 
death than the GISSI study, an observation attributed to the cardioprotective effect of 
the higher baseline fish consumption in the Japanese study.  In a smaller study, EPA 
supplementation (1.8g/day as ethyl ester) was shown to reduce the progression of 
atherosclerosis in T2D (Mita et al., 2007).  Thies et al. (2003) reported that an intake of 
2g per day EPA and DHA resulted in a 25-30% reduction in fasting TAG, while 1.4 g 
EPA plus DHA per day resulted in increased incorporation and improved stability of 
atherosclerotic plaques. A detailed study of the effects of DHA supplementation (3g 
DHA per day) (Kelley et al., 2007) showed: 
 Reduction in:  fasting TAG, concentration of large VLDL (including apoCIII) 
and IDL particles, mean diameter of VLDL particles and TAG:HDL ratio. 
 Increase in:  fasting LDL-C, LDL-C/HDL-C, HDL-C/ApoA1, LDL-C/ApoB, 
concentration of sVLDL, large LDL and HDL particles and in the mean 
diameter of LDL particles. 
 Postprandial decrease in TAG, IDL, sLDL, large VDL and sHDL 
 Postprandial increase of large LDL, HDL and sVLDL 
 No change in fasting or postprandial total and HDL-C 
 LDL-C increased in fasting but not post-prandial plasma. 
Maximum effects were observed within 45 days from the start of the study and 
maintained for the next 45 days except for heart rate, which decreased by 8.3% at 45 
days and by 5% at 91 days.   Overall, DHA intake was correlated with a reduction in 
atherogenic lipids and lipoproteins and an increase in cardioprotective proteins, 
particularly ApoCIII. 
The OPTILIP study  (Griffin et al., 2006, Sanders et al., 2006; Griffin, 2008) aimed to 
optimise the n-6:n-3 intake ratio by dietary changes in a cohort of men and post-
menopausal women between 45 and 70, an age range that typically has an increased 
risk of CVD; 28% of the participants fell within the definition of MetS. This group looked 
for associated changes in IR, plasma lipoproteins and indices of clotting function 
(fibrinogen, factors VII and XII); they found that reduction of the n6:n3 ratio from a 
baseline ratio of 6.7-8.3 to 2.2-2.3 by increasing n-3 PUFA intake (but not merely by 
changing the ratio of precursor LA and ALA) was associated with beneficial decreases 
in basal and post-prandial plasma TAG, and improvement in the profile of lipoprotein 
particle size.  However, there was no significant effect on insulin sensitivity or clotting 
function. This was proposed by the authors to be the maximum effect on n-6:n-3 ratios 
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that can be achieved by dietary management.     Later work has suggested that it may 
be the total n-3 intake rather than the n-6:n-3 ratio that is important in modulation of 
CVD risk (Lovegrove & Griffin, 2011, Griffin, 2012).   
A survey comparing consumption of n-3 LCPUFAs with other dietary variables for 1441 
individuals on the Diabetic Control and Complications (DCTT) database (Cundiff et al., 
2007) was interpreted as showing that the benefits of n-3 LCPUFA may be due to a 
strong correlation between higher fish/fish oil intakes and an overall healthier dietary 
pattern.   
 
1.4.3. Recommendations of n-3 LCPUFA intake for cardioprotection 
 
Consumption of EPA and DHA is now widely recommended by international authorities 
and national cardiac societies (von Schacky & Harris, 2007) to prevent cardiovascular 
incidents, for treatment after MI and prevention of sudden death and secondary 
disease.  The American Heart Association recommends a daily intake of 2-4 g EPA 
plus DHA for patients with high TAG, which is predicted to reduce plasma TAG by 20-
40%. The National Institute for Clinical Excellence (UK) (2012) recommended lifestyle 
changes for patients following MI, including dietary intake of 7 g of n-3 LCPUFA per 
week from oily fish, or at least 1 g daily of n-3 PUFAs as ethyl esters if the former is not 
achievable.   These recommendations were based on a wide portfolio of literature 
describing mechanisms of actions, animal models, and also large intervention trials, 
although an earlier Cochrane analysis of available data (Hooper et al., 2006) showed a 
null result. 
 
1.4.4.   Mechanism of action of n-3 LCPUFA 
 
It is reported that n-3 LCPUFAs act as mediators of the nuclear events governing 
specific gene expression in lipid and glucose metabolism and adipogenesis  
(Lombardo and Chicco, 2006).   Regulation of several transcription factors related to 
TAG or lipoprotein metabolism is observed following FO supplementation. Increased 
expression of antioxidative enzymes was also reported in both normo- and 
dyslipidaemic men, and decreased expression of pro-oxidative enzymes (P450 
enzymes and matrix metalloproteinases). In an extension of this study it was suggested 
that there was evidence for differences between normolipidaemic and dyslipidaemic 
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men in gene expression following FO supplementation (Schmidt et al., 2012a; 2012b; 
2012c).    Possible routes by which EPA and DHA may reduce CVD risk include: 
1.4.4.1. Antiarrhythmic effect  
Sudden cardiac deaths associated with fatal arrhythmia are a frequent cause of death 
in industrialised societies, with up to 80% of sudden deaths due to ventricular fibrillation, 
and only a small effect on mortality due to use of anti-arrhythmic drugs. Studies of n-3 
supplementation have suggested a beneficial reduction in tachycardia and ventricular 
fibrillation, attributed to changes in cell membrane composition (Leaf et al., 2005, Raitt 
et al., 2005).  A recent review of clinical endpoint data reports a small, non-significant 
reduction in sudden cardiac death despite demonstration of biochemical changes 
which would be considered beneficial, most specifically reduction In plasma TAG 
(Khoueiry et al., 2013).  
1.4.4.2    Anti-thrombotic effect  
Increased availability of n-3 LCPUFAs results in a reduction in ArA in membrane PLs in 
platelets, endothelial cells and in heart muscle (Garg et al., 2006 Metcalf et al., 2007), 
which directly decreases the amount of this FA available for eicosanoid synthesis, so 
that the levels of the highly pro-aggregatory TXA2 are greatly reduced (Calder, 2004).      
EPA and DHA are reported to reduce levels of the pro-inflammatory cytokines IL-1ß, 
IL-6 and TNFα, and reduce the mRNA levels in mononuclear cells of the pro-
atherosclerotic growth factors PDGF-A, PDGF-B and MCP-1. There is also some in 
vitro evidence for the effects of EPA and DHA in reducing levels of sICAM, sVCAM and 
sE-selectin, cytokines with a role in endothelial activation although a recent meta-
analysis of n-3 supplementation effects on soluble adhesion molecules reported 
reduction in plasma levels of sICAM-1 but not VCAM, p-selectin or E-selectin (Yang et 
al., 2012). 
 
1.5. SOURCES OF n-3 FATTY ACIDS 
 
The potential health benefits of n-3 LCPUFA have given rise to extensive commercial 
development with concomitant marketing publicity. Traditionally n-3 LCPUFAs were 
obtained from fish liver oil supplements such as cod liver oil as by-products of fish-meat 
harvesting.   It is now impossible to supply global consumer needs from the current 
global fish harvest, leading to a requirement for new sources, which could include 
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microalgae, krill oil, calamari oil and genetically engineered land plant crops 
(Ryckebosch et al., 2014). 
 
1.5.1. Relative efficacy of different n-3 LCPUFA sources 
 
Evidence from feeding studies in pigs indicates that the form in which n-3 or n-6 
LCPUFA are provided may influence their ultimate distribution in plasma lipoproteins 
(Amate et al., 2001), with PL-derived FAs partitioning to HDL rather than LDL 
lipoprotein.  It has been suggested that LCPUFA in PL form may be associated with 
benefits in infant feeding, with a reduction in necrotising enterocolitis and enhanced 
intestinal repair.  Sala-Vila et al. (2004), however, reported that the FA composition of 
plasma lipids did not vary according to the source of the FAs in formula-fed infants, and 
that bioavailability was comparable from PLs and TAG sources, although they did not 
fractionate out the lipoprotein subclasses to determine ultimate distribution.   Plant 
lecithins, which contain high concentrations of PC in addition to choline and betaine, 
are commonly used to improve emulsification of processed foods, but a nutritional role 
in mitigation of alcoholic liver disease (Lieber, 2004) and CVD risk (Sahebkar, 2013) 
has also been suggested.  
1.5.1.1. Triglycerides  
Fish oils  (FO) are the primary source of n-3 LCPUFA in TAG form, and the most 
extensively studied in respect of health benefits.  Fatty acid composition varies 
between species, but is also sex- and season- dependent.   A portion of fish may 
contain between 0.06 and 2.2 g n-3 PUFA (British Nutrition Foundation, 1999), and the 
relative proportions of EPA:DHA may range from 3:1 to 1:4 between species.     ‘White’ 
fish species such as cod, haddock and halibut concentrate oil in the liver, and the oil 
derived from these species also contains high natural levels of fat-soluble vitamins, 
whereas ‘oily’ fish, such as salmon and mackerel, have higher levels of oil in the flesh; 
oil from some species such as tuna is extracted from the eye sockets.   These oils are 
widely available in health food shops or pharmacies as either free bottled oils or in 
capsules (usually gelatine).  Industrial fermentation processes are used to manufacture 
oils rich in DHA, EPA and ArA from microalgae, which are also obtainable as food 
supplements, and are used in supplementation of infant formulae to achieve PUFA 
levels comparable with human breast milk. 
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1.5.1.2. Krill oil (KO) 
Krill (Euphausia superba), a small shrimp-like marine crustacean, forms the world’s 
largest animal biomass, and provides the major nutrient supply for the blue whale.    
Harvested krill contains about 15% high quality protein, with approximately 3% fat and 
minerals, which on a dry-weight basis is equivalent to 60-78% protein, and between 7-
26% fat; KO contains significant proportions of DHA and EPA, partly as TAG but with 
30-58% in the form of PL (PC, phosophatidylethanolamine and phosphatidylinositol) 
(Suzuki, 1981).  The other notable component of KO is the antioxidant astaxanthin 
(Figure 1.7), present with other antioxidants including vitamin E, Vitamin A and β-
carotene.  
 
 
Figure 1.7:  Structure of astaxanthin 
The composition of KO is dependent on factors including seasonal variation, location, 
sex, nutrient availability and condition (Savage & Foulds, 1987; Grantham, 1977; van 
Niewerburgh et al., 2005). Once harvested, krill deteriorate rapidly due to the release of 
visceral enzymes, and must be processed or deep frozen immediately to prevent 
compromise to quality (Suzuki, 1981; personal communication, O Hoestmaelingen & E 
Lied); the PUFAs are reported to be stable for only about 15 days, and astaxanthin is 
less stable.   Indeed, 48 hours is considered to be the maximum time that krill can be 
kept before the sensory characteristics deteriorate to an extent that makes it unfit for 
consumption (Kolokowska, 1988).  
Analysis of commercially available KO reveals wide variation in levels of PL, specific 
FAs and astaxanthin (Kusumoto et al., 2004; Fricke et al., 1984) (Table 1.11).  
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 Aquasource 
Neptune Enzymotec  
(2 products) 
Healthspan 
N-3 fatty acids, total 180 mg 300mg 190mg/300mg 240mg 
EPA  100 mg 150mg 90mg/150mg 140mg 
DHA 60 mg  90 mg 50mg/90mg 64mg 
Astaxanthin  0.2 mg 1.3mg 0.2mg/1.5mg 0.1mg 
PLs 100 mg  400mg 400mg/420 430mg 
Table 1.11:  Composition of krill oils (from Manufacturers’ data) 
Krill forms a critical link between plankton and higher forms of marine life in the 
Antarctic and elsewhere, and there are concerns regarding sustainability of the species, 
but with careful management it is thought to be capable of providing krill for human and 
animal nutrition while maintaining stocks adequate to support marine life (Bender, 
2006).   The fishery for Antarctic krill is the largest by tonnage in the Southern Ocean 
(Nicol et al., 2012). The annual catch remained relatively stable at around 120 000 
tonnes for 17 years until 2009, but has recently increased to more than 200 000 tonnes. 
This is well within the precautionary catch limits set by the Commission for the 
Conservation of Antarctic Marine Living Resources (8.6 million tonnes).  However, 
recent developments in harvesting technology and in product development (some 200 
patents in 2013 alone) indicate renewed interest in exploiting this resource.   
Environmental changes in the Southern Ocean are likely to affect both krill and the 
fishery.  
 
1.5.2. Comparison of FO and KO in relation to lipid metabolism  
1.5.2.1. Animal studies 
Possible effects and mechanisms of action of KO on lipid metabolism have been 
investigated in animal models. In rats fed with a diet enriched with 2.5% KO, KO 
inhibited hepatic lipid synthesis to a greater extent than FO, by reducing the expression 
of the mitochondrial tricarboxylate carrier (Ferramosca et al., 2012a; 2012b).   This was 
associated with a greater reduction in levels of hepatic TAG and cholesterol in KO-fed 
than in FO-fed animals, as well as reduction of plasma TAG and glucose, and a smaller 
increase in plasma insulin. A decrease in the mitochondrial citrate carrier and the 
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cytosolic acetyl-CoA carboxylase and FA synthetase enzymes were observed. 
Increased carnitine palmitoyl-transferase I activity and levels of carnitine were 
interpreted to indicate stimulation of hepatic FA oxidation. Animals supplemented with 
KO also maintained efficient mitochondrial oxidative phosphorylation, with less 
accretion of body weight, and less oxidative damage of lipids and proteins, than are 
often found in high-fat fed animals.   A similar study in mice transgenic for human TNFα 
(a model of chronic inflammation and poor lipid metabolism) investigated the effects of 
krill powder (6.4% lipids, 4.3% protein, w/w) on markers of lipid metabolism (Vigerust et 
al., 2013, Bjorndal et al., 2012), over a 6-week feeding period. Those mice receiving 
KO powder displayed lower hepatic and plasma TAG, with increased β-oxidation and 
reduced hepatic expression of genes involved in lipogenesis and glycerolipid synthesis.   
Plasma cholesterol, enzymes involved in cholesterol synthesis, and hepatic gene 
expression of SREBP2 were also reduced, as were genes involved in glycolysis and 
gluconeogenesis.   An anti-inflammatory effect was indicated by the reduction of 
endogenous hepatic TNFα. The inference from this data was that KO may have a 
greater potential than FO to promote lipid catabolism.   Comparison of TAG with PL in 
n-3 LCPUFA supplementation of corn-oil based high fat diets in C57BL/6J mice (9 
weeks) (Rossmeisl et al., 2012), reported that the PL was more effective than TAG in 
prevention of glucose intolerance and reduction of obesity.   Lipaemia and 
hepatosteatosis were also more effectively suppressed by dietary PLs. This was 
thought to correlate with better bioavailability of DHA and EPA, resulting in higher DHA 
accumulation in the liver, white adipose tissue, and muscle PLs; inflammation in white 
adipose tissue was also reduced.   
Finally, it has been suggested that there may be an association between elevated 
peripheral levels of endogenous ligands of cannabinoid receptors (endocannabinoids) 
and MetS.  Banni et al. (2011) reported more efficient downregulation of the 
endocannabinoid system by KO than by FO in tissues of obese zucker rats.   The same 
group (Piscitelli et al., 2011) investigated the dose-dependent effects of KO on 
metabolic parameters in high fat diet-fed mice, and measured levels of the 
endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG) in inguinal and 
epididymal adipose tissue liver, gastrocnemius muscle, kidneys and heart.      An eight-
week high-fat diet increased endocannabinoid levels in all tissues except the liver and 
epididymal adipose tissue:  KO reduced anandamide and/or 2-AG levels in all tissues 
studied except the liver, usually in a dose-dependent manner.  Levels of 
endocannabinoid precursors were also generally down-regulated.   
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1.5.2.2. Human studies  
An early comparison between KO and FO in humans was a small study to observe 
effects on symptoms of premenstrual syndrome and dysmenorrhoea (Sampalis et al., 
2003). The same group (Bunea et al., 2004) subsequently compared intake of KO at 2-
3 or 1-1.5 g per day with FO containing EPA and DHA for effects on hyperlipidaemia.  
They reported more effective reduction of total cholesterol (TC), TAG, LDL-C, HDL-C 
and glucose by KO than FO, and proposed that KO is an effective alternative n-3 
LCPUFA source for the management of hyperlipidaemia.   A subsequent comparison of 
KO and FO (menhaden) was carried out by Maki et al. (2009), with FO, KO and olive 
oil (control) supplementation at 2g per day for 4 weeks and measurements of plasma 
n-3 LCPUFA and indicators of safety, tolerability and CVD risk. Plasma EPA and DHA 
concentrations increased significantly more (p < 0.001) in the KO (178.4 ± 38.7 and 
90.2 ± 40.3 µmol/L, respectively) and FO groups (131.8 ± 28.0 and 149.9 ± 30.4 
µmol/L, respectively) than in the control group (2.9 ± 13.8 and -1.1 ± 32.4 µmol/L, 
respectively).  A reduction in systolic blood pressure was more significant (p < 0.05) in 
the FO (-2.2 ± 2.0 mm Hg) group than in the control group (3.3 ± 1.5 mm Hg); the effect 
of KO was between the other two groups and was not significantly different from either 
(-0.8 ± 1.4 mm Hg).   Apart from blood urea, which reduced slightly in the KO group 
compared with FO, there were no other significant differences for any other safety 
parameters. This study demonstrated comparable uptake of n-3 LCPUFA from KO and 
FO over 4 weeks, although with little difference in CVD risk markers.  
Ulven et al. (2011) compared KO and FO supplementation to evaluate effects on 
markers of oxidative stress and circulating n-3 LCPUFA levels.  113 adults with normal 
or slightly elevated TC and/or TAG were randomised into three groups; 1) 3g KO 
(543mg EPA/DHA) daily, 2) 1.8g FO daily (EPA plus DHA 864mg), and 3) no 
supplement.   After 7 weeks, similar increases in plasma EPA, DHA and DPA were 
seen in both supplemented groups, with no significant differences in markers of 
oxidative stress or oxidation between any groups.    This was taken to demonstrate that 
KO was as effective at two-thirds the concentration of DHA/EPA of FO in increasing   
n-3 LCPUFA uptake, possibly associated with a higher bioavailability of the KO n-3 
LCPUFA (being partly present as PL) compared with the TAG form of FAs in FO. Three 
EPA+DHA formulations derived from FO (re-esterified TAG [rTAG], ethyl-esters) and 
KO were compared for effects on their effects on fatty acid composition of plasma PLs 
(Schuchardt et al., 2011) over a period of 72 hours.   Single doses of 1680 mg EPA 
given as TAG, rTAG, ethyl ester or KO were taken by each of 12 young men (4 in each 
group).   Higher incorporation of n-3 LCPUFA was seen in those receiving KO, followed 
 50 
by FO TAG; lowest incorporation was seen from the ethyl ester preparation.  The KO in 
this study contained relatively high levels (about 22%) of the n-3 LCPUFA as free FAs:  
the possible effect of this is not known.  
More recently, Trepanowski et al. (2012) compared the effects of KO or coconut oil 
supplementation (2g/day) on 12 men and 27 women carrying out a 21-day Daniel fast.  
This is a highly restricted vegan diet in which participants avoid animal products, 
refined foods, white flour, preservatives, additives, sweeteners, flavourings, caffeine, 
and alcohol.  Although adherence to such a diet for 21 days has been demonstrated to 
improve blood pressure, LDL-C, and certain markers of oxidative stress, it has also 
been shown to lower HDL-C.   There was no measurable difference between KO and 
coconut oil in the effects on a range of markers of metabolic and CVD risk, although 
overall the effect of the Daniel Fast on a number of these markers was significant.   
The cohort of men and women showed wide initial variation in BMI, blood lipids, blood 
glucose and blood pressure, and it is not unreasonable to assume that in such a 
relatively small sample with such a high level of heterogeneity, subtle alterations in 
metabolism from KO supplementation might be obscured by the baseline ‘noise’ and 
changes in metabolic activity due to the change in diet.   Also, the study was only 
pursued for 3 weeks, which is not long enough to achieve maximum effect on lipid 
markers. 
Possible interactions of KO with the endocannabinoid system (ECS) have been 
investigated in human studies (Banni et al., 2011; Silvestri & Di Marzo, 2012; 2013). 
These investigators compared the changes in plasma endocannabinoids resulting from 
supplementation of 2 g/d of KO (309mg EPA/DHA in 2:1 ratio) or FO (menhaden)  (390 
mg EPA/DHA in 1:1 ratio) over a period of 4 weeks in obese and overweight subjects.  
The results showed increased levels of endocannabinoids in overweight and obese 
compared with normal weight subjects. KO (but not FO or olive oil control) decreased 
2-arachidonoylglycerol (2-AG) in obese but not overweight individuals. The decrease of 
2-AG was correlated to the plasma n-6:n-3 PL LCPUFA ratio. It is suggested that 
decreased 2-AG biosynthesis may be caused by the replacement of the ArA precursor 
by n-3 LCPUFAs.    
 
1.6. WORK DESCRIBED IN THIS THESIS 
 
The experimental work described in this thesis addresses two aspects of the 
application of n-3 LCPUFA in mitigation of CVD.   
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The first piece of work aimed to establish whether prawns, as a source of n-3 LCPUFA, 
but also rich in cholesterol, may be beneficial or harmful; the hypothesis for this was 
that daily ingestion of a standard weight of prawns would not confer any increased 
CVD risk compared with a similar weight of a control food (processed white fish meat).   
In addition to measurement of blood indices of CVD risk, food diaries were obtained 
from participants as a measure of compliance.  Recruitment and management of 
participants, and some of the biochemical measurements were carried out by 
colleagues at the University of Surrey; determination of lipid profiles, statistical analysis 
and interpretation of the food diaries was carried out by this investigator, as was the 
comparison of methods for measurement of sdLDL. 
In the second piece of work, the potential effects of KO and FO are compared for their 
effect on some indices of cardiovascular health.  The aim of this investigation was to 
determine whether krill oil (KO) may be more beneficial than fish oil (FO) in effect on 
indices of CVD risk; it was hypothesised that KO may be as beneficial as FO at a lower 
(2/3 w/w) daily dose.  Measurements of blood indices of CVD risk were undertaken, 
using both venous blood and a point-of-care capillary blood measurement system; food 
diaries were also completed to provide a measure of compliance. Recruitment and 
management of participants in this study (including food diaries and collection and 
preparation of blood samples) were carried out by this investigator, with assistance 
from colleagues at LJMU; the automated biochemical assays were carried out by 
Randox, Northern Ireland, and insulin assays by colleague Debbie Scott.  Interpretation 
and analysis of food diaries and all statistical analysis were carried out by the main 
investigator.     
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CHAPTER 2 
Materials And Methods 
 
2.1 . NUTRITION INTAKE STUDIES; CONDUCT OF INVESTIGATIONS 
 
Two nutrition intervention studies were carried out, a) to compare the effects of prawns  
(Pr) and a processed white fish foodstuff (OC) on lipoprotein and CVD markers, and   
b) to compare the effects of FO and KO on CVD risk markers.   A range of techniques 
was employed in these studies, and a brief explanation of application in similar studies 
is given where relevant. 
2.1.1. Recruitment of participants 
 
Participants for both studies were recruited by invitation from among volunteers 
responding to advertisement; the demographics of each group are described in 
subsequent chapters.  Recruitment, project information and all protocols were in 
conformity with the requirements of the Research Ethics Committee appropriate for the 
study in question (detailed in Chapter 3 and 4 respectively).   Volunteers were provided 
with information about the nature and purpose of the study in question and were 
screened for suitability before commencement of the relevant study, as described in 
Chapters 3  (Section 3.3.1) and 4 (section 4.2.1).   All results were anonymised and 
treated with the highest possible level of security and confidence.    
2.1.2. Preparation of plasma samples 
 
At each visit, blood samples were taken by standard venepuncture procedure using a 
vacutainer and anticoagulant tubes suitable for the specific subsequent investigations  
(EDTA, citrate or heparin) as indicated in the table below:  
 
Anticoagulant Assay 
Potassium-
EDTA 
Cholesterol, TAG, LDL-C, HDL-D, NEFA, Lipoprotein subclasses, plasma 
fatty acid profiles,  
Sodium citrate Glucose 
Lithium Heparin Insulin 
Table 2.1.  Anticoagulants and assays 
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For the KO/FO study, capillary samples of blood were also obtained and used for 
immediate measurement of lipid biochemistry markers using a cassette-based 
screening system (Cholestech LDX, Alere), as described in Section 2.2.2.1.   Plasma 
for other analyses was separated by centrifugation in a refrigerated benchtop 
centrifuge (2000 g for 15 minutes at 4oC), removed by Pasteur pipette into a cryovial, 
and stored at -80oC until all samples were available for batch analysis.     
 
2.2. MARKERS OF OBESITY, MetS AND CVD RISK 
 
2.2.1. Physiological measurements  
 
2.2.1.1. Blood pressure 
Measurement of blood pressure reflects the force that blood exerts against the wall of a 
large artery. The pressure of the blood is highest (systolic) at the point when it leaves 
the left ventricle during contraction of the heart, and lowest during relaxation of the 
heart muscle (diastolic).   For the studies described in this thesis, blood pressure was 
measured using an automated sphygmamometer (Omron Healthcare Europe B.V., 
Hoofddorp, Netherlands). 
2.2.1.2. Anthropometric measures 
The body mass of participants was measured using standard platform scales accurate 
to within 0.5kg, and height using a stadiometer to the nearest whole cm.   Body mass 
index (BMI) was derived by the standard equation: 
BMI   = Weight (kg)/(height (m))2 
Waist circumference was measured using a standard tape measure, midway between 
the uppermost border of the iliac crest and the lower border of the costal margin (rib 
cage). BMI Categories (as defined by the National Heart Lung and Blood Institute, 
USA) in standard use by advisory bodies in the UK were used as guidelines:  
 Underweight:  < 18.5 kg/m2 
 Normal weight: 18.5–24.9 kg/m2 
 Overweight:  25–29.9 kg/m2 
 Obesity:  > 30 kg/m2 
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2.2.2. Biochemical methods for measurement of CVD risk; general 
principle 
 
Biochemical markers of CVD risk were measured in the course of the studies described 
in the subsequent chapters.   Although these were conducted using different analytical 
instruments, the principles employed were common to all.   The basis of each was: 
1. To separate out the molecular species of interest if needed (to remove species 
that might interfere with the assay) 
2. To release the species from any other ligands bound to it (by enzymatic 
methods) 
3. To react the species of interest in an enzymatic reaction to produce an active 
molecule (in this series of reactions, hydrogen peroxide) 
4. To react the peroxide with a chromogenic compound to produce a coloured 
quinoneimine dye; the dye produced can be measured by absorbance of 
reflectance photometry at a set wavelength.  The methods have been designed 
so that the absorbance or reflectance is linear over the concentration range 
under investigation. 
 
2.2.2.1. Screening markers using LDX screening method 
Screening of whole blood lipid markers was carried out at all screening visits on 
capillary blood samples using the Cholestech® LDX system (Alere, UK).    This is a 
‘point-of-care’ analytical system designed to permit clinical measurement of selected 
lipid-related parameters using small samples (40 μL) of capillary blood applied to a 
solid-phase cassette, and giving results within a few minutes of sampling.  Cassettes 
are available to provide measurements of total cholesterol (TC), HDL-C, TAG, TC/HDL-
C ratio, LDL-C and glucose, using a combination of established enzymatic 
methodology (Siedel et al., 1983) and solid-phase technology.   This system has been 
certified for use by the CDC Cholesterol Reference Method Laboratory Network in the 
USA, and approved for use by the UK MHRA.   Pluddemann et al. (2012) validated the 
Cholestech LDX device for TC, LDL-C, HDL-C and TAG; correlation with laboratory 
analyses were reported to be 0.91, 0.88. 0.77 and 0.93 respectively.  
Procedure:  40μL capillary blood from a finger-prick was applied to an Alere Cholestech 
LDX® cassette, which was placed in the analyser.   The plasma was separated from 
the blood cells in the sample by membrane filtration; one portion of plasma was 
directed to a cholesterol/TAG analysis pad.  A second portion of plasma was directed 
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to the other side of the cassette, where low and very low-density lipoproteins were 
precipitated with dextran sulphate (MW 50,000) and magnesium acetate (Warnick et al., 
1982, Warnick et al., 1983). 
The analytical methods underpinning the Alere LDX cassette system are based on 
similar enzyme-catalysed reaction series to generate an active molecule (hydrogen 
peroxide).  For all of these measurements the hydrogen peroxide is reacted in the 
same colorimetric reaction to produce a coloured adduct which is estimated by 
reflectance photometry at a chosen wavelength.  Each cassette has a brown magnetic 
strip containing the calibration information required to convert the reflectance reading 
to the total cholesterol, HDL cholesterol, triglycerides and glucose concentrations.   The 
techniques are summarised below: 
Measurement of total cholesterol and HDL cholesterol (HDL-C) 
This is based on the enzymatic method developed by Allain and Roeschlau (Allain 
et al., 1974; Roeschlau et al., 1974), as shown in Figure 2.1.    
1. Cholesterol esters in plasma are hydrolysed to free cholesterol,  
2. Free cholesterol is oxidised by cholesterol oxidase to cholest-4-ene-3-one 
and hydrogen peroxide.   
3. The hydrogen peroxide generated reacts with 4-aap and N-ethyl-N-
sulphohydroxypropyl-m-toluidine (TOOS) to form a purple-coloured 
quinoneimine dye (in a reaction catalysed by horseradish peroxidase).  The 
colour intensity is proportional to the total cholesterol and HDL cholesterol 
concentration of the sample.  
 
 
 
 
 
 
 
 
Figure 2.1 Measurement of total cholesterol (TC) and HDL-C 
 
 
                                                       cholesterol esterase 
 
Cholesterol esters + H2O       Free cholesterol + fatty acids 
      
                  Cholesterol oxidase 
  Cholesterol + O2                         Cholest-4-ene-3-one + H2O2 
 
                   Peroxidase 
2H2O2 + 4-aminoantipyrine +TOOS Quinoneimine dye + 4H2O 
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Measurement of TAG is by an enzymatic method (Figure 2.2) based on  
1. The hydrolysis of TAG by a mixture of lipases to glycerol and free fatty acid 
2. Glycerol is converted to glycerol-3-phosphate  (catalysed by glycerol kinase), 
3. Glycerol-3-phosphate is oxidised to dihydroxyacetone phosphate (DHAP) and 
hydrogen peroxide (Fossati and Prencipe, 1982). 
4. Hydrogen peroxide generation is measured by the same colour reaction as for 
total cholesterol.  
 
Figure 2.2   Measurement of TAG 
Glucose is measured by a similar enzymatic method (Figure 2.3);    
1. The oxidation of glucose by glucose oxidase to generate gluconolactone and 
hydrogen peroxide. 
2. Colour reaction utilising horseradish peroxidase as described above. 
 
 
Figure 2.3    Measurement of plasma glucose 
 
 
Lipase 
 
Triglycerides + H2O       glycerol + free fatty acids 
      
        Glycerol kinase + Mg
2+ 
  Glycerol + ATP               glycerol-3-phosphate + ADP 
 
   Glycerol Phosphate Oxidase 
Glycerol-3-phosphate + O2    dihydroxyacetone phosphate +  H2O2                                               
  
                             Peroxidase 
2H2O2 + 4-aminoantipyrine + TOOS Quinoneimine dye + 4H2O 
 
 
      
                  glucose oxidase 
  Glucose + O2                         α –D-gluconolactone + H2O2 
 
                   Peroxidase 
2H2O2 + 4-aminoantipyrine +TOOS Quinoneimine dye + 4H2O 
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2.2.2.2. Analyses using a RANDOX auto-analyser 
Plasma samples were analysed using a RANDOX auto-analyser (Randox Laboratories, 
Co. Antrim, N. Ireland): for each assay specific quality controls (QCs) were measured 
at 2-hour time intervals.  Each assay was based on an enzymatic reaction, linked to 
endpoint production of a coloured pigment, the concentration of which was proportional 
to absorption at a specific wavelength (Trinder, 1969a; 1969b; Siedel et al., 1983; 
Kattermann et al., 1984; Munz et al., 1974).   The biochemical principles of these 
assays are the same as those described for the Alere LDX analyser, but employing 
different initial separation techniques. 
Total cholesterol (TC):  The measurement of TC includes estimation of all lipoprotein 
subclasses using an enzymatic process as described in 2.2.2.1, with the absorbance of 
the quinoneimine pigment measured bichromatically at 505 and 692 nm. The test 
reagents as provided are stated by Randox to provide a wide measuring range (0.865-
16.6 mmol/L), within-run precision of 3.7% at 1.7 mmol/L and 3.8% at 7.7 mmol/L, with 
between-run precision of 1.3% at 1.7 mmol/L and 1.4% at 7.5 mmol/L. 
 
HDL-C: Measurement of HDL-C depends on isolation and quantitation of the 
cholesterol component of the lipoprotein aggregate.  The Randox Direct Clearance 
method completely removes all non-HDL components (chylomicrons, VLDL-C and 
LDL-C) from plasma using cholesterol esterase, cholesterol oxidase, catalase and a 
selective reagent, followed by release of HDL-C by detergents containing sodium azide 
to inhibit any remaining catalase (Lawlor et al, 1998; Warnick et al., 2001; Mather, 
2013). The intensity of the quinoneimine dye product is directly proportional to the 
cholesterol present at 600 nm within a concentration range of 0.10-2.4 mmol/L.  Intra- 
and inter-assay precision gave CVs for low, medium and high and quality controls of < 
5% respectively. Other methods of measuring HDL-C depend either on 
ultracentrifugation to separate lipoprotein subclasses, or masking of the non-HDL 
subclasses; the method used here has a high (99%) concordance with the 
ultracentrifugation reference method, but the masking methods have been reported to 
underestimate the concentration of HDL-C. The Randox technique has a measuring 
range of 0.189 - 3.73 mmol/L (7.30 - 144 mg/dL), with intra-assay precision 1.8% at 0.8 
mmol/L and 3.1% at 2.0 mmol/L, and inter-assay precision 2.8%.  
LDL-C:  As for HDL-C, measurement of LDL-C is a way of quantitating low-density 
lipoprotein aggregates by measurement of the cholesterol present in the aggregates.   
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The Randox LDL-C kit utilises a similar direct clearance method to remove interfering 
lipoprotein subclasses prior to analysis, analogous to that described for HDL-C.    
Step 1:  Elimination of chylomicrons, VLDL-Cholesterol and HDL-Cholesterol by 
cholesterol esterase, cholesterol oxidase and subsequently catalase. 
Step 2. Release of LDL-C by detergents, followed by estimation of LDL-C as for HDL-C 
(azide is used to inhibit catalase in this step).  TOOS (N-Ethyl-N-(2 hydroxy-3 
sulphopropyl)-3–methylaniline) is the pigment used in the colorimetric reaction.  The 
measurement range (linearity of reaction) is 0.189 - 22.2 mmol/L (7.3 - 860 mg/dL).  
Intra and inter-assay precision gave CVs for low, medium and high and quality controls 
of < 5% respectively.    
An alternative practice is to calculate LDL-C using the Friedewald equation, which 
enables the estimation of LDL when triglyceride and HDL levels are known.  This was 
used for the study described in Chapter 3.  However, this calculation is only accurate if 
plasma TAG levels are <400mg/dL (22 mmol/L), chylomicrons are not present and the 
sample does not contain beta-VLDL. 
 
Glucose:  Glucose is determined in the Randox system by enzymatic oxidation in the 
presence of glucose oxidase (GOD), as described in section 2.2.2.1.  The absorbance 
of the red/violet quinoneimine dye is measured bichromatically at 505/692 nm. Intra- 
and inter-assay precision gave CVs for high and low quality controls of < 5% 
respectively. 
Triglycerides (TAG):  The Randox TAG assay is based on the principle described in 
section 2.2.2.1, with measurement of the resulting quinoneimine pigment measured 
bichromatically at 505 and 692 nm.   The measuring range is reported to be 0.134 - 
12.7 mmol/L, within run precision 3.3% at 0.3 mmol/L and 1.8% at 5.6 mmol/L, and 
between run precision 3.5% at 0.6 mmol/L and 1.3% at 3.0 mmol/L. 
 
ApoA1 and ApoB:  The Randox assays for ApoA1 and ApoB are latex-enhanced 
immunoturbidimetric assays; the apolipoprotein present in the plasma samples 
combines with a highly specific polyclonal rabbit antibody present in the reagent to 
form an insoluble complex.  The turbidity, which is increased by the presence of latex in 
the reagent, is measured at 340nm, and is proportional to the apolipoprotein 
concentration in the sample (Contois et al., 1996a; 1996b). 
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Non-esterified fatty acids (NEFA):  NEFA were measured using the enzymatic 
reactions of Acyl CoA synthetase and Acyl CoA oxidase in sequence to produce 
peroxide, and using the same principle for estimation of peroxide as outlined above 
(Figure 2.4). The intensity of the colour is proportional to the NEFA concentration.   The 
assay is linear up to 2.0 mmol/L with a sensitivity of 0.10 mmol/L.  Low and high quality 
controls were employed with intra-assay CVs of 3.4% and 2.3% respectively (low QC, 
n = 11 and high QC, n = 9) and inter-assay CVs of 8.9% and 7.4% respectively (low 
QC, n = 22 and high QC n = 18). 
 
NEFA + ATP + CoA 
    
Acyl CoA  Synthetase      Acyl CoA + AMP + PPi 
 
Acyl CoA + O2            Acyl CoA Oxidase    2,3,-trans-Enoyl-CoA + H2O2 
 
 2H2O2 + TOOS + 4-AAP
            
  Peroxidase                purple adduct +4H2O 
 (or MEHA) 
Figure 2.4   Measurement of non-esterified fatty acids 
(4-AAP = 4-aminoantipyrine, TOOS = N-ethyl-N-(2-hydroxy-3-sulphopropyl) m-toluidine or 3-
Methyl-N-Ethyl-N-(beta-Hydroxyethyl)-Aniline (MEHA) 
 
2.2.2.3. Insulin 
Plasma insulin was measured using the Mercodia Insulin ELISA, a solid phase two-site 
enzyme immunoassay.  In this assay, based on the sandwich technique, two 
monoclonal antibodies are directed against separate antigenic determinants on the 
insulin molecule. One anti-insulin antibody in the microtitration plate is bound to the 
insulin in the sample and a second peroxidase-conjugated anti-insulin antibody is in 
solution.  A sample of serum (25 μL) was added to the antibody-containing well, 100 μL 
enzyme conjugate solution added and the plate incubated on a shaker for 1 hour at 
room temperature.  The plate was washed six times, and 200 μL substrate 
(tetramethylbenzidine, TMB) added.  After 15 minutes on a shaker at room 
temperature, the reaction was stopped by addition of 50uL Stop solution (pH 0.5), and 
colour development at 450nm was estimated.  The sensitivity of detection was1 pU/L. 
 
 60 
2.2.2.4. Ultracentrifugation methods: Iodixanol gradient ultracentrifugation for 
the separation and estimation of lipoproteins (DGUC) 
A useful method for separation and identification of lipoprotein subclasses is iodixanol 
gradient ultracentrifugation (DGUC), followed by individual analysis and summation of 
subfractions.     
Principle of method:  Ultracentrifugation has been used for many years to separate 
lipoprotein classes and subclasses on the basis of density (Havel et al., 1955, Wilcox & 
Heimberg, 1970).  Early methods were very labour-intensive and time-consuming.  The 
development of density gradient ultracentrifugation (DGUC) depends on the formation 
of a continuous density gradient during the centrifugation process, with lipoprotein 
classes and subclasses stratified according to density (Krauss & Burke, 1982; Swinkels 
et al., 1987, Griffin et al., 1990; Krauss, 1994).  Advances in the design of rotors from 
swing-out design to short path-length vertical or near-vertical rotors allowed a reduction 
in centrifugation times from over 12 hours to under 4 (Chung et al., 1986). The high salt 
concentrations in earlier methods (sodium or potassium bromides) risked disruption of 
apolipoproteins (Murdoch & Breckenridge, 1994): the technique described here used 
iodixanol, which rapidly forms a continuous density gradient, is non-toxic and iso-
osmotic, and reduces the risk of apoliprotein disruption (Ford et al., 1994; Graham & 
Billington, 1996).    The method used was that developed by Davies et al. (2003), 
based on that of Graham et al. (1996) with modifications to save time, reduce inter-run 
variation and improve LDL subclass separation, using smaller samples (3 mL rather 
than 5 mL plasma) which would be more appropriate for large-scale intervention 
studies. A near-vertical rotor rather than a vertical rotor was used to reduce the 
chylomicron adherence to tube walls seen with vertical rotors, while still maintaining the 
necessary relative centrifugal force (RCF).  
 
Materials and equipment:    
 
 Beckman-Coulter ultracentrifuge 
 Beckman-Coulter ultracentrifuge NT65 rotor, with places for 8 Optiseal tubes 
 OptiprepTM (Axis-Shield): This is a commercially available solution (60% w/v) of 
iodixanol, used as a density gradient medium:  a 9% solution was prepared 
from this using phosphate-buffered saline as diluent.    
 OptisealTM tubes (11.2 mL), with caps, plugs and spacers 
 Stainless-steel cannula (1) 
 NVT 65 Beckman-Coulter rotor  
 Beckman-Coulter Ultracentrifuge XL series. 
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Procedure 
Blood was obtained from participants by venepuncture at study visits, into EDTA 
anticoagulant tubes.  Plasma was obtained by centrifugation at 4oC in a bench 
centrifuge (1500 rpm for 20 minutes), transferred to clean sample tubes and stored at   
-80oC until use.  On the day of lipoprotein analysis, samples were thawed on ice prior 
to gradient formation and centrifugation.  Plasma (2.8 mL) was added to 0.7 mL of 
OptiprepTM  (iodixanol) in a bijou tube (7 mL), and mixed by gentle inversion.  The 
density of the resulting plasma/Optiprep mixture was checked using a refractometer 
(Density = 1.050 g/ml, refractive index = 1.3498). A 7.8 mL portion of the 9% 
iodixanol/PBS solution was placed in an 11.2 ml Beckman Optiseal centrifuge tube. 
A steel cannula and syringe were used to under-layer 3 mL of the denser working 
sample beneath the 9% Optiprep solution (making sure there were no air bubbles). The 
tubes were left for 30 minutes to settle, before fitting plugs into the tubes, securing in 
the NVT65 rotor and fitting spacers and caps to each tube.   Caps were tightened to 
180 inch pounds using a torque wrench, before centrifugation at 65 000 RPM, 16C, for 
3h 10 min.   After centrifugation, caps were removed with torque wrench and adapter; 
spacers and plugs were also removed from the centrifuge tubes as they were taken out 
of the rotor and placed in a rack for fractionation.    The products of each gradient were 
divided sequentially into 0.5ml fractions in microcentrifuge tubes using an Eppendorf 
fraction collector, and the lipoprotein concentration of each fraction was estimated by 
an automated technique for cholesterol estimation as described earlier in this chapter.  
Density ranges for lipoprotein subclasses (Davies et al., 2003) are shown in Table 2.2. 
 
Lipoprotein subclass Density (kg/L) 
HDL >1.063 
LDL 1.021-1.041 
LDL-I 1.022- 1.025 
LDL-II 1.025-1.028 
LDL-III 1.028-1.036 
LDL-IV 1.036 
VLDL 1.009 
 
Table 2.2:  Density ranges for lipoprotein subclasses by DGUC 
 
 62 
2.2.2.5. An alternative method for measurement of sdLDL-C 
 
As described in section 1.3.4.1, it is now recognised that elevated levels of LDL 
present a major CVD risk factor, and that a prevalence of small dense particles 
(sdLDL) presents a greater atherogenic risk than large buoyant particles (lbLDL). 
Methods for sdLDL-C measurement have until recently depended on laborious 
ultracentrifugation and electrophoresis-based methods.  A simple and rapid method for 
sdLDL-C quantification based on Mg–heparin precipitation (Hirano et al., 2005) was 
compared with the DGUC method (Davies et al., 2003) for some of the samples 
obtained in the study described in Chapter 3.   Blood sampled into tripotassium citrate 
anticoagulant was obtained from nine adults, and plasma removed by centrifugation 
and separated into two portions that were used for sdLDL analysis by one of the two 
methods.   The two methods were carried out by different operators and results 
compared subsequently. For the Hirano method, heparin–MgCl2 was added to plasma 
to separate VLDL-C, IDL-C and large buoyant LDL-C, while sdLDL-C and HDL-C 
remained in the infranatant fraction.  LDL-C in this fraction was determined by the 
direct LDL-C method on an ILAB 650 autoanalyser (Randox Laboratories Ltd, UK). 
Comparison of methods:  Ultracentrifugation of one portion in an iodixanol gradient 
was followed by fractionation and measurement of the cholesterol in twenty fractions as 
described in Section 2.2.2.4.  A plot of results from the heparin method against those 
from the iodixanol method was linear, with a gradient of 1.026 (R2 = 0.8766) (Jones et 
al, 2009), as shown in Figures 2.5 and 2.6.    
 
Figure 2.5 Comparison of DGUC (iodixanol) and Hirano methods for sdLDL 
estimation 
2.2.2.6.  Measurement of plasma fatty acid profiles 
Plasma samples were stored at -80°C until analysis, then thawed at room temperature, 
vortexed for 5 seconds and centrifuged for 4 minutes at 2500rpm.  Aliquots of 400 µL 
were placed in 10mL glass tubes and 40 µg 1-2-dipentadecanoyl-sn-glycero-3-
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phosphocholine added. Total lipids were extracted following a modified method of 
Folch et al. (1957).  400µL of 0.9% saline solution was added to the plasma and 
vortexed for 30 seconds. 5ml chloroform:methanol (2:1 v/v)/ BHT (0.01% w/v),  
followed by 1mL 1M NaCl, was added to the plasma and vortexed for 30 sec. Samples 
were centrifuged at 2500rpm for 10 minutes;  the lower organic phase was transferred 
into new glass tubes and evaporated to dryness under  a stream of nitrogen. 
Phospholipids (PL) were isolated using amino propyl columns (NH2).  Samples were 
resuspended in 1mL of hexane and loaded onto the columns (500mg, Waters) 
conditioned with 20mL of hexane.  Neutral lipids were washed out with 3ml hexane. 
Free fatty acids were washed out with 6ml diethyl ether/acetic acid (10%). PLs were 
eluted with methanol (3mL).  After evaporation to dryness under nitrogen, PLs were 
transmethylated to fatty acid methyl esters (FAMEs).   The Phospholipids were 
resuspended in 2mL toluene:methanol (4:1 v/v)/BHT (0.01% w/v) and transmethylated 
with 200µl of acetyl chloride for 1 hour at 100°C.;  5mL of 0.25M K2CO3 was added, 
and centrifuged for 2mins at 2500rpm. The upper toluene layer was removed for 
analysis by GCMS. FAMEs were stored at -80°C until GCMS analysis.  
FAMEs were analysed by GCMS (Agilent Technologies 7890a GC system and Agilent 
Technologies 5975c MS system) with a fused silica capillary column (60m x 0.25mm x 
0.15µm). The injector temperature was 250°C and helium was used as the carrier gas. 
The FAMEs (1µL) were injected into the GC in split mode with a split ratio of 20:1 and a 
flow rate of 23.9 ml/min. The oven temperature was initially set at 50°C for 1 min, 
ramping to 175°C (25°C/min) and then to 230°C (2.2°C/min) and held for 9 min; run 
time was 40 mins.  The GCMS was run in SIM/Scan mode; selected ion monitoring 
(SIM) was used to monitor 9 ions (m/z 41, 43, 5, 67, 69, 74, 79, 87, 91).  SIM data was 
used for quantification of FAMEs using Chemstation software.  FAMEs were identified 
by comparison of retention time, Mass Spectra authenticated standards and the NIST 
database. 
FAMEs of the fatty acids 16:0, 18:0, 18:1n-9c, 18:2n-6c,18:3n-3, 20:4n-6, 20:5n-3 and 
22:6n-3 were well separated from each other and clearly identifiable. PL-derived FA 
concentrations were calculated by comparison of the peak area of the individual FAs 
with the peak area of the internal standard using external calibration curves.  
Standards were run before and after each sample batch and an analytical quality 
control was run with each batch. The quality control was a pooled plasma sample 
taken from a selection of healthy adults.   
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2.2.3. Derivation of indices of CVD Risk 
 
Compound indices postulated to provide diagnostic criteria for cardiometabolic risk, 
were calculated as shown in the relevant sections of Chapter 3 and 4.  These were: 
ApoB/ApoA1 ratio (Walldius et al., 2004), HOMA-IR and HOMA-βstatus, QUICKI and 
R-QUICKI. 
 
2.3.   COMPARISON OF CAPILLARY AND PLASMA MEASUREMENTS 
 
In the study described in Chapter 4, measurements obtained using the Cholestech 
point-of-care system were compared with those obtained from Autoanalyser techniques 
to provide information about relative accuracy and comparability.    
Mean values (with SD) for the Cholestech analysis are presented in Table 2.3.   
Inspection of the data revealed no significant outliers in any category.  No deviation 
from normality was observed using either K-S or Shapiro-Wilk tests, except for 
endpoint TAG/HDL-C ratio (FO intervention), for which one individual presented with a 
high value (although less than 2SD from the mean).   Correlation between capillary and 
venous blood results was carried out using the Pearson correlation, as presented in 
Table 2.4. 
Table 2.3:  Mean capillary blood measurements (SD in brackets) 
 FO 
n = 18 
KO 
n = 18 
 Baseline 
 
End Baseline End 
TC (mmol/L) 5.71 
(1.24) 
5.65 
(1.03) 
5.44 
(1.01) 
5.48 
(1.07) 
HDL-C 
(mmol/L) 
1.13 
(0.29) 
1.13 
(0.28) 
1.09 
(0.27) 
1.14 
(0.26) 
TAG 
(mmol/L) 
1.82 
(0.75) 
1.78 
(0.80) 
1.58 
(0.51) 
1.56 
(0.61) 
LDL-C 
(mmol/L) 
3.74 
(1.09) 
3.71 
(1.17) 
3.63 
(0.98) 
3.63 
(0.96) 
Non HDL-C 
(mmol/L) 
4.58 
(1.23) 
4.52 
(1.09) 
4.35 
(1.04) 
4.34 
(1.09) 
TC/HDL 5.36 
(1.69) 
5.29 
(1.53) 
5.27 
(1.52) 
5.07 
(1.39) 
TAG/HDL 1.77 
(0.90) 
2.07 
(1.74) 
1.58 
(0.76) 
1.67 
(0.96) 
Glucose 
(mmol/L) 
5.41 
(0.47) 
5.45 
(0.58) 
5.49 
(0.57) 
5.32 
(0.35) 
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 Pearson correlation p 
 Baseline Endpoint Baseline Endpoint 
TC  0.768 0.655 .000 0.000 
HDL-C 0.705 0.805 .000 0.000 
TAG 0.79 0.975 0.000 0.000 
LDL-C 0.837 0.810 0.000 0.000 
TC/HDL-C .800 0.891 0.000 0.000 
TAG/HDL-
C 
0.892 0.987 0.000 0.000 
Glucose 0.561 0.649 0.001 0.000 
Non-HDL-C 0.830 0.698 0.000 0.000 
 
Table 2.4:  Correlations between capillary and blood testing methods      
 (Pearson correlation, with significance for all parameters) 
 
These results lead to the following observations: 
1. Correlations are generally good in linear terms although not in absolute values. 
2. Correlation varies for certain measurements between batches of measurements 
(e.g. TC, correlation for baseline measurements 0.768, for endpoint 0.655).    
3. The highest and more reproducible between-batch correlations are observed for 
the TAG/HDL and TC/HDL ratios.    
There were no discrepancies observed in relative magnitude between capillary and 
venous blood measurements. Systematic over-estimation of TAG (0.3g/L, 0.34 mmol/L) 
and underestimation of LDL-C (0.043g/L, 0.011 mmol/L) has been reported for capillary 
measurements in hyperlipidaemic individuals (Stein et al., 2002; Mayer et al., 2007; 
Parikh et al., 2009; Pluddemann et al., 2012).    
2.4. MEASURES OF COMPLIANCE  
 
In dietary intervention studies, it is important to understand whether participants comply 
with the intervention process, and consistency or changes in diet or physical activity 
during the course of the study, as such alterations may confound any findings. 
Participants in both studies described here were asked not to alter their normal dietary 
and physical exercise patterns. In order to evaluate compliance, participants were 
asked to return unused capsules at the end of the krill/fish oil study, and were asked to 
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complete food diaries during each study to enable an approximate estimation of major 
changes in dietary habits.  Unfortunately, the majority of the participants did not return 
unused capsules, so that it was not possible to compare compliance and relate this to 
biochemical parameters; full compliance was therefore assumed in the data analysis. 
In addition, retrospective inspection of some of the biochemical data (glucose, insulin 
and plasma FAs) provided indications as to the extent of compliance with 
supplementation and maintenance of normal dietary habits. 
 
2.4.1.  Food diaries 
 
Participants in both studies recorded dietary intakes over periods of 3 or 7 days before 
and during the supplementary intervention times, as described in the relevant chapters.  
For both studies participants were provided with a printed food diary originally designed 
and used at the University of Surrey, set out with a matrix to be filled in for each day of 
the food record period (Appendix A).  This food diary included guideline pictures taken 
from The Food Atlas (Nelson et al., 1997) of common foods in different portion sizes to 
help them in estimating quantities and portion sizes consumed. The data from the work 
described in Chapter 3 was analysed using Windiet, and that in Chapter 4 using 
Microdiet V.  These are both commercially available computer programs which allow 
estimation of major nutrient groups:  Microdiet uses data derived from standard data 
sources of food composition, while Windiet uses data from online food composition 
sources.  Nutrient intakes were subjected to statistical analysis using SPSS v20. 
 
2.5.  STATISTICAL ANALYSIS 
 
Data from all studies were subjected to analysis using the SPSS20 statistical program 
(SPSS Inc., Chicago, USA). Initially, descriptive statistics were undertaken, to 
characterise the study populations at each time point and assess normality of the data 
distribution (Kolgorov-Smirnoff or Shapiro-Wilks test). Within an intervention group, 
paired t tests were applied for comparisons by time, and independent t tests were used 
to investigate any significant differences in outcome measures between intervention 
groups at each time point.  Statistical comparison of changes from beginning to end, 
and in the second study, from beginning to midpoint, of dietary interventions, was also 
carried out.   
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Split-plot analysis of variance (SPANOVA) allowed composite investigation of time and 
treatment effects for all repeated outcome measures.  When controlling for additional 
confounding variables (e.g. baseline measures, gender, body weight) and adjusting for 
baseline measures analysis of covariance (ANCOVA) was employed. Where data 
could not be normalised, it was not possible to employ ANCOVA or ANOVA, and in 
these cases non-parametric statistics were used.  To explore the relationship between 
variables Pearson correlation and product moment (r2) coefficients were determined.  
To test for the relationship between two categorical variables a chi-squared test was 
employed.  
The detail of the statistical tests employed is provided in Chapter 3 for the prawn/OC 
comparison and in Chapter 4 for the KO/FO comparison. 
 68 
CHAPTER 3 
The effect of dietary Prawn intake on Cardiovascular Disease 
Risk 
 
3.1.   INTRODUCTION 
 
Prawns and other shellfish are a source of n-3 LCPUFA (Ackman, 2000) but also 
contain significant amounts of cholesterol (140-190 mg/100g) (Oehlenschlager, 2006). 
Potential benefits of n-3 LCPUFA consumption have been addressed in Chapter 1. 
Dietary guidelines for minimising CVD risk have historically advised against the 
consumption of cholesterol-rich foods on the grounds that they may increase serum 
LDL-C (Weggemans et al., 2001; Tanasescu et al., 2004), although it has long been 
apparent that any CVD risk associated with cholesterol intake may be less clear-cut 
than the association between raised LDL-C and intake of SFA or TFA (Beveridge, 
1964; Kratz, 2005).  The American Heart Association report in 2000 (Krauss et al., 
2000a; 2000b) recommended dietary cholesterol < 300mg per day for healthy 
individuals, with a limit of 200 mg/day cholesterol for those with raised LDL-C, pre-
existing CVD or T2D.  Studies of egg consumption have overall failed to provide 
convincing support for a link with CVD (Djousse & Gaziano, 2008; Harman et al., 2008; 
Gray & Griffin, 2009; Djousse et al., 2010), as summarised in Table 3.1. 
A study of 21327 male doctors (Djousse & Gaziano, 2008) suggested an adjusted 
hazard ratio of 1.41 for all cause mortality in those eating more than one egg per day, 
in contrast to earlier studies (Dawber et al., 1982; Nakamura et al., 2004) reporting no 
association. Djousse & Gaziano reported no association between egg consumption 
and CVD risk overall, but noted an effect for a cohort with diabetes. An association 
between egg consumption and CVD risk in diabetics has been noted in several other 
reports.  A cohort of 5672 T2D women was followed prospectively for 8 years, with diet 
questionnaires every 2 years (Tanasescu et al., 2004). During this period, 619 cases of 
CVD were recorded (including 268 MI, 183 fatal CHD and 168 strokes). The relative 
risk of a cardiovascular incident was estimated at 1.37 for an increase of 200mg 
cholesterol per 1000 kcal (95% CI: 1.12 -1.68; p = 0.003).   Higher cholesterol intake 
was associated with increased BMI, which appeared to be specific for egg intake rather 
than overall cholesterol.  The threshold for increased risk was at the level of 3 eggs per 
week  (Table 3.2), lower than that reported by Djousse & Gaziano (1 egg per day).  
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A study of 45 individuals comparing intake of 2 eggs per day with an egg-free diet, 
combined with energy restriction (Harman et al., 2008), revealed no significant 
difference in LDL-C, plasma lipoproteins, or LDL particle size between groups after 12 
weeks.   This was interpreted to indicate that egg intake in conjunction with energy 
restriction does not increase total plasma or LDL-C, and that advice to avoid eggs in a 
weight loss programme may not be necessary.   More recently however, inferences 
from food frequency questionnaires (Larsson et al., 2010; Houston et al., 2011) have 
supported a possible association between CVD risk and egg consumption. 
In summary, evidence from retrospective and prospective cohort and intervention trials 
up to the commencement of this study suggested that dietary cholesterol has a 
clinically insignificant effect on blood LDL-C and CVD risk in healthy individuals (Hu et 
al., 1999; Lee & Griffin, 2006; Harman et al., 2008) but there was no specific evidence 
to support or refute a possible link between prawn consumption, LDL and CVD risk.  
 
3.1.1. Dietary cholesterol metabolism: implications for CVD risk  
 
Dietary cholesterol is absorbed from the small intestine, taken up into lipoprotein 
aggregates with apolipoproteins and FAs (both as TAG and PLs) and delivered to the 
peripheral tissues where it is an important constituent of cell membranes. It is also an 
important precursor for a range of steroid hormones in the adrenal glands and gonads 
(Hu et al., 2010).   Although the regulation of cholesterol metabolism appears to be 
tightly controlled the reported association between increased plasma cholesterol, 
especially LDL-C, and increased CVD risk, has led to a cautionary approach in dietary 
advice (Krauss, 2000a; 2000b).  Evidence accruing suggests that the response to 
dietary cholesterol and the homeostatic mechanisms are affected by genetic 
characteristics which ultimately determine the balance of lipoprotein subclasses and 
relative CVD risk (Hopkins, 1992). Plasma cholesterol levels are regulated by different 
genetic factors from those which control cholesterol absorption and synthesis (Lecerf & 
de Lorgeril, 2011).   Indeed, polymorphisms in ApoE are reported to be responsible for 
7% of the variation in cholesterol levels, with contributing effects from ApoA4, ApoB 
and Apo C3 (Kanter et al., 2012).    
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Type of study Number of  
participants  
Duration Outcome Reference 
Dietary survey 
(Framingham) 
912 24-year follow-up No association between egg consumption and serum 
cholesterol or incidence of heart disease 
Dawber et al., 
1982 
Prospective cohort study 37,851 men 
80,052 women 
8 years (men),  
14 years 
(women) 
No overall association at 1 egg per day  
(RR = 1.08 for men, 0.82 for women). For diabetic 
men, RR = 2.02, women RR = 1.49  
Hu et al., 1999 
 
Epidemiological survey 5,186 men,  
4077 women 
14 years No significant association between egg consumption 
and CHD risk for men or women 
Nakamura et al., 
2004 
Prospective study of food 
intake 
5,672 women with 
T2D 
8 years, review 
every 2 years 
RR of CVD for increase of 200mg per day dietary 
cholesterol per 1000kcal = 1.37 (95% CI 1.12-1.68; p = 
0.003).   
*Relative risks from egg consumption:  
< 1 egg per week:         1.0 
1- <3 eggs per week:    1.10 
3. eggs per week         1.08 
3-6 eggs per week         1.39 
>6 eggs per week          1.44 
Tanasescu et al., 
2004 
Kratz, 2005 
Retrospective review of 
food intake 
21,327 male 
doctors 
Average 20 
years 
Hazard ratio 1.41 for all CVD-related mortality from >1 
egg per day.    
Hazard ratio for diabetic subjects 2.27-2.48 for 
consumption of 5-6 eggs per week (p <0.01) 
Djousse & 
Gaziano,  2008 
 71 
 
Table 3.1:  Studies of the relationship of dietary cholesterol or egg consumption and CVD 
( *95% CI:  1,05, 1.98:  p for trend 0.001)
Type of study Number of  
participants  
Duration Outcome Reference 
Dietary intervention  
(2 eggs per day) plus 
energy restriction 
45 12 weeks No difference in CVD markers following consumption 
of 2 eggs per day compared with null egg 
consumption. 
Harman et al., 
2008 
Food frequency 
questionnaire 
34,670 women 49-
83 years 
10.4 years Increased risk of stroke (RR = 1.20 for 300mg 
cholesterol per day compared with 170mg/day, 95% CI  
= 1.00-1.44, p  for trend 0.01) 
Larsson et al., 
2012 
Food questionnaire 1,941 adults 
between 70-79 
years 
3 years Overall positive association between egg consumption  
(> 3 per week compared with <1 per week) and CVD 
risk (HR = 1.68, p = 0.01. Subgroup analysis indicated 
increased risk only in T2D (HR 3.66 for dietary 
cholesterol, 5.02 for >3 eggs per week)  
Houston et al., 
2011 
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3.1.2.  Prawns as a source of n-3 LCPUFA 
 
Many people do not enjoy eating oily fish, which are rich in n-3 LCPUFA, but shellfish 
(including prawns), which contain both n-3 LCPUFA and cholesterol, are popular foods.   
The cholesterol and n-3 LCPUFA content of some common foods are summarised in 
Table 3.2.   The cholesterol content of 200g prawns is equivalent to that of a large egg 
yolk, with associated n-3 LCPUFA content of the order of 600mg, a level reported to 
favourably influence CVD risk (Calder, 2004, Kris-Etherton et al., 2002; 2004).   
Typical recommendations for dietary n-3 LCPUFA supplementation to mitigate CVD 
risk are of the order of 1g per day of EPA plus DHA  (Balk et al., 2006; Marchioli et al., 
2007; Yokoyama et al., 2007; Lavie et al., 2009; Rauch et al., 2010).   Intakes of 2 g 
per day EPA plus DHA (Thies et al., 2003) have been used in studies aimed at 
reducing CVD risk.   At these levels of supplementation, compliance with the large 
volumes of FO may become an issue; an alternative is to use highly concentrated FA 
esters but these are expensive and, in some countries, require a medical product 
licence for administration.   Prawns and other shellfish represent a more palatable 
source of n-3 LCPUFA, but have not been widely recommended because of the 
cautionary approach to the perceived risk from dietary cholesterol. 
 n-3 LCPUFA 
mg/100g 
Cholesterol 
(mg/100g) 
Eggs  350 
Prawns (processed, as eaten) 267-332 143-162 
Oily fish 1600-2600 Approximately 70 
Seafood sticks Trace 16 
Light spread  0.7-5 
White fish (cod, haddock) 170-260 49-66 
Crabmeat (brown) 2450 271 
Crabmeat (white) 174 66 
Processed chicken 60 36-48 
Butter  153 
Table 3.2:  Cholesterol and n-3 LCPUFA content of some common foods                    
(Isherwood et al., 2010; https://www.gov.uk/government/policies/reducing-obesity-and-
improving-diet, 2013) 
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3.2.   AIM OF INVESTIGATION 
 
This study was conceived to address the question as to whether dietary cholesterol in 
the form of prawns has an adverse effect on indices of cardiovascular health.  The 
specific aim was to assess the effects of cold water prawns on lipoprotein fractions and 
LDL subclasses, (with an emphasis on sdLDL), in a randomly controlled dietary 
intervention trial in healthy male volunteers:  the null hypothesis was that no difference 
would be observed between prawns and a processed white fish in effects on 
cardiometabolic risk measurements. 
 
3.3.   STUDY DESIGN 
3.3.1.   Recruitment and testing procedures 
 
This study was carried out in collaboration with the University of Surrey (UoS).  
Recruitment of the participants was carried out at UoS, as were study visits and the 
biochemical assays.  Lipoprotein analysis, comparison of sdLDL methods, and the 
analysis of biochemical data and food diaries, were carried out at LJMU. 
3.3.1.1. Recruitment and study visits 
A cohort of 21 healthy, male volunteers aged between 19 and 67 years was recruited 
from existing subject databases at UoS.   The power and sample size for the study was 
based on a previous US study in normolipidaemic men (De Oliveira e Silva et al., 1996) 
reporting that daily intake of 225g shrimp for 21 days resulted in a 5% reduction (0.16 
mmol/L) in plasma LDL-C (the description of shrimp in the USA would be equivalent to 
that of prawns in the UK).   From this it was estimated that a sample size of 19 
participants would be required to detect a significant difference at the 5% level.   
Allowing for a dropout rate of 30%, the initial aim was to recruit 30 participants, but 
from an initial 25, only 21 of those screened were suitable and willing to undertake the 
study.   The criteria for inclusion in the study are shown in Figure 3.1.  At the time of 
recruitment, all participants were normolipidaemic (TC <6.5 mmol/L, TAG <2.3 mmol/L), 
had normal blood pressure (<125/73 mm Hg), were not suffering from any medical 
conditions known to affect lipid metabolism, and had no significant history of recent 
weight loss (> 3kg in the preceding three months).   Criteria for inclusion in the study 
also excluded current intake of dietary supplements such as FO, or specific 
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medications which would be likely to influence lipid metabolism, and previous fish 
allergy. 
 
PRAWN STUDY: Inclusion characteristics for participants 
Healthy males 
Age 19-67 
Total cholesterol <  6.5mM/L,  
Plasma triglycerides < 2.3 mM/L 
Normal blood pressure (SBP/DBP <125/73 mm Hg) 
No recent weight loss history 
Not taking any lipid-modifying dietary supplements or medications 
No history of diabetes or cardiovascular disease 
No previous fish allergy 
Figure 3.1:  Criteria for inclusion in study 
 
Participants attended an initial pre-screening visit (following a 12-hour overnight fast), 
at which the following investigations were completed (as described in Section 2.2.1): 
 Anthropometric and blood pressure measurements 
 Blood sample  
 3-day food diary  
Those who met the inclusion criteria attended for 4 further such visits, at the beginning 
and end of each intervention period. 
The study was a crossover design, as shown in Figure 3.2; participants received both 
prawns (Pr) and processed white fish for separate periods with a washout period 
between. Participants were randomised, using a random number generator, to receive 
a daily portion of either prawns (225g/day) or an equivalent weight of white fish 
provided in the form of crabsticks, also known as ocean sticks (OC) for 4 weeks.  The 
investigator analysing results was not aware of the order in which dietary interventions 
were carried out.   Following a 4-week washout period (no prawns or OC), participants 
changed to the alternative protein portion for a further 4 weeks.  They were requested 
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to follow their habitual diet throughout the study, not to consume additional shellfish or 
fish, and not to change other lifestyle variables such as physical exercise.   
 
                Prawn                             OC 
 
Initial  
Screening   Randomisation                                      Washout               END 
visit 
 
                  
        OC    Prawn 
 
 
                     
 
Anthropometry Pre  1   2                3         4 
Analysis  Pre  1                         2                3                         4 
FOOD DIARY             -               
 
Figure 3.2.   Diagram of intervention protocol 
 
Blood samples were obtained from subjects at the start and end of each intervention 
stage (4 in total) and collected into EDTA; plasma was separated by centrifugation and 
stored in 1 mL aliquots at -80oC until analysis (as described in Section 2.1.2.). 
3.3.1.2.Biochemical markers of CVD risk 
The following were measured as described in Section 2.2.2: 
 TC, TAG, HDL-C, sdLDL-C (enzymatic assay) 
 ApoA1, ApoB  (immunoturbidimetric assay) 
 Plasma Insulin 
LDL-C was calculated from the Friedewald formula (Friedewald et al., 1972). 
3.3.1.3. Lipoprotein analysis by DGUC 
Lipoprotein fractions (LDL, HDL, VLDL) and LDL subclasses were separated from 
plasma by iodixanol density gradient centrifugation (Davies et al., 2003) followed by 
fractionation and estimation of cholesterol in fractions using the cholesterol oxidase 
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method of Roschlau  (Roschlau et al., 1974), as described in Section 2.2.2.4.   Inter 
and intra- assay coefficients of variation for all autoanalyser assays were less than 2%, 
and for iodixanol separations were <3% and <1% (Davies et al., 2003). 
3.3.1.4. Food intake assessment 
Participants were asked to complete 3-day food intake diaries as described in Chapter 
2, section 3: these were analysed using WinDiet software (Robert Gordon University, 
2005).   The parameters estimated from food diaries completed prior to and during 
each of the intervention stages are listed in Table 3.3. 
 
 
 
 
 
 
Table 3.3 Nutrients estimated from food intake diaries 
 
3.4. STATISTICAL ANALYSIS  
 
 All data were subjected to statistical analysis using SPSS v20.  Outliers (more than 
2SD from the mean) were removed from further analysis.   The data were examined for 
normality using the Kolgorov-Smirnov test before applying appropriate significance test.   
Data that could be normalised were tested parametrically using the paired student       
t-test; data that could not be normalised were analysed non-parametrically using the 
Wilcoxon ranked sign test.  Split-plot ANOVA (SPANOVA) and ANCOVA were used to 
compare outcomes between and within groups.   The changes (Δ) between start and 
end of interventions were also compared between Pr and OC groups.   Correlations 
were carried out between baseline and baseline-endpoint change (Δ) for biochemical 
and lipoprotein measurements. Pearson correlation coefficients were determined to 
compare relationships between selected variables. For all statistical analyses a 
probability of p <0.05 was regarded as significant. 
Macronutrients
   
Energy, Fat, Protein and Carbohydrate 
Fat components
  
SFA, PUFA, MUFA cholesterol 
Carbohydrate 
components  
dietary fibre, non-starch polysaccharide (NSP),   sugars, 
 non-milk extrinsic sugars (NMES) 
Alcohol - 
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3.5 RESULTS 
 
3.5.1. Composition of Pr and OCs 
 
The macronutrient composition of Pr and OCs, as provided by the manufacturers, is 
summarised in Table 3.4, together with an estimate of n-3 LCPUFA content and 
cholesterol for each.   
OCs are manufactured from white fish meat, flavoured to taste similar to crabmeat. 
They are low in cholesterol and in n-3 LCPUFA; the manufacturer’s label indicates only 
a trace of these in 100 g.  Overall protein, energy and carbohydrate contents of the two 
foods was significantly different; prawns contained approximately double the amount of 
protein, and half the fat of OC, but very little carbohydrate. By contrast, OC contained 
approximately 1/8 weight as carbohydrate, and nearly double the level of sodium 
compared with Pr. Assuming full compliance, these differences in composition may 
have been significant factors; the possibility that this may have influenced or 
confounded the outcome of the study is discussed at the end of this chapter. 
 
Nutrient Prawns OCs 
 Per 100g Per 225g  
(daily intake) 
Per 100g Per 225g 
(daily intake) 
Energy (kcal) 62 140 115 259 
Protein (g) 17.9 40.3 9.0 20.3 
Carbohydrate (g) 0.1 0.23 15.5 34.9 
Total sugars (g) 0.1 0.23 3.9 8.9 
Fat (g) 0.74 1.67 1.6 3.6 
Saturates (g) 0.4 0.9 0.4 0.9 
Monounsaturates (g) 0.3 0.7 0.3 0.7 
Polyunsaturates (g) 0.1 0.23 0.5 1.1 
n-3 LCPUFA (DHA plus EPA) (mg) 267-311 600-700 Trace Trace 
Cholesterol (mg) 130 295 Trace trace 
Fibre (g) 0.5 1.1 0.6 1.4 
Salt (g) 1.1  2.45 1.9 4.3 
Sodium (mg) 440 990 760 1710 
 
Table 3.4 Composition of Prawns and OCs 
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3.5.2. Anthropometry 
3.5.2.1:  Baseline anthropometry 
 
The anthropometric details for all participants at the start of the study are summarised 
in Table 3.5.  Participants were recruited on the basis of normal healthy profile; 
however, of the 21 individuals, only 9 fell within the recommended range for a normal 
BMI (between 19 and 25).   For a further 9, BMI was between 25 and 30, and for 3 in 
excess of 30 kg/m2.   Although the mean systolic blood pressure at the start of the 
study was <125mm Hg, one individual had an initial systolic/diastolic BP of 171/93. 
This was less than 2SD from the mean: this individual was not excluded from the study. 
 
 Range Mean SD 
Age (yrs) 19-67 41  
Weight (kg) 59.6 – 109.0 82.1 12.2 
Height (m) 1.65-1.94 1.79 0.08 
BMI 18.9-35.1 25.7 4.3 
BP (systolic) 98-171 125 14 
BP (diastolic) 45-101 73 11 
Pulse 51-101 67 10 
Table 3.5.   Anthropometric details for participants (n = 21) 
3.5.2.2. Changes in anthropometric characteristics 
 
Changes in anthropometric measurements are shown in Table 3.6. Distribution for all 
measures was normal (p > 0.05) according to Kolgorov-Smirnoff test except for post-
intervention systolic blood pressure (OC), and pre- and post-intervention pulse (Pr).  
There was no significant change in body weight, BMI, systolic or diastolic blood 
pressure between baseline measurements and those at the end of either dietary 
intervention (p > 0.05).   The pre-post intervention difference was compared for each 
measure using the Wilcoxon Signed Rank test; there was no significant difference in 
changes between interventions except for pulse rate. Pulse measurements showed a 
mean increase during OC intervention compared with a decrease during Pr intake, 
which was significant  (independent t-test, p = 0.016).   A decrease in heart rate was 
previously noted by Kelley et al. (2007) following supplementation with DHA at 3g per 
day:  heart rate decreased by 8.3% after 45 days and by 5% at 91 days.   This 
compares with a mean decrease in pulse rate in the group described here of 8.0%, 
with a combined EPA plus DHA intake estimated at 600-700 mg daily.   
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 OC 
n = 21 
Prawn 
n = 21 
Significance 
ΔOC vs ΔPr
2
 
 Pre 
intervention 
Post 
intervention 
 
1
 p   
 
Change 
(ΔOC) 
% 
change 
Pre 
intervention 
Post 
intervention 
   
1
p   
 
Change 
(ΔPr) 
% 
change 
p  
Weight 
(kg) 
82.0 
(12.6) 
81.6 
(12.4) 
0.21 -0.43 
(1.5) 
-0.5 
(1.8) 
82.1 
(12.2) 
81.8 
(12.2) 
0.205 -0.27 
(0.96) 
-0.3 
(1.2) 
0.642 
BMI 
(kg/m
2
) 
25.7 
(4.3) 
25.6 
(4.3) 
0.196 -0.12 
(0.45) 
-0.5 
(1.8) 
25.7 
(4.3) 
25.6 
(4.3) 
0.226 -0.09 
(0.31) 
-0.3 
(1.2) 
0.696 
BP 
Systolic 
124 
(14) 
126 
(16) 
0.788 1.76 
(9.1) 
1.6 
(7.7) 
125 
(14) 
124 
(13) 
0.383 -0.57 
(9.6) 
-0.2 
(7.3) 
0.715 
BP 
Diastolic 
72 
(12) 
73.1 
(11) 
0.989 1.07 
(6.3) 
2.1 
(9.4) 
73 
(11) 
73 
(9) 
0.443 0.02 
(8.2) 
1.1 
(13.1) 
0.497 
Pulse 69 
(12) 
73.1 
(18) 
0.106 4.3 
(14.2) 
6.6 
(21.9) 
66 
(8) 
61 
(16) 
0.180 -5.3 
(14.3) 
-7.8 
(23.0) 
0.016 
Table 3.6 Changes in anthropometric characteristics following dietary intervention 
All measurements are given as mean with SD in brackets; absolute measures were compared using paired t-test: :  Changes (ΔOC vs ΔPr) 
could not be normalised and therefore were compared using Wilcoxon test2 
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3.5.3. Biochemical markers of MetS and CVD risk 
 
3.5.3.1. Measurement of atherogenic markers 
Mean values pre- and post- intervention of all lipid biochemistry measurements, with 
mean changes, standard deviations and significance for difference between groups, 
are shown in Table 3.7.   Comparison of the baseline values for the prawn and OC 
groups revealed no significant difference in baseline measurements between 
interventions, and SPANOVA analysis revealed no overall significant difference 
between endpoint measurements between groups (p > 0.12 for all measurements, 
assuming equality of variances using Levene’s test).  No significant change between 
baseline and post-intervention measurements was observed for either prawns or OCs 
for cholesterol, TAG, HDL, sdLDL or ApoA1. For ApoB, a mean negative change (Δ) 
was observed between start and end of the prawn intervention (-7.8 mg/dL, p = 0.047), 
with a small increase during the OC intervention (2.4 mg/dL, p = 0.274); the difference 
in overall mean change (ΔOC vs ΔPr) in ApoB was significant (p = 0.023) using 
Wilcoxon rank test. 
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Marker Prawn (n = 18) OC (n = 18)  
Pre- 
intervention 
Post-
intervention 
1
p  
 
Mean  
Change 
 (ΔPr) 
Pre-
intervention 
Post-
intervention 
1
p  
 
Mean 
Change 
(ΔOC) 
Significance  
ΔOC vs ΔPr 
2
p Mean SD Mean SD Mean SD Mean SD 
TAG (mmol/L) 1.06 0.32 1.23 0.50 .459 .03 1.29 0.50 1.25 0.42 .636 -.04 .715 
TC (mmol/L) 5.15 1.00 4.98 0.91 .106 -.17 4.94 0.91 5.29 0.67 .979 0.05 .124 
HDL-C 
(mmol/L) 
1.50 0.34 1.44 0.31 .092 -.03 1.52 0.36 1.50 0.36 .582 -.02 .626 
ApoA1 
(mg/dL) 
141.4 23.4 130.9 19.5 .114 -5.1 135.9 17.6 137.0 19.6 .876 0.48 .336 
ApoB (mg/dL) 97.6 22.4 89.7 16.2 .047 -7.8 91.4 17.6 94.7 16.3 .274 2.4 .023* 
sdLDL-C 
(mmol/L) 
16.1 12.1 15.8 8.4 .914 -0.3 15.39 6.61 17.5 6.6 .297 7.2 .145 
Table 3.7.  Lipid metabolism profiles from Autoanalyser techniques 
All measurements are given as mean and SD; absolute measures were compared using paired t-test1.  Changes (ΔOC vs ΔPr) could not be 
normalised and therefore were compared using Wilcoxon test2: * non-equality of variance assumed (Levene)   
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3.5.3.2.  Lipoprotein profiling by DGUC 
Lipoproteins were separated by ultracentrifugation for 18 of the 21 participants.   The 
results of estimation of lipoproteins and subclasses are shown in Table 3.8.   There 
was no significant difference in mean baseline measurements of any lipoprotein group 
(p > 0.31), nor in mean endpoint measurements of any lipoprotein type between 
interventions (p > 0.11).  Differences between pre- and post-intervention 
measurements were not significant for any lipoprotein during either intervention.    The 
change of each lipoprotein class from start to finish was also calculated.  No significant 
difference was noted for any subclass for either intervention, as shown in the final 
column of Table 3.8. 
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 Prawn (n=18) OCs (n = 18)  
 Pre-
intervention 
Post-
intervention 
Change 
ΔPr 
 Pre-
intervention 
Post-
intervention 
Change 
ΔOC 
 ΔPr vs 
ΔOC 
 Mean 
(SD) 
Mean 
(SD) 
Mean  
Change 
P Mean 
(SD) 
Mean 
(SD) 
Mean 
Change 
p p 
TC (DGUC) 
(mmol/L) 
6.39 
(1.41) 
6.29 
(1.48) 
-0.09 
 
.723 5.87 
(1.04) 
5.84 
(1.01) 
-0.07 .735 .938 
 
VLDL-C (mmol/L) 0.63 
(0.21) 
0.67 
(0.24) 
0.04 .280 0.55 
(0.25) 
0.57 
(0.21) 
0.01 .459
1
 
2
.656 
LDL-C (mmol/L) 3.42 
(0.94) 
3.19 
(0.78) 
-0.23 .228 3.14 
(0.79) 
3.22 
(0.80) 
0.04 .731 .227 
sdLDL-C (mmol/L) 0.98 
(0.37) 
0.98 
(0.35) 
<0.01 .974 1.01 
(0.44) 
1.11 
(0.49) 
0.12 .050 .187 
lbLDL-C (mmol/L) 2.44 
(0.74) 
2.21 
(0.60) 
-0.23 .134 2.13 
(0.61) 
2.10 
(0.63) 
-0.08 .492 .425 
HDL-C (mmol/L) 1.98 
(0.59) 
1.91 
(0.43) 
0.09 .701 1.84 
(0.39) 
1.73 
(0.28) 
-0.10 .527
1 
.429
2 
HDL/SDL ratio 0.87 
(0.31) 
0.89 
(0.20) 
0.03 .287
1 
0.93 
(0.30) 
0.88 
(0.24) 
-0.02 .616 .146
2
 
VLDL % of total  10.1 
(3.2) 
10.9 
(3.4) 
0.84 .100 9.4 
(3.4) 
9.8 
(3.6) 
0.02 .906
1
 .443 
LDL % of total  52.9 
(6.6) 
50.9 
(6.7) 
-1.98 .236 52.9 
(6.5) 
54.4 
(5.7) 
1.29 .073 .074 
lbLDL (%of LDL) 71.4 
(8.0) 
69.3 
(8.0) 
-2.0 .237 68.1 
(10.4) 
65.7 
11.1) 
-3.1 .068
1 
.638 
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TABLE 3.8:  Lipoprotein classes and subclasses (DGUC)   
All measurements are given as mean with SD in brackets; absolute measures were compared using paired t-test for normal distributions, 
except for  1Wilcoxon rank (non-parametric for non-normal distribution),:  Changes (ΔOC vs ΔPr) could not be normalised and therefore were 
compared using Wilcoxon test2 
 
 Prawn (n=18) OCs (n = 18)  
 Pre-
intervention 
Post-
intervention 
Change 
ΔPr 
 Pre-
intervention 
Post-
intervention 
Change 
ΔOC 
 ΔPr vs 
ΔOC 
 Mean 
(SD) 
Mean 
(SD) 
Mean  
Change 
P Mean 
(SD) 
Mean 
(SD) 
Mean 
Change 
p p 
sdLDL (% of LDL) 28.6 
(8.0) 
30.7 
(8.0) 
2.0 .237 31.9 
(10.4) 
34.3 
(11.1) 
3.1 .055 .638 
HDL % of total 31.3 
(7.0) 
32.5 
(7.0) 
1.2 .403 31.9 
(6.3) 
30.0 
(4.9) 
-1.4 .144 .128 
Total cholesterol 6.60 
(1.18) 
6.38 
(0.72) 
<0.01 .798 6.50 
(0.94) 
6.43 
(1.04) 
-0.1 .445 .605 
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3.5.3.3. Correlations between plasma biochemistry and lipoprotein measurements 
The data presented in sections 3.5.3.1.and 3.5.3.2 were further investigated for 
correlation between a) different biochemical measurements at baseline and b) between 
measurements of lipoproteins obtained by autoanalyser and DGUC techniques.   
These results are presented in Table 3.9.    
A strong correlation (r > 0.5) was observed for TC and HDL-C estimated from 
ultracentrifugation and autoanalyser techniques (0.798, p < 0.001) and (0.527, p = 
0.001) respectively.   Strong positive correlations (rho > ρ0.5) were also noted for TAG 
with VLDL-C and sdLDL-C measurements (both by DGUC and autoanalyser 
technique).  TC measurements also showed strong correlation with those for ApoB, 
LDL-C, sdLDL-C and lbLDL-C, as did measurement of HDL-C (by autoanalyser 
technique or DGUC) with ApoA1, and ApoB with sdLDL-C, VLDL-C, and lbLDL-C. 
Moderately positive correlations (rho = 0.3 to 0.49) were noted for TC with HDL, ApoA1,  
sdLDL-C and VLDL-C, for HDL-C with lbLDL-C, for ApoA1 with ApoB, HDL/SDL  and 
HDL-C as a percentage of total lipoprotein, and for ApoB with VLDL-C. 
Strong negative correlations (r > -0.50) were noted for plasma TAG with HDL-C, ApoA1, 
HDL-C, HDL-C (as percentage of TC), lbLDL-C (as a percentage of LDL-C), for TC 
with HDL/SDL ratio and HDL (as percentage of total), and for ApoB with HDL/SDL ratio, 
HDL as percentage of total.   A moderate negative correlation (r between -0.30 and -
0.49) was observed for HDL-C with LDL-C and also with sdLDL-C when these were 
expressed as a percentage of total. Although absolute values for lipoprotein 
measurements differed between methods used, the correlation between values was 
very strong (p < 0.001).    
The data were also inspected for correlation between baseline measurements and 
changes (delta), using the Spearman correlation coefficient (non-parametric):  results 
are shown in Table 3.11.   There was a significant negative correlation between 
baseline measurements and Δ during intervention for TC, ApoB, sdLDL-C, LDL-C, 
lbLDL-C and the HDL/SDL ratio (p < 0.001in all cases) and a less significant correlation 
for plasma TAG (p = 0.011). Correlations for other measurements (HDL-C, ApoA1, 
VLDL-C and sdLDL-C by DGUC) were not significant.  
Use of ANOVA or ANCOVA techniques to compare between-subject effects was 
limited by the non-normality of some of the data, in particularly plasma TAG and HDL-C 
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measurements. It was not possible to normalise data for baseline-endpoint differences 
(Δ measurements).    
 Positive correlation Negative Correlation 
  rho P  rho  P 
Plasma TAG VLDL .530 .001 HDL  -.576 <.001 
sdLDL(DGUC) .549 .001 ApoA1 -.451 .004 
VLDL (%) .521 .002 HDL (DGUC) -.361 .036 
sdLDL (%) (DGUC) .632 <.0001 lbLDL (%) -.632 <.001 
   HDL (%) -.486 .004 
TC 
(autoanalyser) 
HDL .421 .006 HDL/sdLDL ratio -.553 <.001 
ApoA .409 .007 HDL (%) -.544 .001 
ApoB .803 <0.001    
sdLDL .309 .047    
TC (DGUC) .798 <0.001    
VLDL .478 .003    
LDL .872 <0.001    
sdLDL (DGUC) .558 <0.001    
lbLDL .711 <0.001    
LDL (%) .572 <0.001    
HDL  
(autoanalyser) 
ApoA1 .843 <0.001 LDL (%) -.334 .050 
HDL (DGUC) .527 .001    
lbLDL (%) .383 .023 sdLDL (%) -.383 .023 
HDL (%) .341 .045    
ApoA ApoB .357 .020    
HDL (DGUC) .585 < 0.001    
HDL/SDL ratio .341 .042    
HDL% .351 .036    
ApoB sdLDL .508 .001 HDL/SDL  -.517 .001 
TC (DGUC) .680 <0.001 HDL % -.580 <.001 
VLDL .449 .006    
LDL .795 <0.001    
sdLDL (DGUC) .645 <0.001    
lbLDL .598 <0.001    
LDL (%) .604 <0.001    
Table 3.9:  Correlations between biochemical and lipoprotein measurements  
(Spearman correlation used for all comparisons) 
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 Correlation coefficient Spearman’s rho 
TAG -.398 .011 
TC -.526 .000 * 
HDL-C -.291 .065 
ApoA1 -.252 .108 
ApoB -.564 .000 * 
sdLDL-C -.573 .000 * 
VLDL-C -.304 .076 
sdLDL-C (DGUC) -.271 .110 
LDL-C -.574 .000* 
lbLDL-C -.599 .000 * 
HDL-C -.291 .085 
HDL/SDL ratio -.518 .001* 
Table 3.10.   Correlation between baseline value and change for biochemical and 
lipoprotein measurements  
(Spearman rank* significant at 0.01 level (2-tailed). 
 
3.5.4. Impact of baseline measurements on outcome 
3.5.4.1.  Baseline BMI and changes in markers of CVD risk 
To determine whether there might be any impact of baseline BMI on the outcome of 
either dietary intervention, participants were subdivided by BMI, and comparisons of 
post-intervention measurements and changes in biochemical/lipoprotein 
measurements were repeated.   Significant changes are tabulated in Table 3.11.     
Pr intervention:  the only significant difference in ΔPr was for plasma TAG, which 
showed a mean increase of 0.30 mmol/L (SD = 0.51) for participants with BMI ≤ 24.9, 
and a mean decrease of 0.17 mmol/L for participants with BMI ≥ 25.00 (p = 0.028).  
This represented a mean increase of 32.3% (SD 45.2) from baseline value for the 
lower BMI group, compared with a mean percentage decrease of -7.7% (SD 22.3%) for 
the higher BMI group (p = 0.033).  There were no other significant differences between 
ΔPr values between subgroups during the prawn intervention. 
OC intervention:  By contrast, differences between ΔOC of BMI subgroups were 
observed, as follows: 
ΔApoB:   A mean increase of 6.09 mmol/L  (SD = 9.38) for BMI ≤ 24.9, and a mean 
decrease of 1.70 mmol/L (SD = 8.70) for BMI ≥ 25.0, (p = 0.064).  When considered in 
terms of percentage changes, the difference between BMI groups was significant, 
(+8.16%  (SD = 10.86) and -1.55% (SD = 8.51) respectively, (p = 0.036)). 
ΔVLDL:   a mean increase of 0.08 mmol/L (SD 0.97) for BMI < 24.9, compared with a 
decrease of 0.07 mmol/L for BMI > 25.0, (p = 0.091).  As for ApoB changes, the 
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difference between BMI groups achieved significance when calculated as a percentage 
of the baseline value, (+20.79 % (SD  23.54) for the lower BMI group, compared with -
12.31% (SD 40.26) for the higher BMI group, (p = 0.049). ΔVLDL as a percentage of 
total lipoprotein cholesterol showed a mean increase of 2.22% (SD 3.43) for the lower 
BMI subgroup compared with a mean decrease of 2.18% (SD 3.39) for the higher BMI 
subgroup  (p = 0.015). 
ΔHDL:  a mean decrease of 0.32 mmol/L (SD 0.44) or 13.47% (SD 18.67) for the lower 
BMI group, compared with an increase of 0.12 mmol/L (7.27%) for the higher BMI 
group (p = 0.007 and 0.005 respectively).  ΔHDL calculated as a percentage of total 
lipoprotein cholesterol also showed a significant difference between the two BMI 
subgroups, with a mean decrease of 3.78% (SD 2.63) for the lower BMI subgroup, and 
a mean increase of 0.94% (SD 3.69 for the higher BMI subgroup (p = 0.007).  The 
differences in HDL and sdLDL for the two BMI subgroups were also reflected in a 
significant difference between groups in the ΔHDL/sdLDL ratio  (p = 0.043). 
The higher BMI group showed a beneficial change in plasma TAG compared with the 
lower BMI group during the Pr intervention.  For the OC group, the significant 
differences in lipoprotein subclasses and ApoB also indicate a small improvement in 
profile for the higher BMI group relative to the lower BMI group, or may be indicative of 
a small increase in atherogenic risk in this latter group. 
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Measurement Prawn OC 
 BMI≤24.9 BMI≥25.0 p BMI<24.9 BMI>25.0 p 
Δ TAG (mmol/L) 0.30  
(0.51) 
-0.17 
(0.38) 
0.028 0.08 
 (0.30) 
-0.17 
(0.48) 
0.168 
Δ TAG (% of 
baseline) 
32.3  
(45.2) 
-7.7  
(22.3) 
0.033 11.55 
(30.40) 
-6.44 
(33.51) 
0.213 
ΔHDL (mmol/L) -0.11 
(0.17) 
0.02  
(0.14) 
0.067 -0.02  
(0.18) 
-0.01 
(0.10) 
0.916 
ΔApoB (mg/dL) -1.39 
(13.45) 
-12.67 
(18.25) 
0.135 6.09  
(9.38) 
-1.70 
(8.70) 
0.064 
ΔApoB (%of 
baseline) 
1.48 
(19.00) 
-10.23 
(17.06) 
0.136* 8.16 
(10.86) 
-1.55 
(8.51) 
0.036 
ΔsdLDL (AA) 
(mmol/L) 
4.54 
(10.70) 
-3.95 
(13.84) 
0.227* 3.04  
(5.14) 
11.79 
(27.25) 
0.342** 
ΔsdLDL (% of 
baseline) 
87.05 
(126.52) 
2.68 
(58.94) 
0.093 
** 
24.06 
(45.49) 
1.29 
(36.29) 
0.267 
ΔVLDL (mmol/L) 0.09  
(0.16) 
0.01  
(0.15) 
0.291 0.08  
(0.97) 
-0.07 
(0.23) 
0.091 
ΔVLDL (% of 
baseline) 
16.65 
(30.48) 
3.01 
(25.92) 
0.324 20.79 
(23.54) 
-12.31 
(40.26) 
0.049 
ΔsdLDL (DGUC) 
(mmol/L) 
0.14  
(0.25) 
-0.09 
(0.29) 
0.104 0.06  
(0.21) 
0.19  
(0.27) 
0.285 
ΔsdLDL (% of 
baseline) 
18.8 
 (31.1) 
-6.87 
(23.15) 
0.071 12.52 
(24.65) 
18.61 
(24.44) 
0.606 
ΔHDL (DGUC) 
(mmol/L) 
0.10  
(0.56) 
0.08  
(0.42) 
0.946 -0.32  
(0.44) 
0.12  
(0.07) 
0.007* 
ΔHDL (DGUC) (% 
of baseline) 
9.92 
(33.00) 
2.38 
(18.55) 
0.541 -13.47 
(18.67 ) 
7.27 (3.89) 0.005* 
ΔHDL/SDL ratio 0.03  
(0.22) 
0.02  
(0.29) 
0.938 -0.11  
(0.13) 
0.07  
(0.20) 
0.043 
ΔVLDL % of total 
lipoprotein  
0.91  
(2.48) 
0.80 
(1.87) 
0.917 2.22  
(3.43) 
-2.18 
(3.39) 
0.015 
ΔHDL % of total 
lipoprotein 
-0.03 
(4.02) 
2.01  
(7.04 ) 
0.498 -3.78  
(2.63) 
0.94  
(3.69) 
0.007 
Table 3.11:  Changes in biochemical measurements and lipoprotein subclasses stratified 
by BMI   
(* Non parametric test for significance, ** Levene test <0.05, equality of variances not assumed)
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3.5.4.2. ApoB/ApoA1 ratio 
The ApoB/ApoA1 ratio was estimated for both prawn and OC interventions.  No 
significant differences were observed between mean values for the two groups, and 
the mean values within groups also showed no significant differences. Estimation of 
the change in ApoB/ApoA1 ratio was also calculated for each participant, and a 
comparison of these results is shown in Figure 3.3 and in Table 3.12.     One individual 
(case 11/32) showed an increase in ApoB/ApoA1 ratio during OC (but not Pr) which 
was > 2SD from the mean, although measurements for ApoA1 and ApoB individually 
were within 2SD of the mean for both baseline and post-intervention measurements.  
TC following OC (but not prawn) intervention was also more than 2SD above the mean 
for this individual.  This may indicate some abnormality in cholesterol or lipidaemic 
metabolism compared with other members of the cohort. 
 
 
Figure 3.3   Comparison of changes in ApoB/ApoA1 ratio between interventions 
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Diet Group Baseline 
ApoB/ApoA1  
Endpoint 
ApoB/ApoA1  
Δ ApoB/ApoA1  
Prawn 0.698  
(0.16) 
0.683  
(0.131) 
-.0213  
(.073) 
OC 0.675  
(0.135) 
0.693  
(0.140) 
0.018  
(0.070) 
p 
(between 
groups) 
1
0.613 
1
0.815 
2
0.081 
 
Table 3.12:  Changes in ApoB/ApoA1 ratio  
(mean with SD in brackets;  1paired t-test, 2Wilcoxon test for non-parametric 
distribution) 
 
3.5.5. FOOD INTAKES 
 
Eighteen participants completed the initial food record, with 11 completing during the 
prawn intervention and 14 during the OC intervention.   Significant outliers for specific 
nutrients (>2SD away from the mean) were excluded from overall analysis. 
 
3.5.5.1. General observations 
Mean nutrient intakes as calculated from the information provided by the participants 
are shown in Table 3.13.   Nutrient intakes were normal in distribution, with the 
exception of energy intake (both in kcal and as a percentage of RNI) post intervention 
for the OC period.    
The contribution of macronutrients to overall energy intake showed differences 
between baseline and endpoint of interventions, as shown in Table 3.14.  Paired t-tests 
between baseline and endpoint showed a significant decrease in carbohydrate 
between baseline and end of the OC intervention (p = 0.047), although change in 
carbohydrate as a percentage of total energy was not significant  (p = 0.44).  Intakes of 
fibre (p = 0.01), non-starch polysaccharide (p = 0.001), sugars (p = 0.015) and non-milk 
extrinsic sugars (p = 0.032) were all significantly lower at the end of the OC 
intervention; cholesterol intake also decreased between start and end of this 
intervention, from a daily mean of 331 mg (SD 223) to 275 mg (SD 92), (p = 0.01).  
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By contrast, significant changes noted during the prawn intervention were an increase 
in protein both as a percentage of RNI and of total energy (p = 0.024 and 0.021 
respectively), and in mean cholesterol intake from 331 to 794 mg (SD 186, p <0.001).   
Alcohol intake was not significantly altered between baseline and the end of either 
intervention, although the number of participants reporting zero alcohol intake rose 
from 8 at baseline to 12 (OC) and 15 (Pr).   
Differences in mean nutrient intake between the diaries completed at the end of the OC 
and prawn intervention accord fairly closely with the differences in nutrient composition 
of the daily OC and prawn portions for energy, protein, fat and carbohydrate.  The 
mean intake of sugars was higher by about 8g per day for the prawn than for the OC 
records, whereas sugar intake due to the OC would have been approximately 8g 
higher than the sugar intake due to prawns.    
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 Baseline  
(n = 18) 
Post intervention OC  
(n = 14) 
Post intervention Pr  
(n= 11) 
Pr/OC endpoints 
 Mean SD Mean SD 
1
p =  Mean SD 
1
p =  
2
p =  
Energy (kcal) 2205 458 2099 630 .207 1940 393 .457 .661 
Energy as % EAR 88.1 18.2 83.9 24.4 .196 78.6 15.3 .453 .701 
Protein (g) 86.4 23.0 92.2 27.6 .098 109.1 21.7 .020 .052 
Protein as % RNI 155.1 42.4 167.4 49.2 .099 199.7 37.1 .020 .024 
Protein as % energy 15.8 3.3 19.2 4.9 .086 23.7 4.3 .007 .021 
Carbohydrate (g) 277.0 77.3 233.2 68.8 .047 208.1 52.9 .083 .324 
Carbohydrate as % energy 50.2 8.7 46.3 6.7 .441 42.9 6.7 .039 .259 
Fat (g) 76.4 21.7 66.1 26.1 .168 63.7 18.2 .810 .870 
Fat as % DRV 76.7 21.5 61.5 18.6 .132 64.7 17.8 .798 .601 
Fat as % energy 31.2 5.6 29.8 3.1 .100 29.4 4.6 .841 .460 
Saturated fatty acids (g) 24.6 8.8 20.7 10.0 .110 18.9 4.7 .187 >0.99 
SFA as  % DRV 78.4 27.5 66.1 31.6 .105 61.3 15.2 .188 >0.99 
PUFA (g) 15.1 6.1 9.4 3.5 .161 13.5 7.9 .570 .147 
PUFA as % DRV 81.6 32.4 51 19.6 .158 74.0 43.1 .579 .173 
MUFA (g) 25.3 8.0 22.3 10.8 .276 21.2 5.9 .912 .511 
Cholesterol (mg) 331 223 275 91.7 .010 794.1 186.0 .000 .000 
Fibre (g) 17.3 5.7 13.1 2.9 .008 15.7 5.0 .410 .213 
NSP (g) 13.8 4.1 11.2 3.2 .001 11.2 3.4 .121 .784 
NSP as % DRV 76.3 22.8 61.5 17.7 .001 61.5 19.0 .116 .784 
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 Baseline  
(n = 18) 
Post intervention OC  
(n = 14) 
Post intervention Pr  
(n= 11) 
Pr/OC endpoints 
 Mean SD Mean SD 
1
p =  Mean SD 
1
p =  
2
p =  
Sugars (g) 117.6 38.8 87.7 30.3 .015 95.3 31.0 .105 .469 
NMES (g) 81.9 38.0 56.4 18.0 .032 62.5 31.9 .237 .706 
NMES as % DRV 112.7 51.6 78.3 25.1 .031 87.2 43.6 .231 .643 
Alcohol* 22.6 12.5 29.3 18.6 .302 33.7 18.8 .710 .723 
Alcohol as % energy 7.1 4.5 9.9 4.5 .138 12.0 5.9 .445 .409 
Table 3.13 Dietary intake data 
(*Only those with positive alcohol consumption were recorded (n = 13, 9 and 6 respectively) 
 1
Significance – paired t-test between initial and final records.
 2
Wilcoxon non-parametric test for non-normal distribution.
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3.5.5.2. Intake of n-3 LCPUFA and cholesterol 
The key nutrients of interest were n-3 LCPUFA and cholesterol.   Intake of cholesterol 
was derived from the information provided in the food diaries and assuming full 
compliance with the supplementation of Pr or OC.   Overall intake of PUFA (n-6 plus   
n-3), excluding Pr or OC intake, was not significantly different in total weight or as a 
percentage of DRV between baseline and end of either intervention.  It was not 
possible to make an accurate overall assessment of n-3 LCPUFA (total or LCPUFA) 
intake based on food intake records, using the Windiet program version available at the 
time. The decision was therefore taken to make an approximation based on expected 
intakes of PUFA.  It has been suggested based on population surveys that the baseline 
n-3 PUFA intake of these individuals would be of the order of 100-200mg per day 
(Calder, 2004), although there is little data to confirm this.  Calder suggested in this 
review that typical intakes of LCPUFA for adult males in the UK were approximately: 
13.5g LA, 1.7g ALA, 0.3g ArA and 0.25g DHA+EPA (totalling 15.75g).  This 
corresponds reasonably well with the mean baseline PUFA intake from the food diaries 
of the participants (15.1g), which would have provided DHA+EPA at approximately 
1.6% of total PUFA.   Based upon this, assuming daily n-3 LCPUFA intake from OC to 
be <20 mg, and from prawns to be 650mg, estimates of intake and the changes for the 
two groups were derived, as shown in Table 3.14. 
  OC 
(n = 14) 
Prawn 
(n = 11)  
OC 
(n = 14) 
Prawn 
(n = 11) 
 Pre Post Post ΔOC ΔPr 
Mean daily intake (mg) 242 169 856 -80 664 
SD 97 55 135 90 148 
Significance Pre/Post intervention  0.016 <0.001   
Significance between groups    <0.001 
Table 3.14:  Estimates of n-3 LCPUFA intake and changes 
  The mean daily intake was based on records from food intake diaries, assuming n-3 LCPUFA 
to be 1.6% of recorded PUFA intake, and with calculated additional intake for prawn intervention 
assuming full compliance. 
 
3.5.5.3. Changes in food intake  
Difference in nutrient intake between start and finish of each intervention was 
calculated for each individual who completed both baseline and final food records, and 
the mean of this difference then calculated.  Mean changes in intake for macronutrients 
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were calculated as total intake, percentage of daily recommended intakes (RNI, EAR or 
DRV as appropriate) and as percentage of total energy intake for protein, carbohydrate, 
total fat and alcohol.   These are shown in Table 3.15.    
Both groups showed a mean reduction in energy intake between start and finish of the 
intervention (171 vs 199 kcal, 5.5% and 5.4% of baseline value for Pr and OC 
respectively), but the difference in changes was not significant between interventions 
(p = 0.928).   Protein intake increased both as percentage of RNI and as percentage of 
total energy intake for those consuming prawns but less so for the OC intervention; this 
difference was significant as measured by t-test, (p = 0.038 for total protein and 0.046 
for protein as percentage of RNI). Differences between interventions for other nutrients 
were not significant, except for total PUFA, where an increase during Pr intervention is 
contrasted with a decreased during OC intervention (p = 0.048), and the highly 
significant changes in cholesterol and n-3 LCPUFA intake (as described above). 
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 Prawn  
(n = 8) 
OC  
(n= 12) 
  
 Mean change SD % change SD Mean change SD % change SD p 
mean 
change 
p 
% 
change 
Energy kcal -171.5 623.1 -5.5 26.6 -199.2 684.4 -5.4 32.0 0.928 0.993 
Energy as % of EAR -7.0 25.2   -8.3 27.4   0.919  
Protein (g) 31.3 28.8 45.1 47.8 2.6 27.7 6.7 35.2 0.038 0.052 
Protein (%RNI) 57.1 52.1 45.7 48.3 4.6 52.7 7.3 36.8 0.046 0.065 
Protein as % of energy 7.2 6.2   2.2 4.1   0.038  
Carbohydrate (g) -70.3 98.1 -18.8 32.1 -30.2 97.9 -6.0 36.9 .382 .436 
Carbohydrate as % energy -7.9 9.6   -1.3 5.7   .065  
Fat (g) -2.5 28.1 1.4 45.9 -12.5 25.9 -10.9 30.7 0.42 0.482 
Fat % of DRV -2.6 28.2 1.6 46.0 -12.8 25.9 -10.9 30.6 .419 .472 
Fat (% energy) 0.5 7.5   -2.1 4.7   .343  
SFA -4.46 8.7 -35.6 53.6 -2.6 9.3 -22.1 53.2 .654 .588 
SFA (% DRV) 14.5 28.2 14.2 36.4 -8.5 29.8 -0.4 49.1 .658 .508 
PUFA (g) 1.9 9.1 21.0 83.6 -5.3 6.2 -28.1 31.1 .048 .078 
PUFA (% DRV) 10.0 49.2 21.1 84.2 -29.0 33.4 -28.3 31.3 .048 .078 
MUFA (g) 0.36 9.0 7.2 40.4 -4.7 11.7 -9.7 46.1 .312 .410 
Cholesterol (mg) 553.5 169.1 258.1 160.0 -69.6 192.5 3.75 51.7 <.001 <.001 
Dietary fibre (g) -1.9 6.2 -0.7 46.2 -5.6 4.9 -24.7 22.0 .156 .134 
NSP (g) -2.3 3.7 -12.1 32.4 -3.5 3.2 -19.2 18.2 .446 .538 
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 Prawn  
(n = 8) 
OC  
(n= 12) 
  
 Mean change SD % change SD Mean change SD % change SD p 
mean 
change 
p 
% 
change 
NSP (% DRV) -13.0 20.5 -12.6 33.1 -19.4 18.0 -19.4 18.4 .470 .559 
Sugars (g) -28.0 42.5 -19.1 30.4 -21.6 40.0 -12.7 32.7 .737 .667 
NMES (g) -21.1 46.4 -18.1 42.8 -19.3 34.4 -14.3 36.4 .921 .857 
NMEs (% of DRV) -29.3 63.5 -18.2 42.8 -26.3 47.1 -14.7 36.5 .905 .846 
Alcohol (g) 2.6 12.7 10.4 39.9 5.7 15.6 26.7 64.8 .741 .662 
Alcohol (% of energy) 0.7 1.7   2.5 3.8   .421  
Table 3.15:  Changes in nutrient intake between dietary interventions 
(t-test assuming equality of variances (Levene test, p> 0.05 in all cases)
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3.6. DISCUSSION 
 
The aim of this pilot study was to determine whether prawns as a source of n-3 
LCPUFA might present a risk to cardiovascular health because of the associated 
increase in dietary cholesterol.  The participants were ostensibly healthy males 
between 19 and 67 years of age; however, of the 21 who completed the study, only 9 
fell within the recommended range for a normal BMI (between 19 and 24.9). For 9, the 
BMI was between 25 and 30, and for 3 in excess of 30 kg/m2. Benefits in dietary 
management might be more apparent for those with the most extreme baseline 
measurements; conversely, recent work (Tananescu et al., 2004; Houston et al., 2011) 
has pointed to a small increased relative risk of CVD associated with significant egg 
intake in individuals at risk of T2D.     
The choice of OC as the control group for the dietary comparison provided a weight-
for-weight foodstuff containing no cholesterol or n-3 LCPUFA, but the two foods were 
different in other ways.  OC, derived from Asian cuisine, are manufactured from white 
fish combined with starch-based binding ingredients, flavoured to resemble crabmeat.  
A daily ‘portion’ of 225 g prawns provided approximately 300 mg dietary cholesterol 
and an estimated 6-700 mg DHA plus EPA, compared with only trace amounts of either 
from a 225 g portion of OC. However, a 225g portion of OC provided approximately 
twice as many calories (259 kcal compared with 140), approximately 35g carbohydrate 
compared with less than 1 g (0.23 g) for a prawn portion, but only half as much protein 
(approximately 20 g compared with 40 g). Daily fat intake from prawns and OCs was 
low (1.6 g and 3.6 g respectively), and apart from the difference in n-3 LCPUFA, similar 
in the context of total daily intake.  The daily dietary contribution to salt intake was 1.1 g 
for a prawn portion and 1.9 g for OCs, both of which represent a significant intake 
compared with a recommended upper limit in the UK of 6 g per day (18% and 32% 
respectively).   Total salt intake was not estimated in this study. 
An alternative choice to OCs could have been filleted white fish, which would be high in 
protein, low in carbohydrate and also in salt (typically 20-22% w/w protein, < 1% 
carbohydrate and 0.2% salt), but this would have presented practical issues, making it 
more complicated to ensure a measured portion on a daily basis for a 4-week 
intervention study of this nature, in free-living participants.    
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3.6.1. Markers of CVD risk 
 
3.6.1.1. Overall changes in CVD markers 
No significant difference between intervention groups was noted for any 
anthropometric measures.   There was a significant difference in the mean pre-post 
pulse rate, with an increase in the OC group compared with a small decrease in the 
prawn group (p = 0.016).  This decrease of 8% in the mean pulse rate over an 
intervention period of 28 days compares favourably with that of 8.3% reported after 45 
days intervention with 3g per day DHA (Kelley et al., 2007).  
Mean TC at the start of prawn and OC interventions were 5.15 mmol/L (SD = 1.00) 
(range 3.1-7.0) and 4.94 mmol/L (SD = 0.91, range 3.4-7.1) respectively.  Plasma TAG 
at the start of each intervention were 1.06 mmol/L (SD  = 0.32, range 0.64-2.96) and 
1.29 mmol/L (SD = 0.50, range 0.57-2.32) respectively.  These figures compare with 
upper levels of 6.5 mmol/L for TC and 2.3 mmol/L for TAG for normolipidaemic 
individuals, as defined by Cleeman et al. (2001) and which were the criteria for 
inclusion in the study.   Even at the start of the interventions there were one or two 
individuals in each case who had fulfilled the screening criteria but for whom TC or 
TAG were already higher than the inclusion criteria.   This may represent failure to 
comply with the 8-hour fast prior to study visits. 
A small increase in plasma TAG was noted during the Pr intervention; stratification by 
BMI revealed a significant difference between the groups.  There was a small decrease 
in participants with BMI >25.0 (-0.17 mmol/L, SD 0.38, -7.7%, SD 22.3%), compared 
with a small increase for those participants with normal BMI (0.30 mmol/L, SD = 0.51 
and 32.3%, SD = 45.2).   A similar decrease was observed for the higher BMI group 
during the OC intervention, but the difference between subgroups did not reach 
significance.  
 
3.6.1.2. Relation to n-3 LCPUFA intake 
The n-3 LCPUFA content of the 225 g prawns is approximately 600mg, a level which 
has been reported to favourably influence CVD risk (Calder, 2004, Kris-Etherton et al., 
2002; 2004).  The estimated mean increase in daily intake of 664 mg n-3 LCPUFA for 
4 weeks in this study was associated with a small decrease in plasma TAG (mean        
- 0.17 mmol/L, -7.7% of baseline) in those individuals with a BMI in excess of 25 kg/m2 
(p = 0.033).   No other markers of CVD risk were significantly altered in either the 
normal or high BMI subgroup.   This compares with the meta-analysis of 21 
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randomised controlled trials by Balk et al. (2006), which reported a positive effect of n-3 
LCPUFA at an intake of 900 mg per day with a possible reduction up to 0.31 mmol/L.   
This review also reported an increase in HDL-C (0.04 mmol/L) and LDL-C (0.16 
mmol/L) at n-3 LCPUFA intakes between 45mg and 5000 mg per day (Wang et al., 
2006).   Mean HDL-C in the present study was increased by 0.09 mmol/L, although this 
did not reach significance, but mean LDL-C decreased by 0.23 mmol/L.   Kelley et al. 
(2007) in their study of DHA supplementation (3000 mg/day), reported a reduction in 
fasting TAG, TAG:HDL ratio, an increase in fasting LDL-C, LDL-C/HDL-C, but no 
change in fasting HDL-C.   Maximum effects were observed within 45 days from the 
start of this high-dose intervention (3g DHA per day) and maintained for the next 45 
days for these and other lipoprotein markers. Smith et al. (2011) however, compared 
intakes of DHA (1500 mg) or EPA esters (1860 mg) with corn oil over an 8 week period 
in a group of 16 elderly subjects as part of an investigation into muscle protein 
synthesis:  after 8 weeks supplementation they found no significant change in fasting 
TAG levels (mean 0.92 mmol/L, 0.95 mmol/L respectively). The potential reduction in 
TAG estimated by Balk et al. was larger than that seen for the Pr intervention in this 
study, and the level of DHA supplementation reported by Kelley was approximately 4 
times that of the combined DHA/EPA intake in this study.  Up to 65% of n-3 LCPUFA in 
prawns may be present as PL rather than TAG (Tou et al., 2007). As discussed in 
Chapter 4, it might be expected that more efficient absorption of n-3 LCPUFA in this 
form would be reflected in a more beneficial effect on CVD markers, but this was not 
clearly observed in the study described in this chapter.    
Changes in CVD risk markers and lipoprotein types and subclasses also showed a 
difference according to starting BMI during the OC intervention, with the higher BMI 
subgroup showing more beneficial changes in lipoprotein profile.    An increase in 
VLDL-C (21% of baseline) for the lower BMI group contrasted with a decrease of 
12.31% of baseline for the group with BMI > 25 kg/m2 (p  = 0.049), while an increase of 
7.27% of baseline for the high BMI group contrasted with a decrease of 13.47% of 
baseline for the group with normal BMI (p = 0.005).   The changes in VLDL-C and   
HDL-C as a percentage of total lipoprotein also reached significance between the two 
BMI groups for the OC intervention (p = 0.049 and 0.005 respectively).   This may be 
inferred to indicate an overall improvement in cardiometabolic risk profile during the OC 
intervention for participants with a BMI in excess of 25 kg/m2.   There is no published 
data on the possible beneficial effects of OCs on CVD markers, although there have 
been reports that fish protein may play a role.  The amount of protein in the OC 
supplementation was, however, only half that of the prawns, so it is suggested that this 
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would not have contributed to the effect described here. There were significant 
changes in intake of macronutrients during the OC intervention, which may have 
confounded any neutral effect of this supplementary food.  
There was no overall difference between Pr and OC interventions on other markers of 
dyslipidaemia apart from ApoB, which showed a small mean decrease (-7.8 mmol/L, p 
= 0.047) during the Pr intervention compared with a small mean increase              (2.4 
mmol/L) following OC intake.  The difference between mean changes was also 
significant (p = 0.023).  Stratification into groups according to initial BMI revealed some 
further differences.  In the OC intervention, an increase in mean ApoB for the higher 
BMI group (Δ = 6.09 mmol/L) and a small decrease for the lower BMI group                       
(Δ =  - 1.7 mmol/L) was noted; this was significant when expressed as a percentage 
relative to baseline measurement, (p = 0.036). 
The potential mechanisms of n-3 PUFA in improving CVD risk profile are discussed in 
Chapter 5.  Mori & Beilin (2001) suggested that EPA and DHA are comparable in 
respect of TAG reduction.  The apparent relative reduction in CVD risk of the 
lipoprotein profile during OC intervention for the high BMI group compared with the 
normal BMI group is curious, and there is no easily obvious explanation, although this 
is discussed later in this chapter in the light of data on nutrient intakes.    It is inferred 
from the results presented here that there is no disbenefit from prawn intake on overall 
lipidaemic profile.  
The ApoB/ApoA1 ratio has been implicated as a significant index of CVD risk  
(Walldius et al., 2004; Walldius & Jungner, 2005).   The changes in ratios during the 
two interventions (Table 3.15) indicate a small decrease in the ratio during the prawn 
intervention, compared with a small increase during the OC intervention, reflecting the 
changes in the individual apolipoproteins; the difference between mean changes        
(p = 0.081) did not reach significance, despite a significant difference in ApoB.   
 
3.6.1.3. Relationship with cholesterol intake 
The cholesterol content of 225 g prawns (295mg) is approximately equivalent to that of 
a large egg yolk (Table 3.2).  Both eggs and prawns are good sources of important 
nutrients (high quality protein including essential amino acids).  The evidence for a 
direct and specific link between dietary cholesterol and CVD risk has been limited and 
inconsistent, and has mainly focussed on egg consumption (Eckel, 2008).   Studies 
where a link has been reported (Weggemans et al., 2001; Puddu et al., 2011; Sakurai 
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et al., 2011) have not eliminated possible contributions from confounding factors 
(Djousse & Gaziano, 2009). In an extensive review of the relationship between dietary 
cholesterol intake and CVD, Kanter et al. (2012) observe that restriction of dietary 
cholesterol may be associated with increased intake of alternative detrimental nutrients 
such as simple sugars, refined carbohydrates and saturated or trans fats; interestingly, 
in this context, dietary intake records indicated a higher intake of some carbohydrates 
and sugars following Pr than for OC intervention.  It could be speculated that energy-
dense salad dressings or sauces may have contributed to this. 
Djousse & Gaziano (2008) derived an adjusted hazard ratio of 1.41 for all cause 
mortality in adult males eating more than one egg per day, although previous studies 
(Dawber et al., 1982; Nakamura et al., 2004) found no association.   More specifically, 
and of direct relevance to the study described here, associations between egg 
consumption, CVD risk and diabetes have been noted in other reports.    Nakamura et 
al., (2004) reported an increase in CVD risk in a cohort of diabetic individuals.  An 
increased risk (RR= 1.37) of a cardiovascular incident in T2D women   (n = 5672) was 
calculated for an increase of 200 mg cholesterol per 1000 kcal dietary intake  
(Tanasescu et al., 2004). (Table 3.1). Higher cholesterol intake was also associated 
with increased BMI, which appeared to be specific for egg intake rather than overall 
cholesterol.  Later studies by the same group also suggested that significant egg intake 
(3 eggs per day) was associated with an increased relative risk of developing T2D 
(Tanasescu et al., 2006; Houston et al., 2011), although other factors such as 
increased energy intake and body weight may also play a part in this pattern.   Houston 
et al. (2011) reviewed dietary intake over a period of 9 years and reported a significant 
increase in CVD risk associated with egg consumption (p = 0.02), in older people with 
T2D but none for those without T2D.    The association with total dietary cholesterol 
and T2D was less significant (p = 0.08). A further meta-analysis of eight retrospective 
studies (Rong et al., 2013) covered 263,938 participants for CHD and 210,404 
participants for stroke, over periods of between 8 and 22 years.  A total 5,847 cases of 
CHD and 7,579 of stroke were recorded; no overall link between egg consumption and 
either was found, but subgroup analysis indicated a possible link between egg intake 
and risk for those with diabetes (RR  = 1.54, p = 0.01).   The relative risk of coronary 
heart disease from one egg per day was 0.99 (95% confidence interval 0.85-1.15,p = 
0.88), while that for stroke was 0.91 (p = 0.1).   A reduced risk of hemorrhagic stroke 
(25%, p  = 0.04) was reported for those with higher egg consumption.   A positive 
association between dietary cholesterol and risk of stroke (RR = 1.2 for 300 mg per day, 
1.17 for 255 mg/day) was also reported from a study of 34,670 women in Sweden over 
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a 10-year period (Larsson et al., 2012).   A review of 17 studies (556 subjects) 
investigating the effect of dietary cholesterol on the ratio of TC to HDL-C ((Weggemans 
et al., 2001) reported that an increase of 100mg dietary cholesterol per day is 
associated with a similar increase in HDL-C and TC (0.008 mmol/L).    Overall it 
appears that while there may be some individuals (up to a quarter) in whom dietary 
cholesterol may increase LDL-C, HDL-C is also increased, so that the LDL/HDL ratio is 
maintained at a fairly constant level with little attendant increase in CVD risk 
(Fernandez, 2012).  In comparing these reports, it should be borne in mind that the 
meta-analyses will have included data from the individual intervention or food 
frequency studies described.  
In the study reported here, an increase in cholesterol consumption (from prawn intake) 
at the level of 1 egg per day was associated with a small increase in HDL-C (0.09 
mmol/L) and a decrease in LDL-C (0.23 mmol/L), but the differences between pre- and 
post- supplementation were not significant, and the difference between Pr and OC 
interventions did not reach significance for either parameter.  This is in concurrence 
with the findings of Harman et al. (2008):  a study of 45 individuals comparing egg 
intake (2 per day) with no egg intake over a 12 week period, combined with an energy 
restricted diet, did not reveal any significant difference in LDL-C, plasma lipoproteins, 
or LDL particle size at the end of the intervention.   The change in TC reduction of 0.09 
mmol/L in the investigation reported in this thesis was not significant, and not greatly 
different from the very small increase of 0.008 mmol/L reported by Weggemans et al. 
(2001).  
Beveridge, in 1964, suggested that CVD risk associated with cholesterol intake may be 
less clear-cut than the association with raised LDL-C from intake of SFA or TFA 
(Beveridge, 1964).  Beveridge showed that intakes of dietary cholesterol up to 600 mg 
per day  (2-3 times that used in the present study) resulted in an increase in TC, but 
that supplementation above this did not result in any further increase; no evaluation of 
lipoprotein subclasses was possible at that time.  Increases in TC even from 
cholesterol supplementation were clearly also related to associated dietary fat.   A 
subsequent analysis of 27 studies investigating the effect of dietary cholesterol with 
strict control of dietary intake (Hopkins, 1992) confirmed this and also reported that 
individuals with high baseline dietary cholesterol showed smaller changes on 
supplementation.  Based on this work, a supplementary intake of 300 mg cholesterol 
might be expected to result in an increase in TC of approximately 0.1 mmol/L.  This 
was not observed in the investigation reported in this chapter, in which no significant 
change was observed for TC during prawn intervention.   Notwithstanding the 
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conflicting interpretation from meta-analyses and individual studies, it would appear 
that there is little demonstrable CVD risk to normolipidaemic individuals from dietary 
cholesterol consumption.  Overall there may be an increased risk in those with MetS or 
T2D, but this could also be associated with a higher overall energy intake.   By 
extrapolation, it may have been expected that in the higher BMI group of this study, 
prawn consumption would be less beneficial than in the lower BMI group. This was not 
the case; the majority of CVD markers showed no significant difference from start to 
finish, with the exception of TAG, which showed a decrease in the higher BMI 
compared with an increase in the normal BMI group (p = 0.033).   There was an 
apparent improvement in cardiometabolic risk profile for the higher BMI group than the 
lower BMI group during the OC intervention, which was associated with no change in 
cholesterol intake.    Given the changes in overall dietary intake in this group, 
described herein, it may be presumptuous to ascribe this to a reduced risk from lower 
cholesterol intake (or indeed the converse with respect to prawn/cholesterol intake).  
The efficiency of cholesterol absorption in the human is genetically controlled (Hopkins 
1992), ranging between 20 and 80% in normal subjects consuming a diet containing 
moderate levels of cholesterol (Lecerf & de Lorgeril, 2011).   An increased absorption 
tendency is correlated with increased plasma LDL-C concentrations, a result of 
reduced catabolism of LDL-C rather than increased synthesis.   Additionally, the ability 
to down-regulate HMG-CoA reductase activity may reduce the effect of increased LDL-
C as a CVD risk factor.   Hopkins (1992) suggested that for most people, hepatic 
cholesterol overload results in a reduced responsiveness to increased dietary 
cholesterol.   There may remain some individuals for whom increased dietary 
cholesterol results in adverse lipoprotein profiles and associated CVD risk, due to 
effects on intestinal absorption rather than post-absorption synthesis.   It has been 
reported that individuals carrying the ApoE4 allele are more sensitive than others to 
dietary cholesterol, with a possible increase of 10% in total cholesterol from an 
increase of 300 mg in daily intake (Lecerf & de Lorgeril, 2011).   It is not known 
whether any of the participants in the present study were carrying this allele.    
 
3.6.3. Food intakes 
 
3.6.3.1. Patterns of food intake 
Of the original cohort of 21, only 18 completed the pre-intervention food diaries, and 
the numbers completing food records was less post-intervention (14 for OC, 11 for Pr). 
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The variation in nutrient intake within this small sample was considerable (Table 3.13).  
Indeed, there were several individual nutrient intakes more than 2SD from the mean 
reported intakes, which were discarded from further statistical analysis.    There is 
some evidence to suggest that participants may not have maintained a consistent 
lifestyle in terms of diet and other factors throughout the course of the study.   
Specifically, it was noted that the numbers of participants recording alcohol intake 
varied from one food diary stage to another (16 at baseline, 13 and 9 at end of prawn 
and OC intervention respectively).   The food diaries used in this study were completed 
over only a 3-day period, however, and it is possible that this may be a contributory 
factor, as participants might well have different dietary tendencies at a weekend 
compared with midweek.  Beside cholesterol and n-3 LCPUFA, significant differences 
were noted in other nutrient intakes between start and end of interventions. There was 
a mean increase in protein intake between baseline and end of Pr intervention, from 
86.4 to 109.1 g (p = 0.02). This represented an increase from 155-200% of the RNI (p 
= 0.02), and an increase in the proportion of calories from protein from 15.8-23.7% of 
total energy intake (p = 0.007).   The decrease in mean carbohydrate intake, from 277 
to 208 g daily, reached significance when expressed as a percentage of total calorie 
intake (50.2% to 42.9%, p = 0.039), reflecting the change in proportions of 
carbohydrate and protein during the prawn intervention.  
For the OC intervention, food intake reports showed a mean decrease in total daily 
intake in carbohydrate from 277 to 233 g (p = 0.047).  This change, which was smaller 
than for the prawn intervention, represented a change in the energy contribution of 
dietary carbohydrate from 50.2% to 46.3%, which was not significant (p  = 0.44).  This 
decrease was despite a contribution of approximately 35 g per day from the OCs 
themselves. Intake of all carbohydrate categories was also significantly reduced from 
baseline to intervention, including dietary fibre, non-starch polysaccharide (NSP), 
sugars and non-milk extrinsic sugars.  The mean decrease in fibre was from 17.3 to 
13.1 g (p < 0.01), NSP from 76.3 to 61.5 g (p  < 0.01), sugars from 117.6 to 87.7 g (p  = 
0.015) and non-milk extrinsic sugars from 81.9 to 56.4 g (p = 0.032).   These changes 
may represent additional significant change in dietary habits by some or all of the 
participants during the OC intervention stage.   A decrease in carbohydrate intake has 
been linked to improvements in markers of cardiometabolic risk (Shai et al., 2008). 
The difference between post-intervention protein intakes for the two arms of the study 
was also significant (p = 0.024).   
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3.6.4. Conclusion 
 
The results presented here do not show an overall beneficial effect of n-3 LCPUFA in 
lowering TAG, but also do not indicate any harmful effect resulting from the dietary 
cholesterol component.  Although the numbers in the subgroups are very small, these 
findings appear to have some significance.  Of the 21 individuals who completed the 
initial screening, only 9 fell within the recommended range for a normal BMI (between 
19 and 25).   For a further 9, the BMI was between 25 and 30, and for 3 in excess of 30 
kg/m2.   This enabled a comparison between the small subgroups with BMI above and 
below 25 kg/m2.  The higher BMI group showed a beneficial change in plasma TAG 
compared with the lower BMI group during Pr intervention.  The significant differences 
in lipoprotein subclasses and ApoB during OC intervention also indicate a small 
improvement in profile for the higher BMI group compared with the lower BMI group. 
Data from food diaries during the OC intervention indicated that some or all participants 
may have made significant changes to their diet during this intervention, which may 
have confounded these findings.   In view of the small size of the groups, it was not felt 
that there would be validity in exploring individual carbohydrate intakes, although it may 
be interesting to compare between the two BMI groups. The two intervention foods 
were significantly different in composition in several aspects apart from cholesterol and 
n-3 LCPUFA, in protein, carbohydrate and salt, all of which may impact on CVD risk 
markers.   It is also possible, that participants in the high BMI subgroup made 
significant changes to their lifestyle during the intervention, which may have had an 
additive beneficial effect on lipid profiles.   Although the overall mean changes in BMI 
and biochemical parameters did not change to a great extent, changes for some 
individuals may confound the overall pattern. 
In summary, this study has not demonstrated any clear disbenefit from prawns as a 
source of n-3 LCPUFA compared with a weight-for-weight food source containing only 
traces of n-3 LCPUFA and cholesterol (OCs). 
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CHAPTER 4 
A Comparison Of Krill And Fish Oils In Metabolic Syndrome 
4.1. INTRODUCTION 
 
As introduced in Section 1.2, the consumption of oily fish in the general population is 
lower than estimated requirements for healthy living, including the reduction of CVD 
risk (Simopoulos, 2002a; 2002b).   FO supplements have been used for many years as 
a source of n-3 LCPUFA (Wang et al., 2006; Anandan et al., 2009).    There are 
concerns about the sustainability of FO sources, and about possible toxic effects from 
accumulation of heavy metals and dioxins in the marine food chain (Virtanen et al., 
2005, Jenkins et al., 2009).  KO has been suggested as an alternative source of n-3 
LCPUFA.  A high proportion of the n-3 LCPUFA in KO are in the form of PL rather than 
TAG, and it has been suggested that KO may have benefits over FO due to superior 
bioavailability of the n-3 LCPUFA  (Bunea et al., 2004; Colussi et al., 2007).   KO also 
contains astaxanthin, a naturally occurring carotenoid pigment (Tou et al., 2007); this 
may help to protect LCPUFA against oxidation and degradation, or may, contribute to 
enhanced antioxidant status in individuals taking KO supplements (Yang et al., 2013).   
The metabolic syndrome (MetS) is strongly associated with increased CVD risk 
(Despres et al, 2008; Reaven, 2011).  Characteristic findings include increased 
anthropometric measures (waist, weight, BMI), blood pressure and changes in plasma 
TAG and plasma lipoproteins (described in Section 1.3).  The role of insulin is to 
provide a signalling and control mechanism to balance nutrient availability and 
demands, by storing excess dietary energy in times of plenty (as glycogen in liver and 
muscle, as fat in adipose tissue), or to mobilise these when needed by glycogenolysis 
and lipolysis.  In insulin resistance (IR), excess lipid accumulation results in impairment 
of insulin action; dietary glucose is not cleared from the bloodstream even in the 
presence of insulin, and glycogen stores are not accumulated for later use. Impaired 
insulin action in adipose tissue also results in re-esterification of lipids in the liver and 
other tissues, which exacerbates the impairment of insulin action (Samuel & Shulman, 
2012).   IR is a feature of MetS contributing to CVD risk (Lebovitz, 2001, Grundy et al., 
2005; Bradley et al., 2009; Reddy et al., 2010).   Dyslipidaemia observed in IR and T2D 
is typically associated with increased TAG, reduced levels of HDL-C and increased 
levels of sdLDL particles (Adiels et al., 2008).  Increased TAGs result in overproduction 
of VLDL particles, precursors to sdLDL particle formation. This perturbation of normal 
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lipid metabolism, sometimes referred to as the ‘lipid triad’, may precede diagnosis of 
T2D (Rizzo & Berneis, 2005).  
 
4.2. AIM OF STUDY 
 
The aim of this study was to determine whether KO as a dietary supplement may be 
more effective than FO in reducing CVD risk, specifically whether it may be effective in 
reducing CVD risk markers in MetS.  For this investigation, the null hypothesis was that 
there would be no difference between KO and FO in effects on cardiometabolic risk 
measurements. 
 
4.3. STUDY DESIGN 
 
The pilot study described in this chapter was designed with the aim of comparing the 
effects of a low dose of KO versus FO in a group of middle-aged males with MetS, and 
specifically to investigate changes in the markers of IR, MetS, and CVD risk. At the 
point when this project was planned, there was no published work specifically 
addressing the effects of KO in obese or MetS individuals, but some evidence from 
animal studies (summarised in Section 1.5.2.1) and two small studies in individuals 
with menopausal symptoms and arthritis (Bunea et al., 2004; Deutsch, 2007). The 
decision to study males rather than females was to avoid the potential of menstrual 
cycle or menopause-related individual variances.   The choice of participants with MetS 
was on the basis that effects may be more likely to be detected in a group of 
individuals whose glucose and lipid biochemistry is already perturbed from normal, 
rather than in a completely normal group. A recent rationale published for the design of 
a study of possible effects of vitamin D and n-3 fatty acids in prevention of CVD and 
cancer (Manson et al., 2012) proposed a 5-year study in 16000 participants without 
previous disease history or known risk, with associated blood sampling and analysis in 
6000 of these.  This may indicate the size of study required to observe a significant 
outcome in a sample with no known deviation from normal. 
4.3.1.  n-3 LCPUFA supplements 
 
KO was obtained from Azantis, USA, and FO from EFAMOL, UK.   The composition of 
the supplements, as provided by the suppliers, is shown in Table 4.1, and the PL 
composition in Table 4.2.   Although there is some variation between the two methods 
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used, it is evident that the major component of the PLs is PC.  The FA profiles of 
neutral and PL fractions as determined by an independent analytical laboratory (Avanti 
Polar Lipids Inc.) is shown in Table 4.3.   The major components in both fractions are 
the unsaturated FA of the n-3 series, particularly EPA and DHA.       
 
 FO 
per capsule 
(1000mg) 
KO 
per 1000mg 
(619mg per capsule) 
Total dose 
from 
KO 
PL (mg) None 460 
(318mg per capsule) 
1272 
n-3 PUFA (mg) 577 140 
(97mg per capsule) 
388 
EPA (mg) 290 90 
(62mg per capsule) 
250 
DHA (mg) 214 50mg 
(38mg per capsule) 
152mg 
Astaxanthin None 0.4 
(0.37mg per capsule) 
1.5mg 
Vitamin E 8.0mg Not stated Not stated 
Peroxide value 
(mEq/kg) 
3.6 <0.5  
Totox - 16.5  
Table 4.1:  Composition of supplements used  (provided by manufacturers)  
 
Method HPLC/ESD 
31
P-NMR 
Phosphatidylethanolamine 1.6 1.1 
Lysophospatidylethanolamine - 0.9 
PC 28.4 42.1 
Phosphatidic acid ND ND 
Phosphatidylinositiol 2.0 ND 
Phosphatidylserine ND ND 
Lysophosphatidylcholine 1.9 1.6 
Total 33.8 45.7 
Table 4.2     PL composition of KO  
(PLs in weight %, Avanti Polar Lipids Inc.) 
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Fatty acid  
(as methyl ester) 
Total Neutral lipids PL fraction 
C8:0 10.07 6.38 0.0 
C10:0 4.72 3.31 0.0 
C12:0 0.03 0.07 0.0 
C13:1 0.00 0.11 0.0 
C14:0 0.89 0.62 1.54 
C15:0 0.16 0.09 0.18 
C16:0 9.29 4.20 20.71 
C16:1 1.01 0.48 1.23 
C17:0 0.12 0.08 0.08 
C17:1 005 0.00 0.00 
C18:0  1.37 1.20 0.64 
C18:1 cis (oleic acid) 5.26 3.99 4.78 
C18:1 trans 3.14 1.87 3.70 
C18:2 (Linoleic acid) 1.44 1.07 1.13 
C18:3 (6.9.12) (GLA)  0.16 0.28 0.27 
C18:3 (9,12,15) ALA  0.74 0.48 0.57 
C19:0 0.17 0.12 0.0 
C20:0 0.28 0.17 0.02 
C20:1 1.43 1.18 0.38 
C20:2 0.33 0.27 0.19 
C20:3 (8,11,14) eicosatrienoic acid 0.13 0.21 0.0 
C20:4 ArA 1.10 0.94 0.0 
C20:3 (5,8,11) Mead acid 0.19 0.11 0.0 
C22:0 0.12 0.11 0.06 
C22:1 0.82 0.45 0.78 
C20:5  EPA 17.93 14.30 15.77 
C22:5 n3 DPA 1.36 2.57 0.0 
C22:6  DHA   13.53 21.63 12.26 
C24:0 0.06 0.0 0.0 
C24:1 0.31 0.24 0.0 
TOTAL 76.43 66.53 64.30 
 
Table 4.3:  Fatty acids of polar and neutral fractions of KO (Avanti Polar Lipids, 
Inc.) 
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4.3.2.  Recruitment and testing procedures 
 
This study was carried out at LJMU.  Recruitment and management of study visits were 
managed by this investigator with assistance from Dr I.G. Davies and Deborah Scott.  
Analysis of lipid profiles was carried out by Randox Laboratories, Dublin, and insulin 
assays by Deborah Scott.   Additional analyses, including plasma FA profiles, were 
carried out by colleagues of Professor Bruce Griffin at the University of Surrey.  The 
analysis of data from food intake diaries and all data analysis was carried out by the 
investigator.   
 
4.3.2.1. Recruitment and study visits 
Male participants (n=18, 35-65 y) were recruited from LJMU staff and the UK Biobank 
(Liverpool) via poster advertisement.  Criteria for inclusion were a waist measurement 
greater than 94 cm (approximately 37 inches) with one or more additional criteria of 
MetS as defined by the International Diabetes Federation (2006), but not taking any 
medication or food supplements to reduce CVD risk, or with any previously known 
abnormalities in liver function.  Following initial screening, participants were randomly 
assigned to receive 390 mg of EPA/DHA from KO (4 capsules) or 580 mg of EPA/DHA 
from FO (1 capsule) daily for 6 weeks. The study was a single blind randomised 
controlled crossover trial, with a 6-week washout period between interventions, as 
shown in Figure 4.1.  
                Fish oil                              krill oil 
 
Initial  
Screening   Randomisation                                      Washout               END 
visit 
 
                  
        krill oil     fish oil 
 
 
                     
 
Anthropometry Pre  1   3                5         7 
Analysis  Pre  1           2            3      4        5          6             7 
FOOD DIARY    1   3      5               7 
FIGURE 4.1:  Diagram of intervention protocol 
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This was designed as a pilot study, with participants acting as their own controls to 
compare the FO and KO dietary interventions. No formal power calculation was 
undertaken; it was intended that this study may provide sufficient data to inform formal 
power calculations for the design of future larger randomised studies. The dose of 
supplement was also derived by discussion with a scientific consultant representing the 
supplier of the KO.  Ethical committee approval (NRES) was obtained from the Sefton 
NHS Ethics Committee (approval number 09/H1001/48) prior to the commencement of 
the interventions, and the study was also registered with www.clinicaltrials.gov 
(NCT01705678).  The schedule of investigations is summarised in Table 4.4. 
 
 1
st
 intervention Washout 2
nd
 intervention 
Height        
Weight        
Waist        
Blood pressure        
BMI        
Capillary blood: 
CVD risk profile 
       
MetS and CVD risk markers:  Venous blood 
TAG        
Glucose        
TC        
HDL-C       
sdLDL        
Lipoprotein subclasses        
Plasma fatty acids (NEFA)        
Plasma FA profiles       
7-day food diary completed       
Table 4.4:  Schedule of measurements and sampling 
4.3.2.2. Anthropometric measurements 
Anthropometric measurements (height, weight, waist measurement and blood 
pressure) were carried out at the start of the study as described in Section 2.2.1.2.  
With the exception of height, these were repeated at midpoint and end of each 
intervention and the midpoint of the washout period (7 in total).   BMI was also derived 
from these measurements. 
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4.3.2.3. Biochemical markers of CVD risk 
Capillary blood obtained at the beginning and end of each intervention was used to 
obtain a CVD risk profile using a AlereTM LDX point-of-care analyser as described in 
Section 2.2.2.1.  Venous blood (from the antecubital vein) obtained at the start, 
midpoint and end of each intervention period and the midpoint of the washout period (7 
in all at 3-week intervals), were used to measure plasma markers of MetS (Alberti et 
al., 2006) and other features of IR indicative of CVD risk; TAG, glucose, TC, and 
lipoprotein subclasses.  Plasma FA profiles were analysed as described in Section 
2.2.2.6. 
4.3.2.4. Food intake assessment 
All participants were asked to fill in a 7-day food diary prior to starting each intervention 
and in the last week of each intervention (4 in total).   Results of these were analysed 
for macronutrient and micronutrient intake using the MicrodietTM program (Downlee 
Systems Ltd, UK). 
4.3.2.5. Indices of metabolic status 
Some of the measurements described above were used to derive HOMA  
(homeostasis assessment model), QUICKI and R-QUICKI scores.      
a) The homeostasis assessment model (HOMA) is a model devised to assess IR 
and β-cell function from measurement of fasting plasma glucose and insulin (Hanley et 
al., 2002; Grundy, 2006a; 2006b).  A simple derivation of the original model gives the 
following equations: 
HOMA-IR  = [glucose (mmol/L) x insulin (mU/L)]/22.5 
A value greater than 2.5 was initially suggested to indicate IR. 
HOMA-β (beta cell-) function  = [20 x insulin (mU/L)}/{glucose (mmol/l) – 3.5]% 
This is expressed as a percentage assuming that normal β-cell function in non-diabetic 
subjects would be 100%.    
b) QUICKI and R-QUICKI algorithms:  An alternative index of MetS and CVD risk is 
the QUICKI algorithm (Katz et al., 2000) subsequently modified to R-QUICKI 
(Perseghin et al., 2001) by inclusion of FFA (NEFA) in the algorithm:     
QUICKI  =  1/[(log10 glucose (mg/dL)) + log10 insulin (mU/ml)] 
R-QUICKI  =  1/{log10 glucose (mg/dL) +log10 insulin (mU/ml) +log10 FFA (mg/dL)} 
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These indices were calculated at baseline, interim and endpoint of both interventions. 
Brady et al. (2004) reported that the R-QUICKI index correlates well with insulin 
sensitivity derived from intravenous glucose tolerance test.  A later comparison of 
QUICKI and R-QUICKI (Singh et al., 2013) deduced that the inclusion of NEFA 
concentrations improved correlation with other insulin sensitivity measurements.   
4.4. STATISTICAL ANALYSIS 
 
All data were examined for normality and any extreme outliers, using the SPSSv20 
statistics program.   Means and standard deviations were derived, and those more than 
2 SD from the mean were removed from further analysis. In particular, some extreme 
outliers were identified for n-3 LCPUFA intake, as discussed in the results below.    
After review of normal distributions, split-plot repeated measures ANOVA  (SPANOVA) 
tests were used to investigate any differences within and between groups. Where 
distributions were not normal, comparison using non-parametric tests was used. As will 
be described, no differences between or within groups were observed:  therefore, 
trends in changes from start to midpoint and start to end of interventions were also 
compared (∆ values).   It was not possible to normalise these data, which were treated 
using non-parametric statistical tests.  
 
4.5. RESULTS 
 
4.5.1 Baseline measurements 
 
The details of baseline weight, height and other anthropometric measurements, and of 
markers of MetS, are given in Table 4.5.   Distribution was normal according to the 
Kolmogorov-Smirnov test of normality for all markers.   Examination of biochemical 
data revealed one individual with significant deviations from normal distribution on a 
number of measurements, and this participant was removed from further analysis. 
 
 
 
 
 116 
 Range 
(n=18) 
Mean SD Metabolic syndrome 
range  
(IDF, 2006) 
Age (yrs) 36-63 49 9.3 N/A 
Height  (m) 1.56-1.84 1.76 .07 N/A 
Weight (kg) 80.0-124.5 96.7 13.1 N/A 
BMI (kg/m
2
) 27.3-38.4 31.3 3.3 >30
1 
Waist (cm) 94.1-128.4 106.1 8.7 >94 
Systolic Blood pressure  
(mm Hg) 
119-153 135.6 12.8 >130 
Diastolic BP (mm Hg) 70-97 83.7 7.9 >85 
Plasma TAG (mmol/L) 0.74-3.05 1.77 0.64 >1.7 
Fasting plasma glucose 
(mmol/L) 
2.7-9.4 5.45 0.47 >5.6 
Serum cholesterol   
(mmol/L) 
3.94 –7.46 5.55 0.95 N/A 
HDL-C (mmol/L) 0.56-1.65 1.10 0.31 <1.03 
LDL-C (mmol/L) 0.7-3.1 3.64 0.99 N/A 
Non HDL-C (mmol/L) 1.9-5.6 4.45 1.00 N/A 
TC/HDL ratio 2.5-3.8 5.50 1.86 N/A 
Table 4.5     Initial anthropometric measurements, CVD and MetS markers 
(capillary blood measurements) 
 
4.5.2. Intake of n-3 LCPUFA 
 
Inspection of food and nutrient intakes revealed significant (>2SD) anomalies in food 
intakes of individual nutrients at different stages.  It was not practicable with such a 
small starting cohort to eliminate participants completely, but individual data points 
more than 2SD away from the mean for particular measurements were removed.  
Special attention was paid to estimates of n-3 LCPUFA intake from the food diaries as 
this was key to the comparison of the supplements. 
Intake of n-3 LCPUFA was estimated from food intake diaries prior to the start of 
supplementation and estimated from the food intake records and supplementation data, 
assuming full compliance with the supplement instructions. There was significant 
variation in baseline intakes at the start of both interventions, as illustrated in Figure 4.2 
(mean daily intake 0.38g, SD = 0.446g for FO and mean 0.39g, SD = 0.397g for KO).   
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Furthermore, analysis of the daily intake in n-3 LCPUFA from food diaries (without 
allowance for supplement intake) revealed significant variation in endpoint intake, as 
shown in Figure 4.3  (mean daily intake for FO group 0.48g, SD = 0.53, mean for KO 
group 1.02g, SD =1.53).  Inspection of the data revealed one participant who had a 
greatly increased intake of n-3 LCPUFA from dietary sources other than the 
supplements, particularly during KO intervention. This individual was therefore 
eliminated from further statistical analysis of food and biochemical data. 
 
Figure 4.2:  Baseline intakes of n-3 LCPUFA from food diaries 
(intakes in mg per day, estimated from recorded data) 
 
 
        
Figure 4.3:  Endpoint intakes of n-3 LCPUFA from food diaries                        
(intakes in mg per day, including contribution from FO or KO supplements        
assuming full compliance) 
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A wide variation in n-3 LCPUFA intake from dietary sources was recorded, both at 
baseline and endpoint. Mean increases in n-3 LCPUFA intake were 620mg  (SD = 353) 
and 1210 mg (SD  = 1909) for the FO and KO groups, respectively.   Thus, although 
the KO supplementation per se provided less n-3 LCPUFA than the FO, the mean 
increase for the KO group (ΔKO) was twice that for the FO group (ΔFO).  When 
expressed as a percentage of baseline intake, mean ΔFO intake was 556% (a 5-fold 
increase in intake) compared with a mean ΔKO intake of 810%.  Three individuals 
demonstrated changes in n-3 LCPUFA intake significantly higher than the mean.  After 
removal of the most significant outlier, overall intakes of n-3 LCPUFA were recalculated 
(assuming full compliance with supplements), as shown in Figure 4.4.   The 
recalculated mean daily n-3 LCPUFA intakes from dietary sources were 480mg (SD 
528mg) and 580mg (SD 724) for FO and KO groups, respectively.  Assuming full 
compliance with supplementation overall intakes were estimated to be 1060 mg (SD 
529) and 970 mg (SD 725mg) respectively.  Changes in n-3 LCPUFA intake for the FO 
group showed further individuals that were > 2SD from the recalculated mean (Figure 
4.5), but as these were within the comparable range for the KO intervention, it was 
decided not to eliminate further data.  
 
 
 
Figure 4.4  Recalculated n-3 LCPUFA intake for FO and KO groups  
 
(in mg/day, after elimination of extreme outlier as identified from food diaries). 
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Figure 4.5 Changes in n-3 LCPUFA intake (Δ) for KO and FO interventions            
(in mg per day, after elimination of extreme outlier identified from food diaries) 
 
 
4.5.3. Anthropometric Data 
 
Baseline, midpoint and endpoint measurements are summarised in Table 4.6, with 
mean changes and results of tests for significance (paired t-test for normal distributions 
and non-parametric Wilcoxon ranked test for pairs of variables with non-normal 
distribution).   Distributions of anthropometric measurements were normal (Kolgorov-
Smirnov test, p > 0.05), with the exception of baseline systolic blood pressure for KO 
intervention (p = 0.024).   Results show very minor changes in mean anthropometric 
measurements; there was no significant difference between baseline and endpoint for 
any variables in either intervention, nor for the mean change (ΔBE) between 
interventions (p > 0.23 for all variables).   
Split-plot analyses of variance (SPANOVA) were also conducted to compare weight 
and BMI at baseline, midpoint and end of each intervention, between the two  
interventions.   There was no significant effect of intervention for either group or 
between groups for either variable (Wilks’ Lambda >0.83 for all measurements). 
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 FO  
(n= 17) 
KO  
(n = 17) 
 
 Baseline Interim Endpoint p Overall 
change 
(ΔBE) 
Baseline 
(n = 16) 
Interim 
(n=12)  
Endpoint 
(n = 15) 
p Overall 
change 
(ΔBE) 
Significance 
between 
changes (p) 
Weight 
(kg) 
96.6 
(13.9) 
96.4 
(14.2) 
97.1 
(14.9) 
0.35 0.4 
(1.8) 
97.3 
(14.6) 
99.9 
(15.6) 
97.2 
 (15.3) 
0.40 -0.3 
(1.4) 
0.40 
BMI 31.3 
(3.4) 
31.2 
(3.5) 
31.4  
(3.7) 
0.31 0.15 
(0.57) 
31.4  
(3.7) 
31.5 
(3.8) 
31.5  
(3.8) 
0.32 -0.1 
(0.43) 
0.32 
BP s 134  
(12) 
- 134  
(11) 
0.75
1 
-0.3 
(9.3) 
133 
(12) 
- 134 
(10) 
   0.97 
1 
0.8 
(8.7) 
0.66
1
 
BP d 83  
(8) 
- 83  
(6) 
0.84 0.3 
(6.6) 
83  
(6) 
- 81  
(6) 
0.74 -2.2 
(6.2) 
0.75 
Waist 
(cm) 
106  
(9) 
- 107  
(10) 
0.46
 
0.5 
(2.6) 
107 
(10) 
- 107  
(11) 
0.23 -1.0 
(3.1) 
0.23
 
 
Table 4.6  Anthropometric measurements and changes  
Values were compared using paired t-test for normal distributions, and 1Wilcoxon signed rank test for non-normal distributions.     
SPANOVA (not shown) revealed no significant difference between or within groups.   Changes (Δ) between baseline and endpoint 
could not be normalized, and were also compared using Wilcoxon rank test.
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Table 4.7:  MetS markers (SD in brackets) 
Values were compared using paired t-test for normal distributions, and 1Wilcoxon signed rank test for non-normal distributions.     SPANOVA 
(not shown) revealed no significant difference between or within groups (Wilks-Lambda > o.1 for all measurements).   Changes (Δ) between 
baseline and endpoint could not be normalized, and were also compared using Wilcoxon rank test. 
 Fish oil  
(n = 16) 
Krill oil  
(n = 15) 
 Baseline Interim Endpoint Significance  
(BE)  
(p) 
Baseline Interim Endpoint Significance  
(BE) 
(p) 
Plasma glucose  
(mmol/L) 
5.12  
(0.55) 
5.32  
(0.49) 
5.63  
(1.11) 
0.28
1 
5.40   
(0.79) 
5.35  
(0.59) 
5.39  
(0.53) 
0.95
1 
Plasma insulin  
(pmol/L) 
49.9  
(22.4) 
51.5  
(33.9) 
61.8  
(38.4) 
0.15 49.7  
(27.1) 
48.2  
(18.2) 
47.2  
(23.2) 
0.27 
TAG 
(mmol/L) 
1.68 
(0.67) 
1.45  
(0.57) 
1.79  
(0.74) 
0.39
1 
1.47  
(0.50) 
1.61  
(0.42) 
1.57  
(0.62) 
0.69
1 
Serum cholesterol  
(mmol/L) 
5.27 
(0.98) 
5.31  
(1.24) 
5.29 
(0.72) 
0.38 4.90 
(1.10) 
5.04 
(1.20) 
4.99 
(1.04) 
0.56 
HDL-C (mmol/L) 1.24  
(0.25) 
1.25  
(0.30) 
1.28  
(0.24) 
0.27 1.15  
(0.29) 
1.14  
(0.31) 
1.18  
(0.26) 
0.51 
LDL-C (mmol/L) 3.71  
(0.90) 
3.82  
(1.15) 
3.99  
(1.02) 
0.07 3.49  
(0.93) 
3.60  
(0.94) 
3.53  
(0.88) 
0.75 
NEFA (mmol/L) 0.66  
(0.20) 
0.55  
(0.13) 
0.68  
(0.29) 
0.74
1 
0.58  
(0.24) 
0.57  
(0.14) 
0.61  
(0.20) 
0.55
1 
sdLDL-C (mmol/L) 1.16  
(0.59) 
1.11  
(0.57) 
1.29  
(0.55) 
0.08 0.96  
(0.44) 
1.04  
(0.39) 
1.02  
(0.44) 
0.33 
sdLDL-C (% of LDL) 30.0  
(10.2) 
28.3  
(8.7) 
32.4  
(11.0) 
0.09
1 
27.3  
(9.8) 
29.3  
(8.1) 
28.6  
(9.7) 
0.87 
TC/HDL-C 4.35  
(0.77) 
4.32  
(0.70) 
4.35  
(0.74) 
0.78
1 
4.37  
(0.75) 
4.48  
(0.51) 
4.32  
(0.69) 
0.33
1 
TAG/HDL-C 1.41  
(0.60) 
1.27  
(0.71) 
1.51  
(0.85) 
0.41
1 
1.36  
(0.59) 
1.51  
(0.49) 
1.41  
(0.65) 
0.78
1 
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 Baseline to endpoint (BE) Baseline to interim (BI) 
 FO 
n = 16 
KO 
n = 15 
Significance 
of change 
between 
interventions 
FO 
n = 16 
KO 
 n = 15 
Significance 
of change 
between 
interventions 
 ΔBE  
(SD) 
ΔBE  
(SD) 
p ΔBI  
(SD) 
ΔBI  
(SD) 
p 
Plasma glucose (mmol/L) 0.51 
(1.37) 
-0.01 
(0.92) 
0.22 0.21 
(0.57) 
0.02 
(0.75) 
0.36 
Plasma insulin (pmol/L) 13.1 
(33.2) 
-4.5 
(13.4) 
0.08
2
 N/A N/A N/A 
TAG (mmol/L) 0.12 
(0.46) 
0.09 
(0.46) 
0.90 -0.22 
(0.58) 
0.15 
(0.44) 
0.06 
Total cholesterol (mmol/L) 0.14 
(0.60) 
0.10 
(0.62) 
0.85 0.04  
(0.75) 
0.07 
(0.69) 
0.89 
HDL-C (mmol/L) 0.04 
(0.15) 
0.03 
(0.16) 
0.78 .014  
(0.17) 
0.02  
(0.16) 
0.93 
LDL-C (mmol/L) 0.27 
(0.55) 
0.04 
(0.52) 
0.24 0.11  
(0.68) 
-0.01  
(0.64) 
0.64 
Plasma NEFA  (mmol/L) 0.02 
(0.36) 
0.03 
(0.19) 
0.93 -0.10  
(0.20) 
0.02  
(0.20) 
0.10 
Plasma sdLDL-C (mmol/L) 0.14 
(0.29) 
0.06 
(0.23) 
0.34
1
 -0.04  
(0.32) 
0.05  
(0.22) 
0.40 
Plasma sdLDL –C (percentage of 
LDL-C) 
2.4 
(9.2) 
1.3 
(5.8) 
0.62 
 
-1.6   
(7.6) 
1.8  
(3.9) 
0.14 
TC/HDL-C 0.002 
(0.25) 
-0.045 
(0.27) 
0.63 -0.03  
(0.29) 
-0.01  
(0.32) 
0.88 
TAG/HDL-C 0.10 
(0.47) 
0.06 
(0.43) 
0.95
1
 -0.14  
(0.53) 
0.12  
(0.53) 
0.12 
Table 4.8  Changes in plasma measurements between start and end of interventions 
Values were compared using paired t-test for normal distributions, and 1Wilcoxon signed rank test for non-normal distributions.     SPANOVA 
(not shown) revealed no significant difference between or within groups.   Changes (Δ) between baseline and endpoint could not be normalized, 
and were also compared using Wilcoxon rank test. 2Assuming non-equality of variances (Levene test, p = 0.037) 
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4.5.4. Markers of metabolic syndrome 
 
4.5.4.1 Biochemical measurements 
Measurements obtained at baseline, midpoint and endpoint for KO and FO 
interventions are presented in Table 4.7.  Inspection of these data revealed no 
significant outliers for variables except for endpoint plasma cholesterol, (two high 
outliers, FO intervention) and for endpoint glucose  (one, KO intervention). However, 
these were within the overall range for the cohort as a whole and were not eliminated 
from analysis.    
SPANOVA analyses were conducted to compare MetS markers within and between 
the two dietary interventions at each time point, for those variables with normal 
distribution.   There was no significant effect of intervention for either group or between 
groups for any measurement (Wilks’ Lambda p > 0.1 for all measurements).  For those 
variables with non-normal distribution, the Friedman test indicated no significant 
difference in variables across the three time points for either intervention (p > 0.19 for 
all FO variables and > 0.22 for all KO variables). 
No significant overall change was observed in TC, HDL-C, LDL-C, sdLDL-C (total or as 
percentage of LDL-C), NEFA, or in ratios of TC/HDL-C or TAG/HDL-C. No differences 
between baseline and endpoint reached statistical significance for any variable, nor 
was any significance detected between mean changes (ΔBE) for any variable between 
interventions.  
Comparison between intervention groups of ΔBE as presented in Table 4.8, showed no 
significant difference between the groups on any variables measured.  A similar 
comparison of changes from baseline to interim timepoint (ΔBI) also showed no 
significant differences between groups, although the difference for TAG approached 
significance (p  = 0.06). 
 
4.5.4.2. Derived indices of metabolic status 
HOMA-IR and HOMA-β indices were calculated at baseline, interim and endpoint of 
both interventions.  The mean values and changes from baseline-interim and baseline-
endpoint for both interventions are presented in Table 4.9, with statistical comparison 
of measurements between time points.  These data indicate an increase in the mean 
HOMA-IR as a measure of IR during FO intervention, and also between baseline and 
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endpoint in KO intervention, although with a small decrease at midpoint.   Comparison 
of the mean values revealed no significant difference between measurements at 
different time points. The HOMA-β measure of β-cell function showed an overall 
increase in mean value for FO compared with a decrease in mean value for KO.  For 
both interventions the mean interim value was lower than either baseline or endpoint. 
Notably, the HOMA-β values for two individuals at the end of the FO study were very 
high (in excess of 300) compared with the remainder of the group.   SPANOVA was 
carried out, to compare HOMA-IR or HOMA-β measurements at baseline, midpoint and 
end of each intervention.   There was no significant effect of intervention for either 
group or between groups for any measurement (Wilks’ Lambda >0.16 for all 
measurements). 
QUICKI and R-QUICKI indices were calculated at all time points.  Inspection of the 
data showed that one individual presented with indices more than 2 SD outside the 
mean, and this individual was excluded from analysis.  The mean and SD at each point 
are shown in Table 4.10.  Comparison of means using both parametric and non-
parametric analysis indicated no significant difference between indices calculated at 
different time points for either the KO or FO interventions (Table 4.12). The differences 
between these indices (delta-values) from baseline to interim and baseline to endpoint 
were also compared.  No significant differences were observed between FO and KO 
for baseline-interim, baseline-endpoint or interim-endpoint changes. 
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Table 4.9.   HOMA-IR and HOMA- β status and changes  (SD in brackets) 
Values are shown with SD in brackets.  Data were compared using paired t-test for normal distributions, and 1Wilcoxon signed rank test for 
non-normal distributions.     SPANOVA (not shown) revealed no significant difference between or within groups.   Changes (Δ) between 
baseline and endpoint could not be normalized, and were also compared using Wilcoxon rank test.
 FO KO 
 Baseline 
n = 16 
Interim 
n = 16  
ΔBI p  
B vs I 
Endpoint 
n = 15 
ΔBE p 
B vs E 
Baseline 
n = 15 
Interim 
n = 13 
ΔBI p  
B vs I 
Endpoint 
 n = 12 
ΔBE p  
B vs E 
HOMA-
IR 
1.47 
(0.70) 
1.57 
(1.02) 
0.10 
(0.94) 
 
0.67 1.92 
(1.19) 
0.47 
(1.11) 
0.12 1.50 
(0.81) 
1.39 
(0.50) 
-0.03 
(0.59) 
0.87 1.81 
(1.38) 
0.08 
(0.52) 
0.62
1 
HOMA- 
β 
104 
(68) 
88 
(62) 
-15.9 
(56.9) 
0.28 130 
(139) 
32 
(132) 
0.36 97 
(75) 
88 
(64) 
-8.9 
(87.9) 
0.65 92 
(72) 
-27 
(52) 
0.27
1 
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Table 4.10   QUICKI and R-QUICKI indices:  values and changes 
Values are shown with SD in brackets.  Data were compared using paired t-test for normal distributions, and 1Wilcoxon signed rank test for 
non-normal distributions.     SPANOVA (not shown) revealed no significant difference between or within groups.   Changes (Δ) between 
baseline and endpoint could not be normalized, and were also compared using Wilcoxon rank test.
 FO KO 
 Baseline 
 n = 16 
Interim  
n = 16 
ΔBI p
1 
B vs I 
Endpoint  
n = 15 
p
1 
B vs E 
ΔBE Baseline  
n = 15 
Interim  
n = 13 
p
 
B vs I 
ΔBI Endpoint   
n = 12 
p
 
B vs E 
ΔBE 
QUICKI 0.35 
(0.03) 
 
0.35 
(0.03) 
-0.005 
(0.02) 
0.88 0.36 
(0.04) 
0.28 -0.01 
(0.03) 
0.36 
(0.04) 
0.35 
(0.02) 
0.33 -.005 
(0.028) 
0.36 
(0.03) 
0.86 <0.01 
(0.03) 
R-
QUICKI 
0.38 
(0.05) 
0.39 
(0.04) 
-.01 
(0.04) 
0.72 0.37 
(0.06) 
0.17 -0.01  
(-.02) 
0.41 
(0.07) 
0.39 
(0.03) 
0.16 -.024 
(0.05) 
0.40 
(0.05) 
0.55 -.005 
(0.03) 
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4.5.4.3. Plasma FA profiles 
Plasma FA measurements are presented in Table 4.11.   The principal components of 
the FA profile were palmitate  (range of means 32.2 - 35.3%), LA (15.5  - 17.5%) and 
ArA (15.2  - 18.2%).   Mixed between-within subjects analyses of variance (ANOVA) 
were conducted to compare FA percentages at baseline, midpoint and end of each 
intervention, for variables with normal distribution, as shown in Table 4.12.  Inspection 
of the data revealed deviation from normality for several timepoints, for these the 
Friedman test was used (Table 4.13). 
Changes in plasma n-3 and n-6 PUFA:  Total n-3 PUFA (ALA plus EPA plus DHA) 
measurements revealed an increase between baseline and interim for FO (mean from 
6.5 to 8.0 % of total), but no further increase from interim to endpoint (7.9%). The 
proportion of DHA and EPA followed a similar pattern; the contribution from ALA during 
FO intervention showed a small progressive increase from start to finish (0.22 to 
0.36%), from which it may be inferred that the increase was due to FO and not 
increased plant-derived sources of ALA.   However, comparable measurements for KO 
revealed a similar increase in total n-3 PUFA from baseline to interim (mean from 6.8 to 
7.2 %) but a decrease from interim to endpoint, with the mean at endpoint lower than at 
baseline (mean 6.5 %); the concentrations of ALA, EPA and DHA changed in a similar 
pattern.  With respect to n-6 PUFA, significant differences between baseline and 
interim measurements were noted for ArA (-2.41%) but not LA (-1.13%) for the FO 
intervention, and between baseline and endpoint for both LA and ArA. (an overall 
decrease in percentages of both, -2.07 and -1.55% respectively). In the KO 
intervention, percentages of both ArA and LA increased between baseline and interim, 
and decreased towards endpoint; the only significant difference noted during the KO 
intervention was for ArA between midpoint and endpoint.  The n-6/n-3 ratios for both 
interventions reflected these changes in FA composition, falling from 5.7% to 4.1% 
from start to end of FO intervention, and from 5.1% to 4.9% at interim and back to 5.1% 
at endpoint for KO. Significant effects were observed using the Wilks’ Lambda test, for 
total n-3 PUFA both with respect to time (p = 0.02) and to time x intervention   (p = 
0.03), and for the n-6/n-3 ratio (p < 0.001 and 0.004 respectively for time and time x 
intervention). No significant effect was noted for plasma DHA either by time or by 
intervention.    
 128 
 FO KO 
 Baseline    
n = 16 
Interim   
n = 16 
Endpoint n 
= 15 
ΔBI 
 
ΔBE 
1
p 
 
ΔBI vs 
ΔBE 
 
Baseline 
  n = 15 
Interim   
n = 13 
Endpoint     
n = 12 
ΔBI ΔBE 
 
1
p 
 
ΔBI vs 
ΔBE 
 
Palmitate  33.1 (2.0) 34.2 (4.2) 33.8 
(4.6) 
0.99 
(4.35) 
0.66 
(5.22) 
0.59 34.6  
(5.9) 
32.2 (3.2) 35.3 
(3.8) 
-2.99 
(6.98) 
0.73 
(6.72) 
0.05 
Stearate 16.6 (1.6) 17.9 (2.0) 18.2 
(2.2) 
1.28 
(2.03) 
1.56 
(2.44) 
0.94 18.2  
(3.2) 
16.1 (4.3) 18.6 
(2.5) 
-2.37 
(4.79) 
0.40 
(4.54) 
0.05
 
 
Oleate  8.1 
(1.4) 
7.9 (1.5) 8.3 
(1.5) 
-0.30 
(1.64) 
0.18 
(1.68) 
0.37 7.8 
(1.4) 
9.8 (5.5) 7.6 
(0.9) 
2.21 
(5.12) 
-0.20 
(1.66) 
0.20
 
Linoleate 17.5 (2.8) 16.4 (2.8) 15.5 
(2.9) 
-1.13 
(3.28) 
-2.07 
(2.53) 
0.52 15.8  
(3.3) 
17.2 (1.8) 16.3 
(3.1) 
1.67 
(3.24) 
0.56 
(4.38) 
0.55
 
α-linolenate 0.22 (0.10) 0.27 
(0.14) 
0.36 (0.42) 0.06 
(0.16) 
0.14 
(0.41) 
0.51
1 
0.20 
(0.11) 
0.28 
(0.07) 
0.25 (0.09) 0.06 
(0.11) 
0.04 
(0.10) 
0.40 
Arachidonate 18.2 (3.0) 15.6 (2.9) 16.4 
(3.5) 
-2.41 
(3.56) 
-1.85 
(3.26) 
0.33 16.9 (4.4) 17.6 (2.8) 15.6 
(3.4) 
1.03 
(5.32) 
-1.25 
(5.32) 
0.07 
EPA 1.84 (0.41) 3.02 
(1.38) 
2.76 (0.71) -1.20 
(1.16) 
0.94 
(0.93) 
0.70
1 
2.36 
(1.03) 
2.40 
(0.76) 
2.23 (0.71) <0.01 
(1.27) 
-0.13 
(1.08) 
0.74 
DHA  4.44 (0.99) 4.76 
(1.11) 
4.74 (1.01) 0.33 
(0.72) 
0.43 
(1.23) 
0.56 4.20 
(1.26) 
4.56 
(0.82) 
4.04 (0.67) 0.36 
(1.29) 
-0.16 
(1.13) 
0.05 
total n-6 FA (LA  + 
ArA)  
35.6 (2.4) 32.0 (4.6) 31.9 
(4.9) 
-3.54 
(5.06) 
-3.92 
(4.97) 
0.74 32.7 (6.7) 34.8 (2.9) 32.0 
(5.1) 
2.70 
(7.77) 
-0.70 
(8.74) 
0.11 
Total n-3 FA (ALA 
+ EPA + DHA) 
6.5 
(1.3) 
8.0 (2.3) 7.9 
(1.5) 
1.80 
(1.24) 
1.52 
(1.82) 
0.97 6.8 
(2.1) 
7.2  
(1.5) 
6.5 
(1.3) 
0.35 
(2.28) 
-0.35 
(1.65) 
0.24 
n-6/n-3 ratio 5.7 
(1.3) 
4.2 (0.9) 4.1 
(0.7) 
-1.58 
(0.92) 
-1.72 
(1.04) 
0.72 5.1 
(1.3) 
4.9  
(0.8) 
5.1 
(1.2) 
-0.18 
(1.03) 
-0.21 
(1.04) 
0.80 
 
Table 4.11 Plasma FA profiles and changes during study  
All data are shown as percentages of total Fas.  Values are shown with SD in brackets.  Data were compared using paired t-test for normal 
distributions, and 1Wilcoxon signed rank test for non-normal distributions.     SPANOVA (not shown) revealed no significant difference between 
or within groups.   Changes (Δ) between baseline and endpoint could not be normalized, and were also compared using Wilcoxon rank test. 
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 Time Time * intervention 
 Wilks-
Lambda 
p Partial 
eta
2 
Wilks-
Lambda 
p Partial 
eta
2
 
Palmitate 0.97 0.66 0.04 0.86 0.16 0.14 
ArA 0.93 0.41 0.07 0.81 0.08 0.19 
DHA 0.89 0.26 0.11 0.90 0.28 0.10 
Total n-6 
PUFA 
0.94 0.50 0.06 0.79 0.06 0.21 
Total n-3 
PUFA 
0.70 0.02 0.30 0.73 0.03 0.27 
n6/n3 
ratio 
0.47 <0.001 0.53 0.60 0.004 0.40 
Table 4.12    Dependence of FA concentrations on time and/or intervention  
ANOVA for data with normal distributions.    
 
 FO 
p = 
KO 
p =  
Stearate 0.15 0.13 
Oleate 0.46 0.79 
LA 0.26 0.37 
ALA 0.84 0.35 
EPA 0.004
1 
0.40 
Table 4.13  Effect of intervention on plasma FAs 
(Friedman test used for non-normality of distribution of data:  the effect of time across 
three time points for EPA was significant using the Bonferroni correction, α = 0.017) 
Changes in plasma FA between baseline and intervention were maintained to the 
endpoint for FO, but for several measures the FA profile reverted to baseline by the 
endpoint of KO intervention. Comparison of ΔBI with ΔBE for KO revealed a significant 
difference for DHA (p = 0.05).    For EPA, where a non-normal distribution of values 
was observed, the Friedman test revealed a statistically significant difference across 
the three time points in the FO intervention (Table 4.13), (p = 0.004, significant using 
Bonferroni correction). 
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The significance of ΔFA at different time points are shown in Table 4.14.  For n-6 PUFA, 
only ΔBI in the FO intervention reached significance for ArA (p = 0.04). Changes for 
total n-6 PUFA for the FO intervention reached significance for ΔBI (p = 0.023) and 
ΔBE (p  = 0.011): those for the KO intervention were not significant.  For n-3 PUFA, 
differences between ΔBI and ΔBE were significant for EPA in the FO intervention       
(p = 0.003 and 0.001 respectively), but there was no significance between 
measurements for KO, whereas for DHA only ΔIE was significant for KO (p = 0.04). 
Total n-3 PUFA showed a significant difference for FO intervention between baseline 
and interim (ΔBI) and between baseline and endpoint ΔBE (p = 0.002 and 0.008 
respectively), but not for KO intervention.  The ΔBI and ΔBE for the n-6/n-3 ratio were 
also significant for FO but not KO intervention.  
Changes in other plasma FAs:  In addition to changes in n-3 and n-6 FA, significant 
differences were noted between baseline and interim measurements (ΔBI), and 
between baseline and endpoint (ΔBE) for stearate for the FO intervention (p = 0.04 and 
0.05 respectively).  For the KO intervention, no significant differences between 
baseline and interim measurements or between baseline and endpoint were noted (p > 
0.33 for all variables) but a significant difference between interim and endpoint (ΔIE) 
was noted for stearate (p = 0.05). Comparison of the mean difference between 
baseline and interim or endpoint revealed a significant difference in the change for 
palmitate (p = 0.05) and stearate (p = 0.05). For variables with non-normal distribution, 
the Friedman test indicated no statistically significant difference in variables across the 
three time points for either intervention.  
 131 
 
 FO KO 
Fatty acid Baseline: 
interim 
n = 16 
p 
Baseline: 
Endpoint 
n = 15 
p 
Interim: 
Endpoint 
n = 15 
p 
ΔBE vs ΔBI 
p 
Baseline: 
Interim 
n = 13 
p 
Baseline: 
Endpoint 
n = 12 
p 
Interim:  
Endpoint 
n = 12 
p 
ΔBE vs ΔBI  
p 
Palmitate 0.73 0.78 0.66 0.59 0.15 0.53 0.06 0.05 
Stearate 0.04 0.05 0.59 0.94 0.13 0.82 0.05 0.05
1 
 
Oleate 0.64 0.69 0.16 0.37 0.09 0.76 0.20 0.20
1
 
LA 0.19 0.01 0.68 0.52 0.78 0.91 0.55 0.55
1
 
LNA 0.25 0.14 0.51 0.51
1
 0.10 0.26 0.13 0.40 
ArA 0.04 0.07 0.33 0.33 0.60 0.23 0.06 0.07 
EPA 0.002 0.001 0.68 0.70
1
 0.44 0.87 0.35 0.74 
DHA 0.09 0.11 0.47 0.56 0.20 0.67 0.04 0.05 
LA + LNA 0.023 0.011 0.47 0.74 0.42 0.33 0.15 0.11 
n3 total 0.002 0.008 0.86 0.97 0.48 0.78 0.12 0.24 
n6/n3  ratio
1 
0.000 0.000 0.72 0.72 0.55 0.46 0.94 0.80 
 
Table 4.14:  Comparison between plasma FAs at different time points 
 Values are shown with SD in brackets.  Data from Table 4.11 were compared using paired t-test for normal distributions, and 1Wilcoxon signed 
rank test for non-normal distributions.     SPANOVA (not shown) revealed no significant difference between or within groups.   Changes (Δ) 
between baseline and endpoint could not be normalized, and were also compared using Wilcoxon rank test
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4.5.5. Relationship between changes in CVD risk measurements and 
baseline values   
 
The effectiveness of pharmacological interventions to mitigate CVD risk may be related 
to the degree of aberrance from normal at the start of the intervention (Wang et al., 
2003):  thus, an individual with significantly elevated plasma TAG at baseline might be 
expected to show a larger effect from dietary (or indeed pharmacological) intervention 
than one with only moderately raised levels.   In order to investigate whether this might 
be relevant to findings from this study, correlations were calculated between the 
change and baseline levels of plasma measurements, as set out in Tables 4.15 (FO) 
and 4.16 (KO).  Significant correlations are highlighted in these tables. 
 
 ΔBI ΔBE 
 Pearson 
correlation 
p Pearson 
correlation 
P 
Cholesterol 
(mmol/L) 
-.004 .989 -.592 .020 
TAG (mmol/L) -.585 .017 -.166 .540 
HDL-C mmol/L .001 .998 -.345 .191 
LDL-C mmol/L .039 .887 -.062 .819 
NEFA mmol/L -.782 .000 -.601 .014 
sdLDL-C 
mmol/L 
-.324 .221 -.379 .148 
sdLDL (% LDL) -.558 .025 -.177 .511 
TC/HDL -.411 .114 -.280 .293 
TAG/HDL -.222 .408 .254 .342 
Glucose 
mmol/L 
-.616 .011 .626 .009 
Insulin pmol/L -.106 .697 -.092 .744 
Table 4.15:  Correlation between baseline measurements and changes in plasma 
lipid markers at interim and endpoint of FO intervention 
Data were compared using Pearson correlation; significant correlations are shown in 
bold print 
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 ΔBI ΔBE 
 Pearson 
correlation 
p Pearson 
correlation 
P 
Cholesterol -.177 .544 -.373 .171 
TAG -.617 .019 -.168 .550 
HDL-C -.100 .734 -.434 .106 
LDL-C -.224 .441 -.372 .172 
NEFA -.772 .001 -.577 .024 
sdLDL-C -.461 .097 -.269 .332 
sdLDL (% LDL) -.660 .010 -.319 .246 
TC/HDL -.469 .090 -.397 .143 
TAG/HDL -.628 .016 -.217 .437 
Glucose -.721 .004 -.819 .000 
Insulin -.742 .002 -.524 .081 
Table 4.16:  Correlation between baseline measurements and changes in plasma 
lipid markers at interim and endpoint of KO intervention  
Data were compared using Pearson correlation; significant correlations are shown in 
bold print 
 
For FO, the correlation between baseline measurement and both ΔBI and ΔBE was 
significant for NEFA (p < 0.001 at interim and p = 0.014 at endpoint) and for plasma 
glucose (p = 0.011 at interim and p < 0.009 at endpoint).  The correlation between 
baseline and ΔBI but not baseline and ΔBE was significant for plasma TAG (p = 0.017) 
and for sdLDL (as percentage of LDL) (p = 0.025). Correlations between baseline 
measurements and subsequent changes in TC, HDL-C or LDL-C were not significant. 
For KO, a significant correlation between baseline measurements and both ΔBI and 
ΔBE was found for NEFA (p = 0.001 and 0.024 respectively) and glucose (p = 0.004 
and <0.001 respectively) (Table 4.16).   The correlation between baseline and ΔBI but 
not ΔBE was revealed for TAG (p = 0.019), sdLDL-C (percentage of LDL-C) (p = 0.010), 
TAG/HDL-C ratio (p = 0.016) and insulin (p = 0.002).     
 
Scatterplots showing individual changes were inspected to see whether any additional 
inferences could be drawn from these relationships.  These are depicted in Figures 4.6 
through to 4.15 for measurements achieving significance, with Pearson correlation and 
significance for each.  Most participants with baseline TAG in excess of 1.7 mmol/L  
(the cutoff point for MetS) demonstrated a fall in plasma TAG from baseline to interim 
and also from baseline to endpoint (Figures 4.6 and 4.7); the trend was significant for 
 134 
measurement at interim timepoint.   For HDL-C, there was no significant correlation 
between baseline measurements and the extent of change either at interim or endpoint, 
and no evident effect for those individuals with baseline HDL-C below 1.03 mmol/L 
(MetS cutoff point).  Scatterplots for the correlations between sdLDL-C are shown in 
Figures 4.8 and 4.9; visual inspection of these suggests that some individuals with 
baseline sdLDL at more than 30% of total LDL may show larger decreases with n-3 
LCPUFA intervention. 
 
Correlation was observed between the baseline TAG/HDL-C ratio and the magnitude 
of change at the interim time point for KO intervention; visual inspection of the 
scatterplots (Figures 4.10 and 4.11) suggests that most individuals with a baseline 
TAG/HDL-C ratio >1.6 (in accordance with MetS cutoff points for TAG and HDL-C) 
exhibit a fall in the TAG/HDL-C ratio after 3 weeks intervention.  
 
Correlation between baseline and magnitude of change was also noted at interim and 
endpoint for both FO and KO interventions for plasma glucose (Figures 4.12 and 4.13) 
and plasma NEFA  (Figures 4.14. and 4.15).    
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Figure 4.6 Correlation between baseline TAG and ΔBI  
(all values in mmol/L;   correlation = -0.61, p = 0.003) 
 
      
   
Figure 4.7.   Correlation between baseline TAG and ΔBE  
(all values in mmol/L, correlation = -0.158, p = 0.18) 
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Figure 4.8:  Relationship between baseline sdLDL (%) and ΔBI                         
(values expressed as percentages; correlation -0.660, p = 0.01) 
 
 
 
Figure 4.9:   Relationship between baseline sdLDL (%) and ΔBE                           
(all values in percentages, correlation = - 0.32, p = 0.246) 
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Figure 4.10  Relationship between baseline TAG/HDL ratio and ΔBI  
(correlation = -0.628, p = 0.016) 
 
 
 
Figure 4.11 Relationship between baseline TAG/HDL and ΔBE 
(correlation = - 0.217, p = 0.437) 
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Figure 4.12  Relationship between baseline plasma glucose and ΔBI              
(values in mmol/L, correlation = - 0.72, p = 0.004) 
 
 
Figure 4.13  Relationship between baseline plasma glucose and ΔBE             
(values in mmol/L, correlation = - 0.819, p <0.001) 
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Figure 4.14  Relationship between baseline  NEFA and ΔBI  
(values in mmol/L, correlation = -0.77, p = 0.001) 
 
 
 
 
Figure 4.15  Relationship between baseline NEFA and ΔBE   
(values in mmol/L, correlation  - 0.58, p = 0.024)) 
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4.5.6. Food intake records for nutrients other than-3 PUFA 
 
Participants were requested to complete 7-day food diaries for the week before each 
intervention and the last week of each intervention (4 in total).  The data from these 
was recorded and analysed using Microdiettm. Of the 18 participants, only 10 
completed all 4 weeks food records; the number completing the baseline and final diary 
for the first intervention was 14 and 15 respectively, and for the baseline and final diary 
for the 2nd intervention 11 and 14 respectively.  Mean nutrient intakes with SD, and 
mean percentage changes from baseline to endpoint, are shown in Table 4.17. 
A mean increase in overall energy intake was reported during the FO intervention 
(13%), whereas the change during the KO intervention was only 0.6%, although 
variation between participants was wide, and there were large percentage changes in 
several other nutrients, including individual sugars, and in alcohol intake.  Alcohol 
intake was only analysed for those individuals who reported intake.   
Sodium intake was not significantly changed during interventions, as deduced from 
food intake reporting, but potassium intake was increased during FO intervention, and 
fructose intake was also increased during FO but reduced during KO intervention.
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 FO  KO 
 Baseline  
n = 14 
Endpoint   
n = 15 
Percentage 
Change 
Baseline  
n = 11 
Endpoint  
n = 14 
Percentage 
change 
 Mean SD Mean SD  Mean SD Mean SD  
Energy (kcal) 2040 350 2304 643 +13.0 2197 389 2087 321 -0.6 
Energy as % EAR 81.7 14.3 91.6 24.9 +12.1 87.6 15.3 83.2 12.0 -5.0 
Nitrogen (g) 12.7 1.8 14.8 3.1  14.1 1.6 14.5 2.8  
Protein (g) 79.4 11.3 92.1 18.7 +16.0 88.4 11.3 91.4 17.8 +3.4 
Protein as % RNI 146.6 20.2 169.4 32.6  163.3 22.1 168.3 31.7  
Protein as % energy 15.7 2.0 16.5 3.1  16.4 2.5 16.9 2.0  
Carbohydrate (g) 239.9 67.1 281.3 94.3 +17.3 267.0 56.1 256.8 59.7 -3.8 
Carbohydrate as % energy 46.5 6.7 48.6 6.4  48.6 5.8 47.2 7.2  
Fat (g) 77.8 16.6 87.2 27.5 +12.1 82.1 21.2 81.1 21.8 -1.2 
Fat as % energy 34.7 6.5 33.8 3.0  33.4 5.4 33.4 5.0  
Fat as % DRV 99.1 18.5 96.6 8.5  95.6 15.4 95.3 14.2  
Saturated fatty acids (g) 25.6 7.2 29.5 9.6 +15.2 30.2 9.9 27.8 8.8 -7.9 
Saturated fat as % DRV 103.6 26.6 104.9 21.3  111.0 25.9 104.3 24.2  
PUFA (g) 12.0 2.5 14.7 5.3 +22.5 12.3 3.8 14.6 4.3 +18.7 
PUFA as % DRV 83.3 24.5 87.4 17.4  78.0 19.7 92.6 21.6  
MUFA (g) 21.7 4.3 26.3 9.1 +21.2 23.0 7.6 24.5 5.3 +6.5 
Cholesterol (mg) 203 67 167 86 -17.7 162 78 195 89 +20.4 
Fibre (g) 11.0 5.0 12.4 4.2 +12.7 12.1 2.2 11.3 3.3 -6.6 
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 FO  KO 
 Baseline  
n = 14 
Endpoint   
n = 15 
Percentage 
Change 
Baseline  
n = 11 
Endpoint  
n = 14 
Percentage 
change 
 Mean SD Mean SD  Mean SD Mean SD  
Soluble fibre (g) 3.8 2.3 4.1 1.5 - 4.1 2.1 4.7 2.4 - 
NSP (g) 8.2 2.6 9.3 2.4 +13.4 9.1 3.4 9.5 3.7 +4.4 
NSP as % DRV 45.5 14.4 51.5 13.4 - 50.6 19.1 52.8 20.5 - 
Sugars (g) 90.2 45.0 100.5 47.9 +11.4 90.6 28.9 86.0 25.8 -5.1 
Glucose (g) 10.2 7.2 10.4 6.3 +2.0 9.7 5.0 9.6 4.8 -1.0 
Fructose (g) 10.6 7.3 12.5 8.8 17.9 11.1 6.6 10.4 5.9 -6.3 
Sucrose (g) 19.4 15.0 18.1 13.1 -6.7 15.5 9.25.8 19.9 9.5 +28.4 
Maltose (g) 5.8 2.9 5.2 3.4 -10.4 5.4 2.9 5.2 2.4 -3.7 
Lactose (g) 9.0 4.0 10.6 5.2 +17.8 10.2 3.3 12.4 3.9 +21.6 
Sodium (mg) 2889 552 2929 875 +1.4 3178 512 3234 786 +1.8 
Potassium (mg) 2266 569 2534 461 +11.8 2455 653 2502 693 +1.9 
Alcohol g* 18.2 20.2 17.3 22.9 -4.9 15.1 19.8 18.1 17.7 +19.9 
Alcohol as % energy 8.9 6.7 7.3 6.4 - 7.1 5.6 8.0 5.2 - 
 
Table 4.17   Changes in nutrient intakes 
(Nutrient intakes derived from 7-day food intake records;  all values as mean with standard deviations and percentage changes)
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4.5.7. Influence of covariates 
 
An ANCOVA analysis was conducted to investigate the possible relationship of dietary 
patterns on the overall effect of either n-3 supplement on plasma biochemical profiles.  
There was a small potential contribution of change in energy or protein intake to the 
overall changes observed, as indicated in Table 4.18. 
 Change in plasma LDL Change in % plasma sdLDL 
Component P Partial eta
2 
p Partial eta
2 
Estimated  
n-3 LCPUFA 
.522 .042 .302 .106 
Change in energy 
(kcal) 
.094 .255 .049 .335 
Change in protein 
(g) 
.035 .374 .069 .292 
Change in total 
fat (g) 
.316 .100 .152 .194 
Change in 
carbohydrate (g) 
.235 .318 .074 .284 
Group effect .873 .003 .292 .110 
 
Table 4.18  Covariate effects of macronutrient intake on changes in plasma LDL 
and percentage sdLDL  (ANCOVA)  
 
4.6.  DISCUSSION 
 
The aims of this pilot study were to determine whether KO may be an effective 
alternative to FO as a source of n-3 LCPUFA in dietary mitigation of CVD risk.  The 
study compared KO with a FO preparation, to observe effects of FO or KO on any 
perturbation of lipid and glucose metabolism by measurement of recognised markers 
and indices of MetS in conjunction with markers of dietary compliance (food diaries and 
plasma FA profiles).   The main conclusion of this study is that KO vs FO at the doses 
used are comparable in respect of effects on CVD risk markers, and therefore the null 
hypothesis is accepted. 
This small study was designed to obtain preliminary indications of effectiveness of KO 
compared with FO.  The small cohort of 21 initial participants was further reduced by 
elimination of individuals for whom results of CVD markers and/or food intake data 
were more than 2 SD from mean measurements.   At the time of embarking on this 
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study there were only a few studies of the effect of KO in animal models, and two 
reports of KO effects in dysmenorrhea and one in dyslipidaemia (Bunea et al., 2004; 
Deutsch, 2007).   
 
4.6.1.  Choice and dosage of supplements 
 
Total n-3 LCPUFA concentration in the KO capsules (assuming full compliance) was 
388 mg (250 mg EPA and 152 mg DHA, partly in PL).  For FO, total n-3 LCPUFA in the 
form of TAG was 577mg (290 mg EPA and 214 mg DHA), thus providing approximately 
150% n-3 LCPUFA compared with KO. A detailed comparison with the doses used by 
Bunea et al (2004) and Ulven et al (2011) is given in Section 4.6.2.  KO also contained 
astaxanthin, at a level of 1.5 mg per daily intake.   Astaxanthin is a powerful carotenoid 
antioxidant, with the potential to protect against lipid oxidation both in the supplement 
and in vivo (discussed in Section 4.6.2.3.). Preliminary experimental work suggested 
that this would still be available for absorption in the human intestine after exposure to 
the conditions of gastric acid and digestive enzymes; further work is required to extend 
and validate these findings, although recent publications are indicative of effective 
uptake of dietary astaxanthin.   
 
4.6.2. Markers of CVD risk  
 
Participants were recruited on the basis of fulfilling the criteria for MetS (IDF 2006), and 
all still fulfilled these criteria at the completion of the interventions. The mean changes 
were very small in comparison with the range of changes and the change in absolute 
measurements:  there was no significant change in any anthropometric variable within 
or between interventions.  
 
4.6.2.1. Overall changes in CVD markers 
At the doses employed in this study, there was no significant overall effect on any 
markers of CVD risk for KO (388 mg DHA +EPA) or FO (588 mg EPA +DHA).  
As the participants were recruited on the basis of a MetS profile, it was not possible to 
stratify the measurements in the same way as done for the prawn study described in 
Chapter 3.  Correlations of baseline-interim and baseline-endpoint changes vs baseline 
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measurements were conducted, and visual inspection of these data was also carried 
out.   Negative correlations with baseline were observed for FO intervention for 
baseline-interim change for glucose.  Similar negative correlations between baseline 
and endpoint change were recorded for glucose (-0.626, p  = 0.01) ad NEFA (-0.60, p  
= 0.01).   For KO, significant negative correlations were observed between baseline 
and interim change for glucose, TAG, NEFA, sdLDL as % of LDL, and TAG/HDL-C, 
while for baseline-endpoint significant correlations were seen for glucose and NEFA 
only.     Inspection of the scatterplots for these variables suggested that beneficial 
decreases in measurements may be achieved for participants with baseline TAG 
>1.7mmol/L, glucose > 6 mmol/L, NEFA > 0.75 mmol/L, sdLDL% >30% of total LDL 
and TAG/HDL-C > 1.6 mmol/L, arbitrary cutoff points representing values which 
correspond to the lower end of the range seen in MetS (IDF 2006).     
While plasma FA measurements are not normally included in any description of MetS, 
it is suggested that individuals with baseline plasma NEFA > 0.6 mmol/L might be more 
likely to achieve benefit from n-3 LCPUFA intervention; NEFA might be a useful 
screening tool for future investigations of this type. 
The use of compound indices of CVD risk has been proposed to provide more reliable 
markers for IR, T2D or CVD risk than stand-alone measurements while avoiding 
invasive and time-consuming diagnostic procedures such as the glucose clamp 
method (Vaccaro et al., 2004).  In this study the HOMA-IR index of IR, HOMA-β index 
of β-cell function and the QUICKI and R-QUICKI indices were calculated at baseline, 
interim and endpoint, and changes between baseline and both interim and endpoint 
also calculated. No significance was observed for comparisons of any time points for 
these indices, which appear to be less sensitive to changes in this study than stand-
alone measurements.    
Although participants were recruited on the basis of MetS, not all had a baseline TAG 
in excess of 1.7 mmol/L. From the data reported here, it is suggested that the effects of 
KO and FO at the doses used (FO n-3 LCPUFA 1.5 x that of KO n-3 LCPUFA) are 
similar, with more benefit for those with baseline TAG above 1.7 mmol/L, as shown in 
Figures 4.6 and 4.7.   
The study by Bunea et al. (2004) reported effective reduction by KO of LDL-C and 
increase in HDL-C by KO.  This study compared four groups each of 30 participants 
between 25 and 75 years of age over varying periods of at least 3 months:  participants 
took KO (2-3g per day depending on body weight) for 90 days, KO (1-1.5g per day 
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depending on body weight) for 90 days followed by 500mg per day during a follow-up 
period, 3g FO for 90 days or a placebo (unspecified).  Baseline TC was in the range 
5.0 – 9.0 mmol/L and TAG in the range 2.3-9.2 mmol/L: reduction in TC was reported 
as between 13.4-13.7% for those receiving 1.0 or 1.5 g KO daily and 18.0-18.1% for 
those receiving 2-3g KO, compared with a 6% reduction for those receiving FO.      
LDL-C decreases of between 32 and 39% were reported, while HDL-C was reported to 
increase by 43-59%.   Changes in TAG were reported to be non-significant for those 
receiving 1-1.5g KO or FO, compared with reductions of 27-28% for those receiving    
2-2.5 g KO.   Those receiving placebo exhibited a rise in TC (9.1%), an increase in 
LDL-C (13%), no change in HDL-C, but a 9.8% decrease in TAG.   A fall in blood 
glucose levels was also observed for those taking KO:  the reduction of 6.3% for the 
lower KO group compared with a 5.6% reduction for the higher KO group and 4.3% for 
FO, but it is interesting to note that the baseline glucose for the former KO group, at 5.8 
mmol/L, was higher than that for the latter (5.1 mmol/L).    This may be compared with 
the observation made in this thesis, of a potentially greater effect on plasma glucose by 
FO and KO for individuals with higher baseline plasma glucose levels (>6 mmol/L).  
The higher doses of KO used in the Bunea study were comparable with those used in 
the current study, but the study period at 12 weeks was considerably longer.   Variable 
doses of KO were used according to starting BMI, which makes precise interpretation 
and comparison of the results difficult, but there would appear to be a level of 
agreement between the Bunea study and the study described in this thesis regarding 
beneficial effects on plasma TAG, LDL and glucose.  
Maki et al. (2009) reported a comparison of daily supplementation of 2g KO, FO 
(menhaden) or olive oil in 3 separate groups of overweight and obese adults (76 in 
total) over a period of 4 weeks.  Increases reported in plasma EPA and DHA were very 
much higher in percentage terms for FO and KO than reported in this chapter, although 
the daily intake of EPA and DHA (216 and 90 mg respectively) was lower than that in 
the present chapter (250 and 152 mg respectively).  A decrease in TAG, and increases 
in glucose, insulin, HOMA- IR, TC, LDL-C and HDL-C were observed, but the 
differences between FO and KO were not significant.  The finding of a reduction in 
plasma TAG associated with n-3 LCPUFA intake is in agreement with that observed in 
the investigation reported here for individuals with MetS.    
 
Ulven et al. (2011) compared the effects of a daily intake of KO (3g, n-3 LCPUFA 543 
mg) with FO (1.8g, n-3 LCPUFA 864 mg) over a 7 week period.   They reported similar 
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increases in plasma concentrations of EPA, DHA and DPA between the two groups.   
Intakes of n-3 LCPUFA were similar in proportion (FO:KO) to those administered in the 
investigation described in this thesis, although approximately 1.5 times higher for both. 
No significant differences between the two supplements were noted for changes in 
HDL-C, TAG, HDL-C/TAG, TC, ApoA1 or ApoB.   The participants in the Ulven study 
were of normal BMI and thus not directly comparable with the MetS participants 
described in this thesis.   Small changes in levels of HDL-C, LDL-C and TAG were 
reported:  the change in LDL-C was significant for FO compared with KO.  A significant 
increase in the HDL-C/TAG ratio was observed for the KO intervention.  Neither 
intervention was associated with a significant change in TAG, but it was noted that 
there was a greater reduction in TAG for those individuals with higher baseline values 
(those with TAG > 1.7 mmol/L).  This finding is in agreement with the observations 
reported in this thesis.    
It is of interest to note the very wide range of HOMA changes compared with the mean; 
this might indicate failure by some participants to comply with instructions to fast prior 
to blood tests, or a wide variation in individual response to the KO or FO interventions.   
Maki et al (2009) reported an increase in HOMA-IR status in obese individuals 
following 4-weekly intake of KO or FO (2 g daily), whereas in this investigation there 
was no significant difference.   The use of HOMA modelling has been reviewed by 
Wallace et al. (2004), who suggested that use of a single sample for measurement of 
plasma glucose and insulin and hence HOMA-IR and HOMA-β indices may result in 
coefficients of variation up to 10.3% and 7.7% respectively, and that use of three 
samples taken at 5-minute intervals would be advisable.    
4.6.2.2. Relation to n-3 LCPUFA intake 
Given the difference in total n-3 LCPUFA, the higher dose of FO conferred no greater 
benefit overall than KO on cardiometabolic risk profile.  At the interim time point, the 
effect from KO was greater than FO in certain respects. The reasons for the apparent 
fall-off in effectiveness may be related to lack of compliance for the full 6-weeks of the 
intervention, (perhaps combined with alterations in intake of other foods). 
4.6.2.3. Relation to PL or astaxanthin component 
It was not possible to determine in this study whether the apparently greater effect of 
KO over the first three weeks of intervention could be attributed to either n-3 LCPUFA 
in PL form or astaxanthin.  In respect of a potential PL role, different formulations of n-3 
LCPUFA were compared by Schuchardt et al. (2012) in 12 healthy men.  Using doses 
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of 1680 mg EPA+DHA from FO, KO or as ethyl esters, they measured uptake of EPA 
and DHA in plasma lipids over a 72 hour period, and estimated relative mean uptakes 
from KO of approximately 80% compared with 60% from FO and 48% from ethyl esters. 
If this finding is representative for KO from all commercial sources, it is not 
unreasonable to expect that KO and FO administered at relative doses of 1:1.5 (as in 
the study described in this thesis) may have similar effects.  Zhu et al. (2008) reported 
reductions of TAG, glucose, and LDL-C after 4 weeks administration of KO to a group 
of 10 hyperlipidaemic rats.  KO supplementation of a high fat diet (1.25- to 5% w/w) in 
mice (Tandy et al., 2009) was associated with a reduction in mean TC (20-29%) and 
blood glucose (34-42%).    
Earlier work carried out by Lieber (2004) suggested that PC from soybean has a 
protective effect in alcoholic liver damage.  The effects of PC in vitro include reduction 
in TNF-α production by Kuppfer cells: dietary PC (not associated with n-3 LCPUFA) 
has also been reported to reduce liver cholesterol and liver TAG in 
hypercholesterolaemic rabbits and in hyperlipidaemic rats (Cohn et al, 2008).   
Supplementation with purified soybean PL (1800 mg/day for 6 months) has also been 
associated with reductions in TC, TAG and LDL-C in hyperlipidaemic individuals, with 
concomitant increase in HDL-C:  an increase of 12-18% in HDL-C following 
administration of phosphatidylinositol (2800 mg or 5.6 g per day for 2 weeks) has also 
been reported (Cohn et al., 2008).   The doses of PL used in these small uncontrolled 
studies were very much higher than in the investigation reported in this thesis (1272 
mg). 
Very few studies have so far been carried out on the effects of astaxanthin in human 
intervention studies. Hussein et al. (2005) reported that astaxanthin administration to 
spontaneously hypertensive rats was associated with a reduction in blood pressure, 
plasma nitrite/nitrate and lipid peroxidation, although the lipid peroxidation effect (at a 
dose of 5mg/kg/day) was no greater than for olive oil (1 mL/kg/day). Astaxanthin, being 
similar to other carotenoids such as β-carotene and canthaxanthin, might be expected 
to play a role in inhibition of LDL oxidation but this has not been fully substantiated in 
vivo in human studies (Higuera-Ciapara et al. 2006). Fassett & Coombes (2009) 
reviewed a total of 8 studies involving 180 human participants and reported that they 
demonstrated no adverse outcomes but did not comment on any positive findings.    
Possible mechanisms by which KO may exert a beneficial effect compared with FO 
have been the subject of some speculation.   A preliminary comparison of gene 
expression in mice and rats fed with FO and KO (Burri et al., 2011) has provided 
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evidence that KO may downregulate pathways involved in hepatic glucose production, 
and in synthesis of lipid and cholesterol.  Greater reduction of lipogenic enzymes and 
the mitochondrial TCA carrier by KO than FO was also reported in a feeding study in 
rats (Ferramosca et al., 2012a). The potential of KO to downregulate the 
endocannabinoid system in obesity has also been investigated.   Endocannabinoids 
are derived from ArA incorporated in the sn-1 or sn-2 position of PLs, and it has been 
proposed that increased activity in the endocannabinoid system may contribute to 
increased adiposity and other features of MetS.  Increased levels of anandamide and 
2-arachidonoylglycerol (2-AG) have been reported in overweight and obese individuals. 
There have been recent reports of downregulation of the endocannabinoid system in 
obese rats (Batetta et al., 2009), in mice and more recently in a cohort of 63 
normolipidaemic men and women with raised BMI (Piscitelli et al., 2011, Banni et al., 
2011). Increased levels of endocannabinoids were observed in this latter group; KO 
administration at 2g/day  (306 mg n-LCPUFA) for 4 weeks was associated with a 
significant decrease of 2-AG in obese subjects compared with FO (390 mg                  
n-3 LCPUFA).   These authors suggested that a 4-week intervention is not long enough 
to achieve beneficial metabolic effects in MetS.  In the investigation described in this 
thesis, small improvements in TAG, sdLDL and NEFA were evident after 3 weeks of 
FO and KO intervention.  It would be interesting to ascertain the extent to which these 
changes might be enhanced after a longer period of full compliance.  
4.6.2.4. Plasma FA profiles as measure of compliance 
Inspection of data presented here indicate that for KO, changes in FA profile achieved 
at midpoint were reversed by the endpoint of the study. It may be interesting to 
speculate on the reasons for these observations. One explanation could be that 
changes in plasma FA during FO intervention indicate a continuing compliance with the 
supplement by the majority of participants, compared with a lower compliance by 
participants during the second half of KO intervention.  Alternatively, this might reflect 
some other changes in dietary intake during the course of the KO but not the FO 
intervention.  In the study reported by Maki et al. (2009) the percentage rise in plasma 
concentrations of EPA and DHA following 4 weeks KO intervention were very much 
higher (approximately 90% and 23% of baseline) than measured in the investigation 
reported in this chapter (both EPA and DHA changes less than 10% of total plasma 
FAs reported on a w/w basis.   It is speculated that this could be indicative of greater 
compliance in the study reported by Maki.  
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4.6.3.  Food intakes 
 
It was evident from food diaries that there was a large variation in both baseline diet, 
and in changes during intervention periods.  One participant showed evidence of very 
high n-3 LCPUFA intakes and was excluded from the study retrospectively, and 
another was excluded because of dietary intake and plasma FA measurements more 
than 2SD from the mean.   Of the 18 initial participants, only 10 completed all 4 food 
records; the number completing the baseline and final diary for the first intervention 
was 14 and 15 respectively, and for the baseline and final diary for the 2nd intervention 
11 and 14 respectively. 
A mean increase in overall energy intake was reported during FO, and a slight 
decrease during KO intervention, although as with the prawn study, overall variation 
was very large, with large percentage changes in several other nutrients, including 
individual sugars, and alcohol intake. Sodium intake was not significantly changed 
during interventions, as deduced from food intake reporting, but potassium intake was 
increased during FO intervention; fructose intake was also increased during FO but 
reduced during KO intervention. 
 
4.6.4.  Comparison of capillary and plasma measurements 
 
Comparison of measurements of CVD risk markers using the Cholestech LDX point-or 
care analytical system with those obtained by Autoanalyser techniques following 
separation of plasma from venous blood gave good linear correlations for all measures 
used, as described in Section 2.3.   The advantages of the point-of-care method are of 
convenience for the participants; for the investigator also results can be obtained 
immediately at a study visit.  This permits prompt identification of individuals who have 
been non-compliant (e.g. with pre-test fasting) allowing repeat testing or timely 
elimination of those who are repetitively non-compliant.    
The accuracy of point-of-care techniques has been questioned.  There is a need for 
caution in comparing absolute measurements from different studies where different 
analytical methods have been used, but it is suggested that for studies of the type 
described in this thesis, use of the point-of-care system provides a convenient and 
efficient monitoring method.   
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4.6.5. Conclusion 
 
The overall conclusion from this investigation is that KO is comparable to FO in effects 
on markers of CVD risk at approximately 2/3 of the n-3LCPUFA concentration.  There 
are concerns that participants in this study exhibited reduced compliance with the KO 
supplementation compared with FO, as inferred from the plasma FA profiles.    
The cohort studied included only males with features of MetS according to the IDF 
(2006) (Alberti et al., 2006) definition.    There was a wide variation in dietary habits 
within the cohort; this also varied significantly for individual participants between start 
and end or between interventions.  
The timescale for intervention was not sufficient to obtain detailed analysis of 
erythrocyte membrane lipids, which would give a better overall view as to how dietary 
intervention of this nature might affect long-term physiology and cardiovascular risk.  
It is of interest to note that an application was submitted to the European Food Safety 
Agency for consideration of health claims related to a KO product in relation to 
maintenance of normal blood TAG, and of normal blood LDL-C (EFSA Panel on NDA, 
2012).   The Panel adjudicated that maintenance of these parameters is a beneficial 
physiological effect, but that there are at present no published human studies which 
would justify scientific substantiation of these claims. 
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CHAPTER 5 
SUMMARY AND DISCUSSION 
 
The work described in this thesis has contributed to the body of knowledge in respect 
of dietary n-3 LCPUFA sources and human health.  The aspect chosen for 
investigation was cardiovascular health; experimental work specifically compared a) 
the effects of prawns as a source of n-3 LCPUFA with a processed white fish source, 
and b) the effects of krill oil (KO) versus fish oil (FO).  Two questions were addressed:  
a) whether there is a justification for advice to avoid prawns as a source of dietary n-3 
LCPUFA because of associated dietary cholesterol, and b) whether KO may be a more 
effective n-3 LCPUFA supplement than FO in respect of CVD risk profile.  The findings 
for both studies are summarised in Table 5.1.   
From the results described here it is proposed that it is not necessary to avoid prawns 
(and by implication other shellfish) as a source of dietary n-3 LCPUFA because of 
possible adverse effects on cardiovascular health from cholesterol present in these 
foods; evidence also suggests that beneficial effects of prawns as a source of n-3 
LCPUFA are more evident in individuals with clearly defined MetS.   The comparison of 
KO with FO has confirmed previous reports by Bunea et al. (2004) and Ulven et al. 
(2011) that KO is equivalent in effect at approximately 2/3 the n-3 LCPUFA 
concentration of FO, with effects on markers of CVD risk more evident in those 
individuals with baseline measurements raised above normal, i.e. within the criteria for 
MetS. 
 
5.1.     RELEVANCE OF FINDINGS   
 
The question should be asked as to what these studies have added to the already 
extensive body of knowledge/research data in respect of n-3 LCPUFA and human 
health.   Key findings and conclusions are summarised in the following sections.    
The potential importance of n-3 PUFA, in particular LCPUFA, in human health, has 
been extensively reviewed (Chapter 1, Section 1.2). There are clear arguments from an 
evolutionary perspective (Simopoulos 2003; 2011), from experimental evidence, 
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 Prawn/OC KO/FO 
Number  n = 21 healthy males (half 
fulfilled MetS criteria)  
n = 18 males with MetS 
Design Crossover study, 4 weeks 
with washout  
Crossover study, 6 weeks with 
washout 
Measurements Anthropometric, markers of CVD risk and food intake diaries 
Overall finding No adverse effect from 
prawns compared with control  
No difference in effects on MetS 
markers at doses used 
Detailed 
observations 
Pulse:  8% decrease following 
Pr vs 7% increase (OC), p = 
0.016 
No difference between groups 
TAG For high BMI group, ΔPr  = -
0.017 mmol/L vs ΔOC = +0.30 
mmol/L, p = 0.033 
Correlation between baseline 
measurement and magnitude of 
effect:  -0.611 after 6 weeks, p < 
0.01 
ApoB ΔPr = -7.8 mg/dL vs ΔOC = + 
2.4 mg/dL, p = 0.023 
Not measured 
 Differences also noted 
between high and low BMI 
groups for changes in VLDL 
and HDL 
Correlation between baseline and 
magnitude of change also noted 
for NEFA, glucose and sdLDL 
Table 5.1   Summary of findings from clinical studies 
 
and reviews of food intakes and health, that adequate intakes of n-3 are needed for 
growth and development.  At the other end of the human age range, there is increasing 
evidence that n-3 LCPUFA may play a role in risk reduction in a number of 
degenerative diseases of ageing, notably in the mitigation of inflammatory processes 
and the spectrum of cardiovascular diseases (including stroke and MI).  Surveys of n-3 
LCPUFA intake have demonstrated that many adults in developed countries have a 
suboptimal n-3 LCPUFA intake, resulting in a focus on ways to encourage adequate 
intakes.   Reliance on intake of ALA-rich vegetable oils is not recommended, as the 
elongation-desaturation processes are not sufficiently efficient to fulfil the requirements 
for n-3 LCPUFA, particularly in the face of high intakes of n-6 PUFA commonly 
encountered in Western-style diets.  Recommendations to increase consumption of oily 
fish find only limited compliance; possible reasons for this include resistance to flavour, 
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cost, or convenience of preparation.   Prawns and shellfish are a popular and nutritious 
food option, but have not been widely recommended in the context of n-3 –rich foods 
because of concerns regarding risks from associated dietary cholesterol.   The study 
described in Chapter 3 has addressed the question as to whether markers of CVD risk 
are adversely affected by prawn consumption and shown no clear disbenefit from 
prawn intake compared with a white fish control. 
An alternative to n-3 rich foods is the use of n-3 supplements.   Cod liver oil and other 
FOs are now widely available in pharmacies and health food stores, sold both in the 
form of capsules and in bottles, with a range of n-3 LCPUFA concentrations and 
EPA/DHA ratios.   In some cases, n-3 LCPUFA content has either been concentrated 
from the original FO by distillation/chromatographic techniques, or derivatisation into 
ethyl esters.  In the UK (as in the rest of the EU), health claims made for these 
products are required to satisfy the scrutiny of EFSA, the European Food Safety 
Agency, in respect of scientific substantiation. 
An additional approach to achieving increased n-3 LCPUFA consumption is by design 
of foods containing n-3 LCPUFA or compositional modification of standard foods. In 
recent years, n-3 oils have been used to supplement poultry diets to increase              
n-3 PUFA content of the FAs of eggs: there is now a wide variation in n-3 FA content in 
eggs for sale in supermarkets in the UK (Gillian Butler communication at Nutrition 
Society meeting, Edinburgh 2013; Goldberg et al., 2013).  There is also evidence from 
the rapidly expanding aquaculture industry that the nutrient composition of farmed 
shellfish including prawns may vary according to the feedstock provided.   There are 
practical issues associated with supplementation of standard foods while maintaining 
palatability, and commercial considerations of consumer acceptance, which have not 
been fully resolved (S. Salminen, personal communication). 
An alternative development in n-3 LCPUFA ingredients has been that of the so-called 
‘Single Cell Oils’, produced by fermentation from algae such as Mortierella Alpina.  
These have found application both in infant formulae and as supplements in capsules 
similar to the FOs.  Incorporating higher levels of n-3 LCPUFA into plant phospholipids 
using GMO technologies could perhaps be an interesting and exciting way to enhance 
n-3 LCPUFA intake 
The sustainability of FO as an n-3 LCPUFA source is open to question, due to 
concerns about sustainability of overfishing and fish stocks worldwide.  KO has been 
identified as an alternative and possibly sustainable source of n-3 LCPUFA, as 
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described in Chapters 1 and 4 of this thesis.  KO was chosen for this study on the 
basis that on a dose/dose basis of n-3 LCPUFA it may be a more effective mitigant for 
CVD risk than either FO or other n-3 LCPUFA preparations such as ethyl esters.   The 
small study carried out here appears to corroborate this in respect of FO. Krill are found 
in oceans worldwide and although until recently commercial krill harvesting has been 
aimed at aquaculture and sport fishing applications, it is suggested (Tou et al., 2007) 
that a conscientious ecosystem approach to maintaining krill stocks should allow long-
term sustainability of this as a source of n-3 LCPUFA for human consumption.     
 
5.1.1. Health benefits or risks associated with prawn consumption 
 
The work described in Chapter 3 indicates that prawns as a source of n-3 LCPUFA are 
of benefit in improving CVD health markers in normolipidaemic male volunteers. There 
is no direct evidence that the ingestion of dietary cholesterol from prawns adversely 
affected this cohort. This is consistent with findings from other cholesterol-containing 
foods, which do not adversely affect markers of cardiovascular disease in the majority 
of individuals (Kanter et al., 2012; Tanasescu et al., 2006; Houston et al., 2011); while 
there may be some individuals in whom serum cholesterol may be increased 
(Fernandez, 2012), it is not clear at present whether the overall increase in LDL-C and 
HDL-C may obviate any increased CVD risk.  This is an interesting topic for future work. 
As described in Section 3.1, evidence from prospective cohort and intervention trials 
had shown that dietary cholesterol has a clinically insignificant effect on blood LDL-C 
and associated CVD risk, but at the time of commencing this study there was no 
specific evidence to refute a link between prawn consumption, LDL-C and CVD risk. 
Prawns are a popular foodstuff, often used in contemporary cuisine in the UK.  Given 
recommendations to increase n-3 consumption, it may be that this is one way of 
providing variety in n-3 sources in the regular diet.   The fact that approximately 2/3 of 
the n-3 LCPUFA in prawns are present as PL (Tou et al., 2007) may confer benefits in 
terms of uptake of n-3LCPUFA compared with fish oil sources at similar concentrations 
of DHA and EPA.   It would be interesting in a future study to provide a control 
supplement which contains n-3 LCPUFA in TAG form alongside a white fish protein 
source, to distinguish between the effects of n-3 LCPUFA and cholesterol content of 
the diets.   
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5.1.2.   Relative efficacy of krill and fish oils as sources of n-3 LCPUFA 
 
At the doses used, the KO and FO supplements used in this study show equivalent 
effects on CVD health markers in male volunteers with a profile of MetS as shown in 
overall changes after 6 weeks.  There was evidence for both KO and FO that 
improvements in CVD markers (TAG, sdLDL as percentage and glucose, as well as 
NEFA) were more noticeable for those with a more dyslipidaemic baseline profile.  
These correlations were greater for KO in respect of the change at the interim time 
point than at the endpoint.  Taken together with the plasma FA profiles, there is a 
strong supposition that compliance may have diminished in the second half of the KO 
intervention.  It is interesting to speculate whether the KO would have demonstrated 
greater benefit compared with FO in those individuals with 100% compliance. The dose 
of KO used provided a lower daily intake of n-3 LCPUFA compared with FO (388 mg 
and 577 mg respectively): the mean calculated daily n-3 LCPUFA intakes including 
other dietary sources were 970 and 1060 mg respectively.    
It was not possible to demonstrate in this study whether, as suggested elsewhere, the 
PL-derived n-3 LCPUFA may be absorbed more efficiently than the TAG in the FO.    
Mechanisms by which PL-derived n-3 LCPUFA may exert beneficial effects include 
reduction of TNF-α, and beneficial modifications of the lipoprotein profile, although at 
present most of the evidence in this respect comes from studies in animal models.   
The possibility that phospholipid-derived n-3 LCPUFA may influence the 
endocannabinoid system and thus contribute to control of obesity and dyslipidaemia 
through these pathways is an exciting avenue for future exploration. 
The role of astaxanthin, which is present at significant concentrations in KO, might also 
be beneficial in protection of cardiovascular health: this is an area which requires 
further investigation.  Some preliminary work was carried out which suggested, in an in 
vitro model of digestion, that astaxanthin in KO might reasonably be expected to be 
absorbed into the bloodstream and therefore exert some biological antioxidant function 
in vivo. A mechanism for the role of astaxanthin in protection against LDL oxidation 
merits further investigation.   It is not known whether the benefits of n-3 LCPUFA and 
astaxanthin may be synergistic; a future study could include an additional group for 
intervention with an astaxanthin supplement alone.    Another approach to this would 
be to compare FO alone with FO plus astaxanthin. It would be useful to be able to 
measure astaxanthin uptake in the blood following intake, and to compare varying 
intakes of astaxanthin to determine an optimum dose.    
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5.1.3. Mechanisms of n-3 LCPUFA in mitigation of CVD risk 
 
A common effect observed in both investigations was a reduction of TAG, with a 
demonstrable correlation between baseline TAG level and magnitude of reduction.       
The role of n-3 LCPUFA in reducing CVD risk in dyslipidaemic individuals may be in 
modification of the lipoprotein profile to alter the balance of transport functions between 
lipoproteins, increasing the clearance of lipids from blood vessels to the liver compared 
with transport of lipids and cholesterol to the blood vessel and tissues (where they may 
contribute to development of atherosclerotic lesions). There is an increasing body of 
evidence for inflammatory processes in atherosclerotic disease, and for the role of n-3 
LCPUFA in moderation of such processes in other degenerative inflammatory diseases.  
This may be by competition with ArA for eicosanoid synthesis, resulting in reduced 
synthesis of the highly pro-aggregatory TXA2, by reduced synthesis of other pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α, and reduced expression of PDGF-Q, 
PDGF-B and MCP-1.   The main mechanism by which n-3 LCPUFA affect TAG levels 
is believed to be via upregulation of genes involved in TAG metabolism, particularly in 
dyslipidaemic individuals (Schmidt et al., 2012c).   The transcription factor peroxisome 
proliferator-activated receptor–α (PPAR-α) is up-regulated within days of n-3 LCPUFA 
supplementation; expression of ApoCIII and ApoB is reduced, resulting in both a 
reduction in VLDL synthesis and an increase in VLDL catabolism. Regulation of other 
transcription factors by n-3 LCPUFA has been reported, including hepatic nuclear 
factors involved in glucose and cholesterol metabolism, and other genes with an 
influence on cholesterol synthesis and efflux.  The role of n-3 LCPUFA in increasing 
HDL-C levels in dyslipidaemia is not well understood; the existence of subclasses of 
HDL lipoproteins has only recently been identified, and elucidation of individual roles is 
yet to be established. 
 
5.2. STUDY LIMITATIONS 
 
There were some limitations to the studies performed which, together with the results 
obtained, may provide feedback for design of future studies of this kind.    
In the first study, the effects of prawns vs a white fish product (OCs) were compared in 
21 male volunteers, employing a cross-over study design. Both study components 
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were purchased from regular supermarket sources and provided for the participants to 
utilise as part of the normal diet.   The KO study compared the effects of KO capsules 
vs FO capsules in a group of 18 men with indices of MetS, also using a cross-over 
study. The interventions were randomised so that half of each group received the 
intervention or ‘placebo’ first, with reversal for the second intervention phase. The 
advantage of this type of study is that it enables a direct comparison for each individual 
between the two interventions.  Disadvantages are, from the point of view of the 
participants, that the study is more complicated and requires participation for, in this 
case, 18 weeks, allowing for a 6-week washout period.  This reduces the potential for 
full compliance. 
 
5.2.1. Selection of participants 
 
Only male subjects were recruited for either study, the intention being to reduce 
individual variations due to hormonal fluctuations which might occur in a study involving 
female participants.   In a small study it is desirable to limit confounding factors as far 
as possible.  The KO study recruited men with two or more indices of MetS, 
anticipating that beneficial effects of n-3 LCPUFA interventions would be more evident 
than in individuals with no initial deviation from normal. However, this then begs the 
question as to whether a supplement which may be of benefit to an ‘at risk’ group of 
individuals may also be justifiably recommended for use in prevention of disease in a 
normal sample or population.  For the Pr/OC study, the participants were not known to 
be at any increased risk of MetS, T2D or CVD compared with a random sample of the 
population, although approximately half of the participants in this study were 
overweight or fell within the MetS criteria as deduced from BMI measurements.   One 
candidate who came forward for inclusion in the krill study had to be declined on the 
basis of screening tests which suggested that he may already have T2D.   It has been 
suggested that the individual variation seen in response to diet and medication could 
be associated with specific genotypes; although it was not possible to pursue this line 
of enquiry in this study, a number of advances have been made in technologies which 
would enable this in future studies. 
The initial screening data for participants in the prawn study enabled stratification of 
results between those with high and normal BMI, from which it became evident, even in 
the small numbers studied, that there were greater effects on CVD markers in those 
with higher baseline measurements.  In the KO/FO study, volunteers were recruited on 
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the basis of fulfilling the criteria for MetS at initial screening.  It was not possible, 
therefore, to carry out a stratification of results in the same way as for the prawn study.  
Nevertheless, inspection of the data and comparison of changes with baseline 
measurements also gave a clear indication that benefits of n-3 LCPUFA from either 
source were more evident in those with higher baseline measurements.     
 
5.2.2. Size of studies  
 
The number of participants in each clinical study was calculated as a minimum to 
obtain statistically significant data, based on previous published information.   Of the 
number of potential participants, some were eliminated at an early stage due to 
unsuitability from screening tests, and others were excluded from the final analysis 
because either they demonstrated characteristics outside the expected range, or 
because it was evident from the results that they had failed to comply with the 
instructions provided (specifically failing to fast prior to blood tests).  This reduced the 
numbers available for analysis.   It was not possible to extend the time period for 
recruitment to include additional participants.   Notwithstanding these limitations, it has 
been possible to derive conclusions in both intervention studies to provide a basis for 
future work. 
 
5.2.3. Duration of interventions and washout periods 
 
The intervention and washout period for the prawn study (chapter 3) was 4 weeks, and 
for the krill study (Chapter 4) 6 weeks.    Although recent work has indicated that 
effects of n-3 LCPUFA on expression of transcription factors may be seen within one 
week of supplementation (Schmidt et al., 2012a; 2012b; 2012c), a 4-week intervention 
period is a short length of time in which to reasonably determine dietary effects on 
lipidaemic profiles.  A longer period would enable more detailed analysis of the uptake 
of FAs in, for example, red cell membranes or muscle PLs: the average lifespan of a 
human erythrocyte is 120 days (Shemin & Rittenberg, 1946), so that it may be 
unrealistic to estimate changes in turnover of erythrocyte membranes or lipid 
composition in less than a 3-month period.  However, this may result in greater 
difficulties in recruitment, reduction in compliance and larger variations in individual 
habits, so that a much larger study would be required.  
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5.2.4.   Clinical measurements 
 
The measurements chosen were standard measures of dietary compliance, and of 
cardiovascular health such as are routinely used in clinical practice. These are 
therefore accessible for comparison between studies, although it is important to take 
varying methodologies into consideration when comparing absolute measurements.  
Reporting of percentage changes is a way of enabling such comparisons.   Compound 
indices such as HOMA-IR and QUICKI have been developed and tested against the 
‘gold standard’ techniques of measuring IR, such as the frequently-sampled 
intravenous glucose tolerance test or the glucose clamp (Brady et al., 2004).   The 
advantage in that context is the avoidance of invasive techniques requiring specialist 
expertise (e.g. insertion of intravenous cannulas), and they have been shown to be 
useful comparators for assessment of IR.   The use of compound indices (HOMA, 
QUICKI or R-QUICKI) did not, however, provide any additional insights to the simpler 
single-measurement indices in the studies reported here.   
Central obesity as determined by waist measurement has previously been shown to be 
a valid risk indicator for lipid over-accumulation (Kahn & Valdez, 2003, Ross & 
Katzmarzyk, 2003).   This simple measurement can be reliably compared with fasting 
TAG concentrations and with increased risk of mortality after middle age.  Waist 
circumference has been reported to be a better predictor than BMI for hypertension 
and diabetes (Menke et al., 2007) although correlation with CRP is less reliable. A 
combination of high BMI (≥30kg/m2) and waist circumference was linked to the 
development of MetS in 32% of subjects, compared with 10% of those with low BMI 
and waist circumference (Han et al., 2002).  A more recent study in a cohort of 1758 
middle-aged Swedish men has suggested that both overweight (as measured by high 
BMI) and MetS are risk factors for CVD (Arnlov et al., 2011), contradicting a perception 
that overweight in the absence of MetS is a benign condition.    
Raised plasma TAGs have been consistently identified as a risk factor for development 
of CVD.   Onat et al. (2006), in a cohort of 2682 Turkish adults initially free of CVD but 
with MetS, reported increased risk of CVD in the highest quintile of TAG measurements. 
Another prospective study of 926 adults in Argentina  (Salazar et al., 2013), 
investigated whether the TAG/HDL-C ratio may be a more reliable indicator of CVD risk 
than a MetS diagnosis.   They reported that MetS and elevated TAG/HDL-C ratio were 
equivalent in identification of individuals at high risk of CVD, and inferred that a single 
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TAG/HDL-C measurement is as effective a diagnostic tool as a MetS diagnosis.  Given 
the observation reported in this thesis of a stronger correlation between capillary and 
venous blood measurements for TAG/HDL-C than for TAG, HDL-C or other single 
measures, the use of these ratio measurements may be more suitable for 
diagnostic/prognostic screening. 
The association between impaired fasting glucose and the risk of incipient T2D and/or 
CVD has been widely studied.  The Multi-Ethnic Study of Atherosclerosis (Yeboah et 
al., 2011) followed 6753 participants  (45-84 years of age), initially free of clinical CVD, 
but 25% of whom had T2D or abnormal fasting glucose, for an average of 7.5 years. 
Those with T2D exhibited an increased CVD risk, while those with impaired fasting 
glucose had an increased risk of progressing to T2D, a correlation also noted by Park 
et al. (2013). In the Cooper Centre Longitudinal Study (DeFina et al., 2012), individuals 
with plasma glucose between 6.1-7.0 mmol/L exhibited a higher rate of conversion to 
T2D than those with normal (5.6 mmol/L) or slightly raised (5.6-6.0 mmol/L) glucose.  
Raised glucose in association with obesity or MetS doubled this risk.  It is not possible 
to comment on the prognosis of the participants in the investigations reported in this 
thesis, except to note that those with higher plasma glucose showed greater reductions 
following n-3 LCPUFA intervention. 
With respect to lipoprotein profiling, a relationship between CVD risk and LDL-C, as 
well as an inverse relationship with HDL-C has been reported (Parish et al., 2012): 
reduced HDL-C has been identified as a potential indicator of CVD risk.   A low HDL-C 
phenotype has been associated with increased lipid peroxidation and platelet activation 
(Hoenselaar, 2012). Further subclassification of lipoprotein particles has led to reports 
of particularly high risk associated with sdLDL-C  (Ip et al., 2009), although Parish et 
al., (2012) inferred little difference in predictive value between lipoprotein particles, 
apolipoproteins and cholesterol fractions of LDL, and therefore very little gain from LDL 
subclass analysis. Measurement of ApoB provides good correlation with LDL-C, since 
there is a good stoichiometric relationship (1:1), but ApoA1 concentrations are not 
directly proportional to HDL because the particles contain variable numbers of the 
apolipoprotein molecules.  
The measurements used in the investigations reported in this thesis have a sound 
basis for use as markers in future studies. The measurement of sdLDL-C by the Hirano 
method gave good correlation with estimates of sdLDL obtained by the more time-
consuming DGUC method (Jones et al., 2009), suggesting that the Hirano method 
would be suitable for larger scale studies.  
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5.2.5. Quality of nutritional supplements 
 
The prawns and OCs used in the study described in Chapter 3 were obtained from 
standard grocery sources.  Instructions given to participants would have been as 
provided on the commercial packaging, but it was not possible to ensure that 
participants complied fully with these instructions.  
The FO and KO supplements used in the study described in Chapter 4 were obtained 
from different suppliers.   There seemed to be a lower degree of compliance with the 
KO supplement, possibly because of a larger number of capsule or a stronger fish 
odour from these compared with the FO.   This odour suggests to the author that the 
quality of the KO may not have been as high as that of the FO.   The degradation of    
n-3 FAs by oxidation results in the production of hydroperoxides and amines which are 
responsible for the ‘fishy’ odour.   This necessarily indicates that the product contains 
less of the potentially beneficial n-3 LCPUFA than the original sample.  It is not fully 
understood whether these degradation products are merely not beneficial, or indeed 
whether they may have adverse nutritional and health effects (Turner et al., 2006). 
 
5.2.6. Compliance 
 
Participants in both studies were asked to adhere to their normal lifestyles and not to 
make any major modifications to diet or exercise regimes, and to include the nutritional 
ingredients (prawn/OCs) or n-3 LCPUFA supplements in addition to their normal diet.  
They were also asked to fast for 8 hours prior to attending for blood tests.   It was not 
possible to assess with accuracy whether individuals had complied fully with the dietary 
interventions per se.     Participants in the KO study were asked to return all unused 
capsules at the end of the krill/fish oil study, and were asked to complete food diaries 
to enable an approximate estimation of major changes in dietary habits at intervals 
during each study.  Unfortunately, the majority of the participants did not return unused 
capsules:  full compliance was therefore assumed in the data analysis, as it was for the 
prawn/OC study.  The evidence regarding compliance and the issues highlighted by 
this are summarised here. 
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5.2.6.1. Biochemical measures of compliance 
It was evident from fasting TAG analysis that some participants had failed to fast prior 
to blood testing.  Measurements of plasma FA profiles in the KO study also provided an 
interesting insight into compliance over the 6-week interventions, suggesting that 
compliance with KO in particular decreased during the second half of the intervention 
period. 
5.2.6.2. Food intake records 
For both studies, food intake diaries revealed very large variations in nutrient intakes, 
and very large ranges compared with mean values for individual macronutrients.   
Bearing in mind the wide range and variety of foods on sale in the UK at the present 
time, this is to be expected in any study group of free-living participants.  It may also be 
exacerbated by day-to-day or week-to-week changes for individuals during the course 
of a 12 or 18-week period, due to holidays or natural changes in work patterns.  
Additionally, individuals who enrol on dietary or other lifestyle research programmes 
may subconsciously make modifications to their lifestyle even when requested to 
maintain a constant pattern (Wrieden et al., 2003).  In these studies, there was clear 
evidence of changes; in the prawn study, several of the participants changed their 
alcohol consumption dramatically during the study.  Two participants in the KO/FO 
study were retrospectively withdrawn from analysis of results when it became apparent 
that n-3 LCPUFA intake for one, and overall nutrient intake and CVD markers for 
another, were more than 2SD away from the mean. 
The design of these studies meant that the duration for each participant was 12 weeks 
for the prawn study and 18 for the FO/KO study.  For a study of several months 
duration it is impractical to impose a strict baseline diet against which to measure 
changes.   For participants accommodated in laboratory conditions such that all dietary 
intakes are quantitatively and qualitatively evaluated, it would be possible to make 
more accurate assessment of the effect of a particular dietary supplement, but this 
would be neither practical, acceptable, nor economic to implement, and would not 
reflect real life situations.    
The use of food diaries as a tool in dietary interventions is the subject of some concern.  
For example, 24-hour records are known to be a poor indicator of dietary intake 
(Beaton et al., 1979; 1983; Dodd et al., 2006).  It is recognised that under-reporting is 
common in dietary assessment methodology, especially by obese or potentially obese 
subjects.  Yao et al. (2013) recently examined the challenges faced in the design and 
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reporting of dietary intervention trials, and point out that the relationship between food 
intake and the effects of bioactive components in the gut is an additional factor which 
should be addressed. They also highlight the difficulty of masking study foods and the 
difficulty of choosing appropriate placebo diets. In this case, there were notable 
differences in overall dietary habits between those receiving prawn and OC, which may 
have indicated some difference in palatability/satiety of the interventions.   
Reporting of food intake may be inaccurate due to memory or diligence of the 
participants, and individuals may have different perceptions of portion size, although 
pictures of typical portion sizes were provided in the food diary booklets used.  It is also 
evident that the exact composition of particular dishes may be highly variable, 
depending on whether the dish has been compiled at home from fresh ingredients, 
purchased in a restaurant or pub, or purchased as a ‘ready meal’ from a supermarket.  
Supermarkets typically offer ranges of ready meals including ‘economy’, ‘luxury’ and 
‘low fat’, each distinct in portion size, fat and carbohydrate content. In both studies, 
transcription of data from the diaries into the program for analysis (Windiet or Microdiet) 
was performed by a single investigator to maximise consistency of interpretation.  
Nutrient data from supermarket labels (e.g. www.sainsburys.co.uk, www.tesco.com) 
was used wherever possible for composite foods, including, for example, the size of 
portions of snacks, bread, and biscuits.  However, these did not always include 
complete nutritional data.   For food and beverages obtained from retail outlets, 
information from the relevant website was used where available                                  
(e.g. http://www.costanutrition.co.uk/).  If not, values obtained from suppliers of catering 
supplies to public houses (e.g. www.brakes.co.uk) were used to obtain the closest 
approximation.   Some 500 foods at current nutrient values (2012) were thus added 
into the MicrodietTM database.   The database used by the MicroDiet program 
employed was not fully up to date:  although composite foods are provided with 
compositional data, there have been changes in the use of ingredients in supermarket-
purchased foods, including bakery products.  For example, the use of hydrogenated 
margarines containing trans-fatty acids is now largely excluded from products sold in 
British food stores, and the use of vegetable oils in food preparation have replaced 
saturated animal fats to a large extent.   Portion sizes indicated in the MicroDiet 
program in some cases did not correspond with values of portions normally available.  
For example, biscuits as sold in supermarkets are frequently 2g heavier (approximately 
10%) than the weights suggested in the database.  Wherever possible, new versions of 
such foods were entered into the database. 
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The process of transferring data from a 3- or 7-day food diary into the program for 
analysis is slow, and would not be efficient for a large-scale study. Although it might be 
desirable to monitor the behaviour of participants in studies of this nature, the extent to 
which additional compliance prompting (to take supplements, fast prior to attending for 
study visits, etc), may improve overall compliance, is open to question.   The advent of 
smartphone technology with the ability to communicate by SMS and to easily obtain 
images of food consumed, admits the possibility of much closer day-to-day 
communication with volunteer participants but could be regarded as intrusive and might 
result in withdrawal from studies or refusal to participate.   There are some initial 
reports of the use of wearable cameras to improve accuracy of dietary analysis or 
lifestyle monitoring (O’Loughlin et al. 2013; Gurrin et al., 2013). Analysis of the 
information generated by such devices will require the ability to undertake image 
analysis and involve extensive calculation of nutrient intakes for each item.    
 
5.3.  SUGGESTIONS FOR FUTURE WORK 
 
Consideration of the results presented in this thesis give rise to some suggestions to 
enhance the value of data obtained from future studies.    
 
5.3.1. Study design 
 
It would be preferable to carry out an intervention in a much larger sample, which 
would allow for elimination of individuals who had not complied in one or more respects 
and still allow sufficient numbers for robust statistical analysis of results.  The use of 
longer intervention and washout periods would enable evaluation of the uptake of n-3 
FA in muscle PLs and cell membranes, but in the author’s view would also increase 
rates of non-compliance and would therefore also require larger starting sample sizes.    
A parallel study design where larger groups were used and compared directly against 
each other for a longer initial period, say 12 weeks, might overcome the difficulties of 
compliance and would reduce the need for a washout period. 
5.3.1.1. Choice, dose and quality of supplements  
The choice of supplements to achieve maximum ongoing compliance is a key issue for 
consideration in development of the work described here. The quality of supplements 
used in n-3 LCPUFA studies has not been widely studied and related to either 
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compliance or potential biochemical benefit.  Even high quality supplements may 
deteriorate if not stored under ideal conditions, resulting in decreased palatability and 
potentially reduced compliance.   In addition, it is not clearly understood what, if any, 
the health implications may be of consuming supplements which contain a significant 
percentage of degradation products. The free radical processes initiated by oxidation 
and ultraviolet radiation are self-perpetuating, resulting in generation of additional free 
radical species. It is recommended that storage of supplement capsules is carefully 
monitored and strategies put in place for recovering any unused capsules for analysis 
and determination of compliance. it may be interesting and informative to measure the 
quality of any n-3 LCPUFA supplements used at the start of an intervention and at the 
end, in particular the presence of volatile breakdown products of LCPUFA. It may then 
be possible to relate the quality of the supplements to any variation in compliance.  Use 
of metabolomic analysis could also be valuable in detecting absorption of breakdown 
products. 
The choice of ‘active’ supplement and placebo or control is an important factor in the 
design of nutritional intervention studies.  Ideally supplement and placebo or control 
should be indistinguishable in sensory characteristics and of closely comparable 
nutritional content except in the parameter under study (in this case, n-3 LCPUFA 
and/or cholesterol).    In the prawn/OC study, the use of OCs provided an equivalent 
weight of foodstuff with negligible cholesterol and/or n-3LCPUFA, but considerably 
higher carbohydrate content than the prawns.   The two food materials were quite 
different in sensory characteristics.  In the KO/FO study, the comparison between the 
two supplements may not have been at an ideal dosage, and the total daily quantity of 
n-3 LCPUFA was not exactly comparable.  Also, the acceptability of the supplements 
may have been different, contributing to differences in compliance. 
5.3.2. Clinical measurements 
 
Based on the correlations between capillary and venous blood measurements reported 
here, it is suggested that a point-of-care system is an acceptable tool to use for future 
studies; this would also allow rapid screening of compliance by measurement of 
plasma glucose and TAG. The reporting of the TAG/HDL-C ratio appears to give good 
correlation between capillary and venous blood measurements.   Other measurements 
could have included red cell membrane lipids.     Measurement of sdLDL by the Hirano 
method is also proposed to be a useful and timesaving technique compared with 
DGUC.    Methods of measuring HDL-C as described in Chapter 4 depend either on 
ultracentrifugation to separate lipoprotein subclasses, or masking of the non-HDL 
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subclasses; the method used in Chapter 4 has a high (99%) concordance with the 
DGUC reference method.   
It has been suggested that measurement of clinical outcomes is more relevant than 
measurements of biochemical, lipidaemic or inflammatory status (Lovegrove & Griffin, 
2013).  While this is a reasonable viewpoint, it is not always practicable to achieve this 
in the relatively short timescale of studies such as described in this thesis, and 
therefore it is necessary to use appropriate biochemical and immunological 
measurements.   Developing techniques to evaluate HDL and LDL subclasses in more 
detail may be useful in future studies.    It is strongly proposed that measurement of 
inflammatory markers including IL-1, IL-6, MCP-1, CRP, TNF-α, IL-8, should be 
included.   It would also be informative in any future studies of KO to measure 
astaxanthin uptake by participants.  
   
5.3.3. Markers of compliance 
 
The use of plasma FA profiling in KO/FO study described in Chapter 4 raised a 
question as to the compliance of some participants with the n-3 LCPUFA 
supplementation, particularly in the KO intervention.   Further studies should have a 
more rigorous focus on establishing compliance, perhaps by questionnaires, reminders, 
return and counting of unused supplements, and also additional biochemical 
measurements (such as FA profiling or metabolomics analysis).   
The use of food diaries in the studies described here revealed both a wide variation in 
baseline diet between participants, but also large changes in nutrients by some 
participants during the 4- or 6- week duration of interventions. There are several 
alternative methods of estimating food intake, but each have limitations of accuracy or 
difficulty of administration.   The use of weighed food records, although more accurate, 
would not be applicable in a study of this length. An easier method from an 
administration point of view is that of estimated food records where participants or 
investigators estimate intakes based on the use of standard household measures and 
photographs or food models, although this is also subject to significant mis-reporting  
(Wrieden et al, 2003).   A trained interviewer may be able to elicit an accurate record of 
food intake over a single 24-hour period, although this would be unlikely to be typical of 
intake averaged over days or weeks, and is still dependent on accurate recall by the 
interviewee. A further alternative is the use of a food frequency questionnaire, which 
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provides a list of foods for respondents to check intake against. This type of 
questionnaire can be administered by interview, telephone or by written response (e.g. 
by the use of an internet-based questionnaire, and could be a suitable option for future 
investigations.   Wrieden reported two types of effect in mis-reporting of food intakes by 
participants:  an observation effect, meaning that individuals may change their eating 
behaviour when asked to record intakes (as noted when intake activity is independently 
observed).  Men tend to reduce alcohol intake, and women to reduce fat intake by 
approximately 12% when undertaking any type of food survey. Additionally, 
participants may mis-report changes in eating behaviour by up to 20%, especially when 
at home rather than in a ‘laboratory’ setting. 
Possible ways to improve reporting of food intake in future studies might include the 
use of online food diaries, which might be linked to mobile phone technology.   Use of a 
wearable camera to facilitate recording of meals of snacks (which could be combined 
with image analysis techniques) has been reported (O’Loughlin et al (2013), Gurrin et 
al (2013); comparison with use of smartphones indicates that this may be a viable 
mode of image capture for dietary studies.   Another option proposed by Beckman et al 
(2013) is the metabolomic analysis of urine samples as a tool to supplement the use of 
food frequency questionnaires in epidemiological studies of food intake and disease 
risk.  The use of urine signals for distinguishing between specific foods may allow more 
stringent evaluation of dietary influences on biomarkers and disease processes; 
markers reported for oily fish intake included methyl-histidine and anserine.     
5.3.4. Use of metabolomic profiling in future studies 
 
Metabolomic analysis may be a useful tool in future studies of this nature in monitoring 
compliance, and in beginning to understand differences in individual responses to 
interventions of this nature.   The opportunity arose in the KO investigation for some 
preliminary metabolomic profiling of plasma and urine samples. Metabolomics is a 
branch of molecular biology which arose from the development of genome sequencing 
and identification technology (Venter et al., 2001; Goodacre et al., 2004). The 
sequencing of the human genome has opened up the potential for identification of 
genes which may be valid targets for pharmacological therapeutic intervention, by 
explaining the nature and role of protein expression and translation (proteomics) and 
the metabolic network (metabolomics).   In metabolomics, a combination of molecular 
separation tools (mass spectrometry) with identification and analytical technologies 
(automated chromatographic methods), using advanced computational techniques to 
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interrogate the large volumes of data thus obtained, enables observations of subtle 
variations in individual molecular species, which may provide clues to important 
metabolic changes.  
The proteome of a cell or organism is the full complement of proteins expressed in a 
cell at a particular state of development or activity; similarly the metabolome is idefined 
as the full complement of lower molecular weight molecules (Oliver et al., 1998).   
These may participate in any of the many reactions required for the normal 
maintenance, growth and function of the cell (Beecher, 2003).   The primary objective 
of a metabolomics experiment is to identify and quantify all metabolites present in a cell 
or tissue at a specific point in time; however, no automated analytical technology is 
capable of total capture and reproducibility of this information and metabolomic 
approaches may be targeted towards a specific aspect of cellular metabolism.   The 
advantage of metabolomic techniques over traditional biochemical analyses is in 
quantification of large numbers of metabolites, permitting observation of perturbations 
in intermediates, accumulation or depletion of the endpoint products of biochemical 
pathways.   It may thus be possible to observe more subtle effects of pharmacological, 
dietary or other health-related interventions than has previously been feasible. 
A typical metabolomics analysis involves extraction of a metabolite fraction from cells, 
tissue sample, urine or plasma, followed by derivatisation, chemical treatment of the 
sample to render it suitable for mass spectrometry. The many molecular species are 
separated and identified by mass spectrometry coupled with an analytical technique 
such as gas chromatography.   The large volume of data generated is interpreted by 
reference to one or more databases compiled by collaboration between systems 
biology researchers, and which are continually in the process of curation and 
classification  (Mendes, 2002; Kanehisa et al., 2002; Famili et al., 2003; Forster et al., 
2003; Wishart et al., 2013).   Validation of metabolite profiles is an ongoing challenge 
to ensure comparison between research groups using identical experimental protocols. 
Supervised machine learning algorithms may be used to transform data from 
metabolite profiles and identify patterns that may be interpreted on the basis of known 
variations or interventions (e.g. susceptibility to disease, pharmacologic or dietary 
treatment).    
Early interpretations of metabolomics results has led away from the more traditional 
concepts of biochemical pathways to the concept of metabolite neighbourhoods and 
networks (i.e. that a metabolite is not necessarily involved in only one pathway at a 
time, but that the whole array of biochemical processes is far more dynamic than the 
models used in the mid to late 1900s).  A number of novel pathways have already been 
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identified using metabolomic approaches (Kholodenko et al., 2002; Weckwerth & Fiehn, 
2002; Steuer et al., 2003). 
An advantage in the use of metabolomic techniques in nutritional studies is the ability 
to demonstrate subtle changes in small subject groups rather than the large cohorts 
customarily required. The first reported nutritional metabolomics study was reported in 
2003 (Solanky et al.  2003), following ingestion of isoflavones in a group of healthy 
premenopausal women.   Data from plasma analysis showed changes in lipoproteins, 
carbohydrates and proteins, while urinary analysis demonstrated changes considered 
to imply alterations in gut microflora. More recently, targeted approaches in nutritional 
metabolomics have allowed analysis of specific subsets of metabolic species, including 
lipids (German et al. 2007).  Examples include the analysis of eicosanoid metabolism 
following FO interventions (Lankinen et al. 2009) and of PL metabolism (Wang et al. 
2009).   
Metabolomic analysis has recently been applied to the T2D-CVD spectrum. Shui & 
Lam (2013) profiled and compared over 300 plasma lipid species from subjects with 
and without T2D.They found increases in sphingolipids including ceramides, 
sphingomyelins, lactosylceramides  (LacCer) and ganglioside GM3, with concomitant 
decreases in glucosylceramides.  This was interpreted to indicate increased conversion 
of GluCer to LacCEr in milder T2D.  Individual GM3 species were altered according to 
chain lengths – long chains (C>18) were increased, but 18:1/16:0 were decreased.   
Long-chain GM3 were negatively correlated with HOMA-β indices, and positively 
correlated with fasting blood glucose, allowing distinction between mildly diabetic 
patients with similar HOMA-β. Friedrich (2012) has reviewed metabolomics research in 
diabetes over the last few years, and pointed out findings indicating possible effects by 
alterations in gut flora, increased FA and changes in amino acid levels. It has been 
suggested that abnormal amino acid levels predictive of T2D development may be 
observed as much as 12 years before clinical presentation and diagnosis.   Wang-
Sattler et al. (2012) identified three metabolites with significantly altered levels in 
impaired glucose tolerance; glycine, lysophosphatidylcholine (LPC) 18:2 and 
acetylcarnitine.  In addition to glycosuria, other plasma metabolites may be elevated in 
the urine of diabetic individuals ((Roussel et al., 2007).   This includes an increase in 
products of β-oxidation, as well as changes indicative of perturbation of nucleotide 
metabolism and gut microflora.    
The possibility to observe changes in eicosanoid or PL metabolism in plasma or urine 
in MetS and T2D resulting from dietary intervention with FO, KO and/or astaxanthin is a 
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very exciting possibility for future research.   In summary, the use of metabolomics 
analysis is seen as a key tool in future studies of the type described in this thesis.   
 
5.4. FINAL SUMMARY 
 
The investigations described in this thesis have provided answers to the research 
questions posed.   It has been shown that there is no clear increase in cardiometabolic 
risk from prawns as a source of n-3 LCPUFA compared with a white fish food source, 
and that KO is comparable in effect on markers of cardiometabolic risk at an               
n-3-LCPUFA concentration approximately 2/3 that of a FO supplement.    These results 
are in accordance with other published work, and may provide support to the pursuit of 
improving n-3 LCPUFA intake either for individuals or at a public health level.   It is 
clear from both studies that greater benefits from n-3 LCPUFA supplementation are 
possible for those with more dyslipidaemic profiles.  It is hoped in future studies to 
refine understanding of this by the use of nutrigenomic or metabolomic analysis.    
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APPENDIX 2 
 
FOOD DIARY 
 
 
 
Thank you for completing this diary 
 
Please return it to the study team as requested 
 
 
 
 
 
 
 
Study Contacts 
 
Wendy S Jones  Ian G Davies 
 
Science Base, LJMU  Science Base, LJMU 
IM Marsh Campus  IM Marsh Campus 
Mossley Hill Road  Mossley Hill Road 
Liverpool L17 6BD  Liverpool L17 6BD 
  
0151 231 5271  0151 231 5290 
07778 310146 
W.s.jones@2007.ljmu.ac.uk i.g.davies@ljmu.ac.uk  
 
 
 
 
 
__________________________________ 
Food Diary ID 
 
 
 
____________________________________________________ 
Volunteer ID 
 
 
 
 
____________________________________________________ 
Date Started 
 
Details of how to fill in the diary 
 
 
It is very important that you do not change what you            
normally eat and drink just because you are keeping this 
record. Please keep your usual food habits. 
 
 
Each day is divided into sections, from the first thing in the 
morning to late evening and through the night. 
 
 
When recording your food include the brand name (if 
known), portion size (using household measures, 
weights from labels or the picture examples to help), any 
additions to the food (fats, oils, sugars/sweeteners, sauces, 
salt, pepper etc), cooking methods (fried, grilled, baked, 
roasted etc) and any leftovers. 
 
 
Please record everything at the time of eating, not from 
memory at the end of the day. The diary covers a 24h    
period, so please include any food or drinks that you may 
have had during the night. You may have had some foods 
and drinks between meals (snacks), or food that you have 
not recorded earlier, so please include these in the extras 
section. 
 
 
It helps a great deal if you enclose labels from any unusual 
foods and also from any supplements you take when        
returning your completed food diary. 
 
 
Overleaf you can see an example of how we would like you 
to record your food and drink intake. 
 
………………………………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
   
 EXAMPLE………………………………………………………………… 
Day of Week       Date 
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
7.30 Water 
 
 
 
 
Tap water, no additions 
 
 
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
8.00am 
 
 
 
 
 
 
8am 
 
 
 
 
8am 
Toast 
 
Margarine 
Marmalade 
 
 
 
Tea 
Milk 
Sugar 
 
 
Breakfast Cereal 
Milk 
Hovis, wholemeal, pre 
sliced, thin cut 
Flora original 
Robetson’s low sugar, thin 
cut orange and lime 
 
 
Medium strength Tetley 
Semi skimmed pasteurized 
White castor 
 
 
Kellogg’s cornflakes 
Semi skimmed pasteurized 
 
2 slices (left 
crusts) 
 
2 medium spread 
2 thin spread 
 
 
1 mug (incl milk) 
Dash in tea 
1 teaspoon in tea 
(drank all) 
 
1 pict 1 b (ate all) 
Approx 1/3 pint 
MID-MORNING—between breakfast time and lunch time 
Time Food/Drink Description & Preparation Amount 
10.30 
am 
 
10.30 
am 
Coffee 
Milk 
 
Biscuit 
Nescafe original caffein-
ated 
Full fat pasteurized 
 
McVities chocolate  
digestive 
1 cup, drank all 
1 average in coffee 
 
2 biscuits, ate all 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
EXAMPLE……………………………………………………………………………… 
Day of Week       Date 
LUNCH 
Time Food/Drink Description & Preparation Amount 
1.15 
pm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.15 
pm 
 
1.30 
pm 
 
Ham Salad 
Sandwich 
 
Bread 
 
 
Mayonnaise 
 
Ham 
 
Lettuce 
Cucumber 
Seasoning 
 
 
 
Can of cola 
 
 
Crisps 
 
 
 
Tesco’s own brand, me-
dium sliced white 
 
Hellman’s ordinary mayon-
naise 
Bernard Matthews thin 
slices lean ham 
Iceberg Lettuce 
Including Skin 
Black Pepper, coarse 
ground 
 
 
Pepsi Max 
 
 
1 average pack, Walkers 
cheese and onion flavour 
 
 
 
2 slices 
 
 
2 thin spreads on 
bread 
2 thin slices 
 
1 leaf 
3 thin slices 
from mill 
 
 
1 can, 20% extra 
free (396ml) drank 
all 
 
1 25g packet left 
half 
TEA—between lunch and the evening meal 
Time Food/Drink Description & Preparation Amount 
4.00 
Pm 
 
4.10 
Pm 
 
4.15 
pm 
Coffee 
 
 
Apple 
 
 
Banana 
Same as mid morning 
 
 
Golden Delicious 
 
 
Small 
 
 
2 cups 
 
 
1 with skin peeled 
Didn’t eat core 
 
1 
 EXAMPLE…………..………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
6.30 
pm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.50 
pm 
Lamb 
Potatoes 
 
 
 
Cabbage 
 
Carrots 
 
Potatoes 
 
 
Gravy 
 
 
Water 
 
 
Ice cream 
Roast 
Old, boiled in salt water, 
mashed with semis 
skimmed milk and anchor 
butter 
Green, boiled in salt water 
 
Boiled in salt water 
 
Old, boiled in salt water, 
roasted in meat fat 
 
Bisto Gravy granules made 
with veg water 
 
Highland spring            
carbonated water 
 
Tesco’s vanilla non-dairy 
 
 
 
3 thin slices 
Picture 4b 
 
 
 
Picture 7a 
2 tablespoons 
3 medium         
potatoes, 1 left 
 
4 tablespoons left 
approx 1/4 
 
1 tumbler drank all 
 
 
2 scoops 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
7.30 
pm 
9.15 
pm 
 
9.30 
pm 
12-
6am 
Tea 
 
Whiskey 
Lemonade 
 
Chocolates 
 
water 
Same as breakfast 
 
Blackbush 
Diet own brand lemonade 
 
Cadburys roses 
 
Tap water 
2 mugs 
 
2 shots in average 
size glass 
To top of glass 
2 from box 
 
1 average glass 
 
………………………………………………………………………………………………… 
Day of Week       Date 
LUNCH 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEA—between lunch and the evening meal 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MID-MORNING—between breakfast time and lunch time 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
EXAMPLE...………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
8.30 
pm 
Coffee 1 mug with cream, 1 tsp 
sugar 
 
1 mug incl cream 
(drank all) 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
Sanatogen 
 
Boots own 
brand 
1 a day gold A-Z 
 
Cod liver oil capsule (normal strength) 
1 
 
1 500mg capsule 
Use the pictures to help you to indicate the size of the portion you have 
eaten. Write on the food record the picture number and size A, B or C 
nearest to your own helping. 
 
The pictures could also be used for foods not shown i.e. pasta shapes   
similar to spaghetti, ham pie similar to quiche and peas similar to baked 
beans. 
 
Remember that the pictures are  much smaller than life size. The actual 
size of the dinner plate is 10 inches (25cm), the side plate, 7 inches 
(18cm) and the bowl 6.3 inches (16cm). 
 
………………………………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
   
 ………………………………………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
LUNCH 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEA—between lunch and the evening meal 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MID-MORNING—between breakfast time and lunch time 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MID-MORNING—between breakfast time and lunch time 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
   
 ………………………………………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
LUNCH 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEA—between lunch and the evening meal 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
LUNCH 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEA—between lunch and the evening meal 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MID-MORNING—between breakfast time and lunch time 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
   
 ………………………………………………………………………………………………… 
Day of Week       Date 
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MID-MORNING—between breakfast time and lunch time 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
   
 ………………………………………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
LUNCH 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEA—between lunch and the evening meal 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 ………………………………………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
   
 ………………………………………………………………………………………………… 
Day of Week       Date 
EVENING MEAL 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LATER EVENING—and through the night 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
BETWEEN MEALS SNACKS & DRINKS if not already written in 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please name any medication, vitamins, minerals or food supplements and 
what they were taken with. Please give all details and enclose label(s) if 
possible 
Brand Number: pills,      
capsules,          
teaspoons 
Name  (in full) 
   
 ………………………………………………………………………………………………… 
Day of Week       Date 
BEFORE BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
BREAKFAST 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MID-MORNING—between breakfast time and lunch time 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
………………………………………………………………………………………………… 
Day of Week       Date 
LUNCH 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEA—between lunch and the evening meal 
Time Food/Drink Description & Preparation Amount 
   
 
 
 
 
 
 
 
 
 
